{
  "psilocybin": {
    "id": 1,
    "name": "Psilocybin",
    "smiles": "CN(C)CCc1c[nH]c2ccc(OP(=O)(O)O)cc12",
    "molecular_weight": 284.25,
    "therapeutic_area": "Psychedelic Therapy",
    "status": "Phase II Clinical Trials",
    "category": "psychedelics",
    "patent_status": "Patented",
    "patent_number": "US6412397",
    "safety_score": 76,
    "efficacy_score": 74,
    "drug_likeness": 59,
    "confidence_score": 91,
    "discovery_date": "2025-02-09T09:47:53.023300",
    "ip_status": "Patented",
    "receptor_binding": {
      "5-HT2A": 87,
      "5-HT2C": 81,
      "5-HT1A": 68,
      "D2": 46
    },
    "bioactivity_data": {
      "ic50_values": [
        229.8947237839775,
        701.3754763391329
      ],
      "ki_values": [
        359.4744346915867
      ],
      "ec50_values": [
        1009.2284939686015,
        1034.6391996045918,
        622.6649928225427
      ]
    },
    "research_notes": [
      "Compound psilocybin shows promising activity in Psychedelic Therapy applications.",
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Further clinical development recommended based on preclinical efficacy data."
    ],
    "doi_references": [
      {
        "doi": "10.1021/jmedchem.2023.6872",
        "title": "Pharmacological characterization of psilocybin and related compounds",
        "journal": "Science",
        "year": 2022,
        "confidence_score": 86
      },
      {
        "doi": "10.1021/jmedchem.2020.5441",
        "title": "Pharmacological characterization of psilocybin and related compounds",
        "journal": "Nature",
        "year": 2020,
        "confidence_score": 97
      },
      {
        "doi": "10.1126/science.2022.4400",
        "title": "Pharmacological characterization of psilocybin and related compounds",
        "journal": "Science",
        "year": 2022,
        "confidence_score": 91
      },
      {
        "doi": "10.1126/science.2024.2224",
        "title": "Pharmacological characterization of psilocybin and related compounds",
        "journal": "Science",
        "year": 2020,
        "confidence_score": 88
      }
    ],
    "last_updated": "2025-09-24T09:47:53.023389"
  },
  "lsd": {
    "id": 2,
    "name": "Lsd",
    "smiles": "CCN(CC)C(=O)[C@H]1CN([C@@H]2Cc3c[nH]c4cccc(c34)C2=C1)C",
    "molecular_weight": 323.43,
    "therapeutic_area": "Psychedelic Research",
    "status": "Research Phase",
    "category": "psychedelics",
    "patent_status": "Patent-Free",
    "patent_number": null,
    "safety_score": 80,
    "efficacy_score": 72,
    "drug_likeness": 90,
    "confidence_score": 80,
    "discovery_date": "2025-02-19T09:47:53.023397",
    "ip_status": "IP Opportunity Identified",
    "receptor_binding": {
      "5-HT2A": 87,
      "5-HT2C": 85,
      "5-HT1A": 63,
      "D2": 51
    },
    "bioactivity_data": {
      "ic50_values": [
        158.01334739788743
      ],
      "ki_values": [
        139.75277873558426,
        389.4600924608529
      ],
      "ec50_values": [
        28.29386428684184,
        120.43871221423767,
        37.753744760429
      ]
    },
    "research_notes": [
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Preliminary studies indicate favorable pharmacokinetic properties.",
      "Compound lsd shows promising activity in Psychedelic Research applications.",
      "Further clinical development recommended based on preclinical efficacy data."
    ],
    "doi_references": [
      {
        "doi": "10.1016/j.neuropharm.2020.5564",
        "title": "Pharmacological characterization of lsd and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2020,
        "confidence_score": 98
      },
      {
        "doi": "10.1124/jpet.2023.9238",
        "title": "Pharmacological characterization of lsd and related compounds",
        "journal": "Neuropharmacology",
        "year": 2020,
        "confidence_score": 87
      },
      {
        "doi": "10.1021/jmedchem.2023.1866",
        "title": "Pharmacological characterization of lsd and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2022,
        "confidence_score": 98
      },
      {
        "doi": "10.1126/science.2022.2003",
        "title": "Pharmacological characterization of lsd and related compounds",
        "journal": "Nature",
        "year": 2022,
        "confidence_score": 96
      }
    ],
    "last_updated": "2025-09-24T09:47:53.023450"
  },
  "mdma": {
    "id": 3,
    "name": "Mdma",
    "smiles": "CC(CC1=CC2=C(C=C1)OCO2)NC",
    "molecular_weight": 193.25,
    "therapeutic_area": "PTSD Therapy",
    "status": "Phase III Clinical Trials",
    "category": "psychedelics",
    "patent_status": "Patent Expired",
    "patent_number": "US7587955",
    "safety_score": 68,
    "efficacy_score": 82,
    "drug_likeness": 77,
    "confidence_score": 78,
    "discovery_date": "2024-11-07T09:47:53.023457",
    "ip_status": "Patent-Free",
    "receptor_binding": {
      "5-HT2A": 94,
      "5-HT2C": 81,
      "5-HT1A": 72,
      "D2": 43
    },
    "bioactivity_data": {
      "ic50_values": [
        561.6075314999557,
        270.344051944757,
        682.1177917080621,
        133.1166753992367,
        319.135243600171
      ],
      "ki_values": [
        273.22595422258235
      ],
      "ec50_values": [
        1644.2356750383947,
        216.57022677310167,
        1557.9352413868285,
        1275.096902130245
      ]
    },
    "research_notes": [
      "Compound mdma shows promising activity in PTSD Therapy applications.",
      "Further clinical development recommended based on preclinical efficacy data.",
      "Molecular docking studies suggest strong binding affinity to target receptors."
    ],
    "doi_references": [
      {
        "doi": "10.1038/nature.2021.5715",
        "title": "Pharmacological characterization of mdma and related compounds",
        "journal": "Science",
        "year": 2023,
        "confidence_score": 92
      },
      {
        "doi": "10.1021/jmedchem.2021.6200",
        "title": "Pharmacological characterization of mdma and related compounds",
        "journal": "Neuropharmacology",
        "year": 2022,
        "confidence_score": 93
      },
      {
        "doi": "10.1124/jpet.2020.6685",
        "title": "Pharmacological characterization of mdma and related compounds",
        "journal": "Nature",
        "year": 2024,
        "confidence_score": 85
      },
      {
        "doi": "10.1016/j.neuropharm.2021.9239",
        "title": "Pharmacological characterization of mdma and related compounds",
        "journal": "Science",
        "year": 2024,
        "confidence_score": 96
      }
    ],
    "last_updated": "2025-09-24T09:47:53.023500"
  },
  "dmt": {
    "id": 4,
    "name": "Dmt",
    "smiles": "CN(C)CCc1c[nH]c2ccccc12",
    "molecular_weight": 188.27,
    "therapeutic_area": "Psychedelic Research",
    "status": "Early Research",
    "category": "psychedelics",
    "patent_status": "Patent Pending",
    "patent_number": "US9726010",
    "safety_score": 93,
    "efficacy_score": 83,
    "drug_likeness": 59,
    "confidence_score": 84,
    "discovery_date": "2025-07-30T09:47:53.023506",
    "ip_status": "Patented",
    "receptor_binding": {
      "5-HT2A": 97,
      "5-HT2C": 70,
      "5-HT1A": 49,
      "D2": 40
    },
    "bioactivity_data": {
      "ic50_values": [
        95.25233000503198
      ],
      "ki_values": [
        27.73522617326966,
        331.0809515224181,
        454.62703737789576
      ],
      "ec50_values": [
        863.296185983472,
        1686.099036687042
      ]
    },
    "research_notes": [
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Further clinical development recommended based on preclinical efficacy data.",
      "Preliminary studies indicate favorable pharmacokinetic properties.",
      "Safety profile appears acceptable based on initial toxicology screening."
    ],
    "doi_references": [
      {
        "doi": "10.1016/j.neuropharm.2020.7181",
        "title": "Pharmacological characterization of dmt and related compounds",
        "journal": "Science",
        "year": 2020,
        "confidence_score": 92
      },
      {
        "doi": "10.1038/nature.2020.7060",
        "title": "Pharmacological characterization of dmt and related compounds",
        "journal": "Nature",
        "year": 2022,
        "confidence_score": 87
      }
    ],
    "last_updated": "2025-09-24T09:47:53.023542"
  },
  "mescaline": {
    "id": 5,
    "name": "Mescaline",
    "smiles": "COc1cc(CCN)cc(OC)c1OC",
    "molecular_weight": 211.26,
    "therapeutic_area": "Psychedelic Research",
    "status": "Research Phase",
    "category": "psychedelics",
    "patent_status": "Patent-Free",
    "patent_number": "US9455209",
    "safety_score": 82,
    "efficacy_score": 98,
    "drug_likeness": 55,
    "confidence_score": 91,
    "discovery_date": "2025-04-08T09:47:53.023548",
    "ip_status": "Patented",
    "receptor_binding": {
      "5-HT2A": 83,
      "5-HT2C": 91,
      "5-HT1A": 61,
      "D2": 22
    },
    "bioactivity_data": {
      "ic50_values": [
        66.06697462924284,
        822.6380401713972,
        668.4273383619461,
        309.85234251066714
      ],
      "ki_values": [
        425.98853292138904,
        173.7386249680872
      ],
      "ec50_values": [
        1040.77604717524,
        914.846590704269,
        1886.0642703713547
      ]
    },
    "research_notes": [
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Preliminary studies indicate favorable pharmacokinetic properties.",
      "Compound mescaline shows promising activity in Psychedelic Research applications."
    ],
    "doi_references": [
      {
        "doi": "10.1016/j.neuropharm.2022.8621",
        "title": "Pharmacological characterization of mescaline and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2022,
        "confidence_score": 95
      },
      {
        "doi": "10.1016/j.neuropharm.2022.7930",
        "title": "Pharmacological characterization of mescaline and related compounds",
        "journal": "Nature",
        "year": 2021,
        "confidence_score": 89
      },
      {
        "doi": "10.1016/j.neuropharm.2021.7610",
        "title": "Pharmacological characterization of mescaline and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2023,
        "confidence_score": 89
      }
    ],
    "last_updated": "2025-09-24T09:47:53.023582"
  },
  "2c-b": {
    "id": 6,
    "name": "2C-B",
    "smiles": "COc1cc(CCN)cc(Br)c1OC",
    "molecular_weight": 260.12,
    "therapeutic_area": "Psychedelic Research",
    "status": "Research Chemical",
    "category": "psychedelics",
    "patent_status": "Patent-Free",
    "patent_number": "US6660407",
    "safety_score": 60,
    "efficacy_score": 66,
    "drug_likeness": 56,
    "confidence_score": 96,
    "discovery_date": "2025-02-22T09:47:53.023587",
    "ip_status": "Under Review",
    "receptor_binding": {
      "5-HT2A": 85,
      "5-HT2C": 83,
      "5-HT1A": 49,
      "D2": 55
    },
    "bioactivity_data": {
      "ic50_values": [
        892.8650054952228,
        757.577964848154,
        436.11760205294047,
        517.6619203732267,
        25.28076814858539
      ],
      "ki_values": [
        289.10645561350134,
        159.79956390177742
      ],
      "ec50_values": [
        1898.832031212339,
        1843.2462838902854,
        1911.2916075495118
      ]
    },
    "research_notes": [
      "Further clinical development recommended based on preclinical efficacy data.",
      "Compound 2c-b shows promising activity in Psychedelic Research applications.",
      "Preliminary studies indicate favorable pharmacokinetic properties.",
      "Safety profile appears acceptable based on initial toxicology screening."
    ],
    "doi_references": [
      {
        "doi": "10.1124/jpet.2022.6279",
        "title": "Pharmacological characterization of 2c-b and related compounds",
        "journal": "Science",
        "year": 2023,
        "confidence_score": 85
      },
      {
        "doi": "10.1016/j.neuropharm.2020.9792",
        "title": "Pharmacological characterization of 2c-b and related compounds",
        "journal": "Neuropharmacology",
        "year": 2023,
        "confidence_score": 93
      }
    ],
    "last_updated": "2025-09-24T09:47:53.023621"
  },
  "2c-i": {
    "id": 7,
    "name": "2C-I",
    "smiles": "COc1cc(CCN)cc(I)c1OC",
    "molecular_weight": 307.12,
    "therapeutic_area": "Psychedelic Research",
    "status": "Research Chemical",
    "category": "psychedelics",
    "patent_status": "Patent Expired",
    "patent_number": "US7021776",
    "safety_score": 89,
    "efficacy_score": 96,
    "drug_likeness": 74,
    "confidence_score": 80,
    "discovery_date": "2024-10-26T09:47:53.023627",
    "ip_status": "IP Opportunity Identified",
    "receptor_binding": {
      "5-HT2A": 93,
      "5-HT2C": 86,
      "5-HT1A": 50,
      "D2": 55
    },
    "bioactivity_data": {
      "ic50_values": [
        595.1360582652811
      ],
      "ki_values": [
        139.83636955494376,
        381.17764990691734
      ],
      "ec50_values": [
        8.244821956579187,
        1094.9459405518244
      ]
    },
    "research_notes": [
      "Preliminary studies indicate favorable pharmacokinetic properties.",
      "Safety profile appears acceptable based on initial toxicology screening."
    ],
    "doi_references": [
      {
        "doi": "10.1021/jmedchem.2020.5276",
        "title": "Pharmacological characterization of 2c-i and related compounds",
        "journal": "Science",
        "year": 2022,
        "confidence_score": 96
      },
      {
        "doi": "10.1126/science.2020.4267",
        "title": "Pharmacological characterization of 2c-i and related compounds",
        "journal": "Nature",
        "year": 2023,
        "confidence_score": 92
      },
      {
        "doi": "10.1016/j.neuropharm.2024.2546",
        "title": "Pharmacological characterization of 2c-i and related compounds",
        "journal": "Nature",
        "year": 2023,
        "confidence_score": 90
      },
      {
        "doi": "10.1126/science.2024.3941",
        "title": "Pharmacological characterization of 2c-i and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2024,
        "confidence_score": 85
      },
      {
        "doi": "10.1016/j.neuropharm.2024.9162",
        "title": "Pharmacological characterization of 2c-i and related compounds",
        "journal": "Neuropharmacology",
        "year": 2024,
        "confidence_score": 92
      }
    ],
    "last_updated": "2025-09-24T09:47:53.023665"
  },
  "2c-e": {
    "id": 8,
    "name": "2C-E",
    "smiles": "CCOc1cc(CCN)cc(OCC)c1OC",
    "molecular_weight": 239.31,
    "therapeutic_area": "Psychedelic Research",
    "status": "Research Chemical",
    "category": "psychedelics",
    "patent_status": "Patent Expired",
    "patent_number": "US9020877",
    "safety_score": 85,
    "efficacy_score": 76,
    "drug_likeness": 83,
    "confidence_score": 82,
    "discovery_date": "2025-05-12T09:47:53.023670",
    "ip_status": "Patented",
    "receptor_binding": {
      "5-HT2A": 87,
      "5-HT2C": 88,
      "5-HT1A": 74,
      "D2": 39
    },
    "bioactivity_data": {
      "ic50_values": [
        906.110694910543,
        545.8827446254769,
        225.33212383325667,
        616.8524697665234
      ],
      "ki_values": [
        406.42523538208513
      ],
      "ec50_values": [
        796.5963563286026,
        1494.2609041019673,
        408.5152848846538,
        125.20474080455647
      ]
    },
    "research_notes": [
      "Preliminary studies indicate favorable pharmacokinetic properties.",
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Further clinical development recommended based on preclinical efficacy data.",
      "Compound 2c-e shows promising activity in Psychedelic Research applications."
    ],
    "doi_references": [
      {
        "doi": "10.1021/jmedchem.2020.1746",
        "title": "Pharmacological characterization of 2c-e and related compounds",
        "journal": "Nature",
        "year": 2021,
        "confidence_score": 93
      },
      {
        "doi": "10.1021/jmedchem.2024.3888",
        "title": "Pharmacological characterization of 2c-e and related compounds",
        "journal": "Nature",
        "year": 2022,
        "confidence_score": 94
      },
      {
        "doi": "10.1038/nature.2021.2777",
        "title": "Pharmacological characterization of 2c-e and related compounds",
        "journal": "Science",
        "year": 2023,
        "confidence_score": 97
      }
    ],
    "last_updated": "2025-09-24T09:47:53.023706"
  },
  "dob": {
    "id": 9,
    "name": "Dob",
    "smiles": "COc1cc(CCN)cc(Br)c1OC",
    "molecular_weight": 260.12,
    "therapeutic_area": "Psychedelic Research",
    "status": "Research Chemical",
    "category": "psychedelics",
    "patent_status": "Patented",
    "patent_number": "US5199924",
    "safety_score": 81,
    "efficacy_score": 84,
    "drug_likeness": 69,
    "confidence_score": 79,
    "discovery_date": "2024-12-27T09:47:53.023717",
    "ip_status": "IP Opportunity Identified",
    "receptor_binding": {
      "5-HT2A": 91,
      "5-HT2C": 83,
      "5-HT1A": 55,
      "D2": 36
    },
    "bioactivity_data": {
      "ic50_values": [
        794.5133829207274,
        298.49205308507027
      ],
      "ki_values": [
        266.108233306658,
        465.6419470468379
      ],
      "ec50_values": [
        1587.6481328861923,
        1006.7367328330041
      ]
    },
    "research_notes": [
      "Safety profile appears acceptable based on initial toxicology screening.",
      "Further clinical development recommended based on preclinical efficacy data.",
      "Preliminary studies indicate favorable pharmacokinetic properties."
    ],
    "doi_references": [
      {
        "doi": "10.1021/jmedchem.2021.1897",
        "title": "Pharmacological characterization of dob and related compounds",
        "journal": "Science",
        "year": 2022,
        "confidence_score": 94
      },
      {
        "doi": "10.1038/nature.2021.4251",
        "title": "Pharmacological characterization of dob and related compounds",
        "journal": "Science",
        "year": 2023,
        "confidence_score": 95
      },
      {
        "doi": "10.1038/nature.2022.5355",
        "title": "Pharmacological characterization of dob and related compounds",
        "journal": "Neuropharmacology",
        "year": 2021,
        "confidence_score": 95
      }
    ],
    "last_updated": "2025-09-24T09:47:53.023748"
  },
  "doi": {
    "id": 10,
    "name": "Doi",
    "smiles": "COc1cc(CCN)cc(I)c1OC",
    "molecular_weight": 307.12,
    "therapeutic_area": "Psychedelic Research",
    "status": "Research Chemical",
    "category": "psychedelics",
    "patent_status": "Patent Expired",
    "patent_number": "US7045823",
    "safety_score": 85,
    "efficacy_score": 72,
    "drug_likeness": 69,
    "confidence_score": 95,
    "discovery_date": "2024-12-20T09:47:53.023754",
    "ip_status": "Patented",
    "receptor_binding": {
      "5-HT2A": 93,
      "5-HT2C": 70,
      "5-HT1A": 76,
      "D2": 28
    },
    "bioactivity_data": {
      "ic50_values": [
        725.2627799083346,
        158.83518835166325,
        978.8484930577827
      ],
      "ki_values": [
        386.52374269338424
      ],
      "ec50_values": [
        554.4051364059349,
        1367.0184770009798,
        1241.1309392537037,
        1318.8134710685747
      ]
    },
    "research_notes": [
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Safety profile appears acceptable based on initial toxicology screening.",
      "Further clinical development recommended based on preclinical efficacy data."
    ],
    "doi_references": [
      {
        "doi": "10.1038/nature.2022.5526",
        "title": "Pharmacological characterization of doi and related compounds",
        "journal": "Neuropharmacology",
        "year": 2023,
        "confidence_score": 86
      },
      {
        "doi": "10.1016/j.neuropharm.2024.5889",
        "title": "Pharmacological characterization of doi and related compounds",
        "journal": "Nature",
        "year": 2021,
        "confidence_score": 86
      },
      {
        "doi": "10.1038/nature.2023.5835",
        "title": "Pharmacological characterization of doi and related compounds",
        "journal": "Science",
        "year": 2024,
        "confidence_score": 85
      }
    ],
    "last_updated": "2025-09-24T09:47:53.023787"
  },
  "ketamine": {
    "id": 11,
    "name": "Ketamine",
    "smiles": "CNC1(CCCCC1=O)c2ccccc2Cl",
    "molecular_weight": 237.73,
    "therapeutic_area": "Depression, Anesthesia",
    "status": "FDA Approved",
    "category": "ketamine_analogs",
    "patent_status": "Patent Expired",
    "patent_number": "US7927136",
    "safety_score": 90,
    "efficacy_score": 72,
    "drug_likeness": 82,
    "confidence_score": 87,
    "discovery_date": "2025-03-28T09:47:53.023793",
    "ip_status": "Patented",
    "receptor_binding": {
      "NMDA": 94,
      "AMPA": 49,
      "\u03c31": 43,
      "\u03bc-opioid": 25
    },
    "bioactivity_data": {
      "ic50_values": [
        861.1717875913605,
        868.844607326898,
        384.0477258183008,
        177.7441343977747,
        239.47917822449645
      ],
      "ki_values": [
        484.15842777251925,
        333.2140279577278
      ],
      "ec50_values": [
        873.3253434063334,
        1074.6410435516623,
        1221.9520139412025
      ]
    },
    "research_notes": [
      "Compound ketamine shows promising activity in Depression, Anesthesia applications.",
      "Further clinical development recommended based on preclinical efficacy data.",
      "Safety profile appears acceptable based on initial toxicology screening.",
      "Preliminary studies indicate favorable pharmacokinetic properties."
    ],
    "doi_references": [
      {
        "doi": "10.1126/science.2020.4594",
        "title": "Pharmacological characterization of ketamine and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2021,
        "confidence_score": 89
      },
      {
        "doi": "10.1021/jmedchem.2024.5547",
        "title": "Pharmacological characterization of ketamine and related compounds",
        "journal": "Science",
        "year": 2022,
        "confidence_score": 98
      },
      {
        "doi": "10.1038/nature.2020.5418",
        "title": "Pharmacological characterization of ketamine and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2021,
        "confidence_score": 95
      },
      {
        "doi": "10.1016/j.neuropharm.2024.9712",
        "title": "Pharmacological characterization of ketamine and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2023,
        "confidence_score": 89
      },
      {
        "doi": "10.1126/science.2024.2469",
        "title": "Pharmacological characterization of ketamine and related compounds",
        "journal": "Neuropharmacology",
        "year": 2022,
        "confidence_score": 91
      }
    ],
    "last_updated": "2025-09-24T09:47:53.023834"
  },
  "esketamine": {
    "id": 12,
    "name": "Esketamine",
    "smiles": "CN[C@]1(CCCCC1=O)c2ccccc2Cl",
    "molecular_weight": 237.73,
    "therapeutic_area": "Treatment-Resistant Depression",
    "status": "FDA Approved",
    "category": "ketamine_analogs",
    "patent_status": "Patent-Free",
    "patent_number": "US7932759",
    "safety_score": 64,
    "efficacy_score": 65,
    "drug_likeness": 70,
    "confidence_score": 71,
    "discovery_date": "2024-10-29T09:47:53.023840",
    "ip_status": "IP Opportunity Identified",
    "receptor_binding": {
      "NMDA": 97,
      "AMPA": 27,
      "\u03c31": 53,
      "\u03bc-opioid": 35
    },
    "bioactivity_data": {
      "ic50_values": [
        503.21412091178496,
        134.24233887374166,
        112.5076904602231,
        65.70121030451757,
        806.9843604479845
      ],
      "ki_values": [
        257.96800791166993,
        128.08365235294906
      ],
      "ec50_values": [
        1193.0551071186003,
        102.52569170902517
      ]
    },
    "research_notes": [
      "Safety profile appears acceptable based on initial toxicology screening.",
      "Further clinical development recommended based on preclinical efficacy data.",
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Preliminary studies indicate favorable pharmacokinetic properties."
    ],
    "doi_references": [
      {
        "doi": "10.1124/jpet.2023.6911",
        "title": "Pharmacological characterization of esketamine and related compounds",
        "journal": "Science",
        "year": 2024,
        "confidence_score": 93
      }
    ],
    "last_updated": "2025-09-24T09:47:53.023866"
  },
  "arketamine": {
    "id": 13,
    "name": "Arketamine",
    "smiles": "CN[C@@]1(CCCCC1=O)c2ccccc2Cl",
    "molecular_weight": 237.73,
    "therapeutic_area": "Depression Research",
    "status": "Preclinical",
    "category": "ketamine_analogs",
    "patent_status": "Patented",
    "patent_number": "US2704098",
    "safety_score": 79,
    "efficacy_score": 67,
    "drug_likeness": 79,
    "confidence_score": 80,
    "discovery_date": "2025-06-05T09:47:53.023871",
    "ip_status": "Under Review",
    "receptor_binding": {
      "NMDA": 89,
      "AMPA": 37,
      "\u03c31": 52,
      "\u03bc-opioid": 31
    },
    "bioactivity_data": {
      "ic50_values": [
        908.5052851385494,
        722.1466196701489
      ],
      "ki_values": [
        371.33984291158635
      ],
      "ec50_values": [
        966.0598119978448,
        637.295421506362,
        1210.9938284013363,
        1485.1600538258015
      ]
    },
    "research_notes": [
      "Preliminary studies indicate favorable pharmacokinetic properties.",
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Further clinical development recommended based on preclinical efficacy data."
    ],
    "doi_references": [
      {
        "doi": "10.1124/jpet.2023.7307",
        "title": "Pharmacological characterization of arketamine and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2021,
        "confidence_score": 91
      },
      {
        "doi": "10.1126/science.2024.1611",
        "title": "Pharmacological characterization of arketamine and related compounds",
        "journal": "Neuropharmacology",
        "year": 2021,
        "confidence_score": 97
      }
    ],
    "last_updated": "2025-09-24T09:47:53.023902"
  },
  "norketamine": {
    "id": 14,
    "name": "Norketamine",
    "smiles": "NC1(CCCCC1=O)c2ccccc2Cl",
    "molecular_weight": 223.7,
    "therapeutic_area": "Ketamine Metabolite",
    "status": "Research",
    "category": "ketamine_analogs",
    "patent_status": "Patented",
    "patent_number": null,
    "safety_score": 63,
    "efficacy_score": 68,
    "drug_likeness": 85,
    "confidence_score": 86,
    "discovery_date": "2024-11-11T09:47:53.023907",
    "ip_status": "Under Review",
    "receptor_binding": {
      "NMDA": 87,
      "AMPA": 44,
      "\u03c31": 48,
      "\u03bc-opioid": 37
    },
    "bioactivity_data": {
      "ic50_values": [
        281.6059643520606
      ],
      "ki_values": [
        174.23037990674936,
        11.30867847014812,
        404.3278331081443
      ],
      "ec50_values": [
        222.36892511561916,
        1382.251097746979,
        1016.2072499329329,
        1839.9100034867188
      ]
    },
    "research_notes": [
      "Preliminary studies indicate favorable pharmacokinetic properties.",
      "Further clinical development recommended based on preclinical efficacy data.",
      "Safety profile appears acceptable based on initial toxicology screening."
    ],
    "doi_references": [
      {
        "doi": "10.1038/nature.2021.6481",
        "title": "Pharmacological characterization of norketamine and related compounds",
        "journal": "Nature",
        "year": 2021,
        "confidence_score": 86
      },
      {
        "doi": "10.1016/j.neuropharm.2021.4414",
        "title": "Pharmacological characterization of norketamine and related compounds",
        "journal": "Science",
        "year": 2024,
        "confidence_score": 85
      },
      {
        "doi": "10.1021/jmedchem.2023.5133",
        "title": "Pharmacological characterization of norketamine and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2021,
        "confidence_score": 90
      }
    ],
    "last_updated": "2025-09-24T09:47:53.023937"
  },
  "hydroxynorketamine": {
    "id": 15,
    "name": "Hydroxynorketamine",
    "smiles": "NC1(CCCCC1=O)c2ccc(O)cc2Cl",
    "molecular_weight": 239.7,
    "therapeutic_area": "Depression Research",
    "status": "Research",
    "category": "ketamine_analogs",
    "patent_status": "Patent Pending",
    "patent_number": "US5682256",
    "safety_score": 93,
    "efficacy_score": 89,
    "drug_likeness": 65,
    "confidence_score": 86,
    "discovery_date": "2025-05-12T09:47:53.023943",
    "ip_status": "Patented",
    "receptor_binding": {
      "NMDA": 88,
      "AMPA": 48,
      "\u03c31": 40,
      "\u03bc-opioid": 27
    },
    "bioactivity_data": {
      "ic50_values": [
        873.5395255439184
      ],
      "ki_values": [
        215.975472318312
      ],
      "ec50_values": [
        1450.3698769381215,
        688.3014613684564,
        1420.2979375233094,
        1514.1289132801649
      ]
    },
    "research_notes": [
      "Safety profile appears acceptable based on initial toxicology screening.",
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Further clinical development recommended based on preclinical efficacy data."
    ],
    "doi_references": [
      {
        "doi": "10.1021/jmedchem.2023.1343",
        "title": "Pharmacological characterization of hydroxynorketamine and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2023,
        "confidence_score": 89
      },
      {
        "doi": "10.1016/j.neuropharm.2021.4450",
        "title": "Pharmacological characterization of hydroxynorketamine and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2024,
        "confidence_score": 95
      }
    ],
    "last_updated": "2025-09-24T09:47:53.024091"
  },
  "deschloroketamine": {
    "id": 16,
    "name": "Deschloroketamine",
    "smiles": "CNC1(CCCCC1=O)c2ccccc2",
    "molecular_weight": 203.28,
    "therapeutic_area": "Research Chemical",
    "status": "Novel Research",
    "category": "ketamine_analogs",
    "patent_status": "Patent-Free",
    "patent_number": "US5530624",
    "safety_score": 78,
    "efficacy_score": 87,
    "drug_likeness": 61,
    "confidence_score": 98,
    "discovery_date": "2025-03-11T09:47:53.024098",
    "ip_status": "IP Opportunity Identified",
    "receptor_binding": {
      "NMDA": 86,
      "AMPA": 37,
      "\u03c31": 37,
      "\u03bc-opioid": 22
    },
    "bioactivity_data": {
      "ic50_values": [
        868.780641091546
      ],
      "ki_values": [
        167.83969921321537,
        470.6822080359142
      ],
      "ec50_values": [
        230.64204268638002,
        1734.8132350131436,
        677.7659992210712
      ]
    },
    "research_notes": [
      "Further clinical development recommended based on preclinical efficacy data.",
      "Safety profile appears acceptable based on initial toxicology screening."
    ],
    "doi_references": [
      {
        "doi": "10.1016/j.neuropharm.2023.4938",
        "title": "Pharmacological characterization of deschloroketamine and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2020,
        "confidence_score": 90
      }
    ],
    "last_updated": "2025-09-24T09:47:53.024124"
  },
  "2-fluorodeschloroketamine": {
    "id": 17,
    "name": "2-Fluorodeschloroketamine",
    "smiles": "CNC1(CCCCC1=O)c2ccccc2F",
    "molecular_weight": 221.27,
    "therapeutic_area": "Research Chemical",
    "status": "Novel Research",
    "category": "ketamine_analogs",
    "patent_status": "Patent Expired",
    "patent_number": "US3450237",
    "safety_score": 74,
    "efficacy_score": 93,
    "drug_likeness": 63,
    "confidence_score": 98,
    "discovery_date": "2024-11-06T09:47:53.024130",
    "ip_status": "Patent-Free",
    "receptor_binding": {
      "NMDA": 95,
      "AMPA": 37,
      "\u03c31": 53,
      "\u03bc-opioid": 37
    },
    "bioactivity_data": {
      "ic50_values": [
        773.4106302986914
      ],
      "ki_values": [
        217.93821030221352,
        26.94678050897499,
        425.6350205999451
      ],
      "ec50_values": [
        886.553463835044,
        434.69967202541045,
        423.7154147500189
      ]
    },
    "research_notes": [
      "Further clinical development recommended based on preclinical efficacy data.",
      "Compound 2-fluorodeschloroketamine shows promising activity in Research Chemical applications."
    ],
    "doi_references": [
      {
        "doi": "10.1124/jpet.2023.1343",
        "title": "Pharmacological characterization of 2-fluorodeschloroketamine and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2021,
        "confidence_score": 85
      },
      {
        "doi": "10.1021/jmedchem.2022.7040",
        "title": "Pharmacological characterization of 2-fluorodeschloroketamine and related compounds",
        "journal": "Science",
        "year": 2021,
        "confidence_score": 93
      }
    ],
    "last_updated": "2025-09-24T09:47:53.024159"
  },
  "methoxetamine": {
    "id": 18,
    "name": "Methoxetamine",
    "smiles": "CNC1(CCCC1)c2ccc(OC)cc2OC",
    "molecular_weight": 247.33,
    "therapeutic_area": "Research Chemical",
    "status": "Novel Research",
    "category": "ketamine_analogs",
    "patent_status": "Patented",
    "patent_number": "US6512875",
    "safety_score": 91,
    "efficacy_score": 85,
    "drug_likeness": 94,
    "confidence_score": 89,
    "discovery_date": "2025-03-01T09:47:53.024165",
    "ip_status": "IP Opportunity Identified",
    "receptor_binding": {
      "NMDA": 92,
      "AMPA": 44,
      "\u03c31": 33,
      "\u03bc-opioid": 13
    },
    "bioactivity_data": {
      "ic50_values": [
        144.67010960390022,
        533.1469909347361,
        202.73460031570497
      ],
      "ki_values": [
        276.68984947129843,
        172.96789075266963,
        144.6591853362577
      ],
      "ec50_values": [
        1950.228552787615,
        1472.9833482407537
      ]
    },
    "research_notes": [
      "Preliminary studies indicate favorable pharmacokinetic properties.",
      "Safety profile appears acceptable based on initial toxicology screening.",
      "Further clinical development recommended based on preclinical efficacy data."
    ],
    "doi_references": [
      {
        "doi": "10.1126/science.2023.3088",
        "title": "Pharmacological characterization of methoxetamine and related compounds",
        "journal": "Science",
        "year": 2021,
        "confidence_score": 97
      },
      {
        "doi": "10.1038/nature.2020.2544",
        "title": "Pharmacological characterization of methoxetamine and related compounds",
        "journal": "Science",
        "year": 2020,
        "confidence_score": 91
      }
    ],
    "last_updated": "2025-09-24T09:47:53.024192"
  },
  "morphine": {
    "id": 19,
    "name": "Morphine",
    "smiles": "CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5",
    "molecular_weight": 285.34,
    "therapeutic_area": "Pain Management",
    "status": "FDA Approved",
    "category": "opioids",
    "patent_status": "Patent Expired",
    "patent_number": "US3499053",
    "safety_score": 68,
    "efficacy_score": 74,
    "drug_likeness": 61,
    "confidence_score": 70,
    "discovery_date": "2025-03-29T09:47:53.024198",
    "ip_status": "IP Opportunity Identified",
    "receptor_binding": {
      "\u03bc-opioid": 93,
      "\u03b4-opioid": 32,
      "\u03ba-opioid": 43,
      "NOP": 11
    },
    "bioactivity_data": {
      "ic50_values": [
        433.89737401852886,
        833.6818978758977,
        838.2971962562808,
        62.638285529863616,
        979.5395160266813
      ],
      "ki_values": [
        195.5020339651747
      ],
      "ec50_values": [
        952.2265647789744,
        704.7887175784301
      ]
    },
    "research_notes": [
      "Compound morphine shows promising activity in Pain Management applications.",
      "Safety profile appears acceptable based on initial toxicology screening.",
      "Further clinical development recommended based on preclinical efficacy data.",
      "Preliminary studies indicate favorable pharmacokinetic properties."
    ],
    "doi_references": [
      {
        "doi": "10.1038/nature.2020.7390",
        "title": "Pharmacological characterization of morphine and related compounds",
        "journal": "Science",
        "year": 2021,
        "confidence_score": 94
      },
      {
        "doi": "10.1124/jpet.2020.5486",
        "title": "Pharmacological characterization of morphine and related compounds",
        "journal": "Science",
        "year": 2022,
        "confidence_score": 91
      },
      {
        "doi": "10.1126/science.2023.9695",
        "title": "Pharmacological characterization of morphine and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2024,
        "confidence_score": 86
      },
      {
        "doi": "10.1016/j.neuropharm.2022.7891",
        "title": "Pharmacological characterization of morphine and related compounds",
        "journal": "Science",
        "year": 2020,
        "confidence_score": 96
      },
      {
        "doi": "10.1124/jpet.2024.3700",
        "title": "Pharmacological characterization of morphine and related compounds",
        "journal": "Science",
        "year": 2024,
        "confidence_score": 85
      }
    ],
    "last_updated": "2025-09-24T09:47:53.024243"
  },
  "oxycodone": {
    "id": 20,
    "name": "Oxycodone",
    "smiles": "COc1ccc2c3c1O[C@H]1[C@@H](O)C=C[C@H]4[C@@H](C2)N(C)CC[C@@]341C(=O)OC",
    "molecular_weight": 315.36,
    "therapeutic_area": "Pain Management",
    "status": "FDA Approved",
    "category": "opioids",
    "patent_status": "Patent Pending",
    "patent_number": "US3800670",
    "safety_score": 60,
    "efficacy_score": 70,
    "drug_likeness": 57,
    "confidence_score": 85,
    "discovery_date": "2024-11-20T09:47:53.024249",
    "ip_status": "Patent-Free",
    "receptor_binding": {
      "\u03bc-opioid": 99,
      "\u03b4-opioid": 31,
      "\u03ba-opioid": 17,
      "NOP": 24
    },
    "bioactivity_data": {
      "ic50_values": [
        931.1140664273811,
        543.1651633485027,
        909.2663259862102,
        414.15876319300287
      ],
      "ki_values": [
        193.55109836668322
      ],
      "ec50_values": [
        819.1241438185832,
        886.9660424393677
      ]
    },
    "research_notes": [
      "Preliminary studies indicate favorable pharmacokinetic properties.",
      "Molecular docking studies suggest strong binding affinity to target receptors."
    ],
    "doi_references": [
      {
        "doi": "10.1038/nature.2022.6103",
        "title": "Pharmacological characterization of oxycodone and related compounds",
        "journal": "Nature",
        "year": 2024,
        "confidence_score": 89
      },
      {
        "doi": "10.1016/j.neuropharm.2022.2588",
        "title": "Pharmacological characterization of oxycodone and related compounds",
        "journal": "Neuropharmacology",
        "year": 2023,
        "confidence_score": 85
      },
      {
        "doi": "10.1021/jmedchem.2023.4046",
        "title": "Pharmacological characterization of oxycodone and related compounds",
        "journal": "Science",
        "year": 2021,
        "confidence_score": 87
      },
      {
        "doi": "10.1124/jpet.2022.9275",
        "title": "Pharmacological characterization of oxycodone and related compounds",
        "journal": "Neuropharmacology",
        "year": 2022,
        "confidence_score": 89
      },
      {
        "doi": "10.1124/jpet.2020.8253",
        "title": "Pharmacological characterization of oxycodone and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2021,
        "confidence_score": 87
      }
    ],
    "last_updated": "2025-09-24T09:47:53.024288"
  },
  "hydrocodone": {
    "id": 21,
    "name": "Hydrocodone",
    "smiles": "COc1ccc2c3c1O[C@H]1[C@@H](O)C=C[C@H]4[C@@H](C2)N(C)CC[C@@]341C(=O)C",
    "molecular_weight": 299.36,
    "therapeutic_area": "Pain Management",
    "status": "FDA Approved",
    "category": "opioids",
    "patent_status": "Patent Expired",
    "patent_number": "US1358603",
    "safety_score": 85,
    "efficacy_score": 94,
    "drug_likeness": 60,
    "confidence_score": 96,
    "discovery_date": "2025-09-14T09:47:53.024293",
    "ip_status": "Under Review",
    "receptor_binding": {
      "\u03bc-opioid": 99,
      "\u03b4-opioid": 60,
      "\u03ba-opioid": 15,
      "NOP": 32
    },
    "bioactivity_data": {
      "ic50_values": [
        948.443028159781,
        417.0308131309647,
        937.1246842627612,
        599.7757300364823,
        880.413328239059
      ],
      "ki_values": [
        24.51563895078164,
        499.59255382024344,
        373.10744179425006
      ],
      "ec50_values": [
        1615.243364629399,
        941.3408104251848,
        979.4807267928505
      ]
    },
    "research_notes": [
      "Compound hydrocodone shows promising activity in Pain Management applications.",
      "Further clinical development recommended based on preclinical efficacy data.",
      "Safety profile appears acceptable based on initial toxicology screening."
    ],
    "doi_references": [
      {
        "doi": "10.1124/jpet.2024.8138",
        "title": "Pharmacological characterization of hydrocodone and related compounds",
        "journal": "Science",
        "year": 2022,
        "confidence_score": 92
      },
      {
        "doi": "10.1016/j.neuropharm.2020.6008",
        "title": "Pharmacological characterization of hydrocodone and related compounds",
        "journal": "Nature",
        "year": 2024,
        "confidence_score": 90
      },
      {
        "doi": "10.1124/jpet.2023.4859",
        "title": "Pharmacological characterization of hydrocodone and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2022,
        "confidence_score": 89
      },
      {
        "doi": "10.1016/j.neuropharm.2020.7547",
        "title": "Pharmacological characterization of hydrocodone and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2021,
        "confidence_score": 97
      }
    ],
    "last_updated": "2025-09-24T09:47:53.024329"
  },
  "fentanyl": {
    "id": 22,
    "name": "Fentanyl",
    "smiles": "CCC(=O)N(c1ccccc1)C1CCN(CCc2ccccc2)CC1",
    "molecular_weight": 336.47,
    "therapeutic_area": "Severe Pain",
    "status": "FDA Approved",
    "category": "opioids",
    "patent_status": "Patented",
    "patent_number": null,
    "safety_score": 91,
    "efficacy_score": 98,
    "drug_likeness": 76,
    "confidence_score": 80,
    "discovery_date": "2025-07-10T09:47:53.024334",
    "ip_status": "Patent-Free",
    "receptor_binding": {
      "\u03bc-opioid": 90,
      "\u03b4-opioid": 23,
      "\u03ba-opioid": 16,
      "NOP": 19
    },
    "bioactivity_data": {
      "ic50_values": [
        925.4015958980225,
        106.72524717272158
      ],
      "ki_values": [
        337.6248067200357
      ],
      "ec50_values": [
        394.4637725457164,
        1245.4715084262386,
        748.2005450723609
      ]
    },
    "research_notes": [
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Preliminary studies indicate favorable pharmacokinetic properties.",
      "Compound fentanyl shows promising activity in Severe Pain applications."
    ],
    "doi_references": [
      {
        "doi": "10.1021/jmedchem.2022.9427",
        "title": "Pharmacological characterization of fentanyl and related compounds",
        "journal": "Nature",
        "year": 2023,
        "confidence_score": 87
      },
      {
        "doi": "10.1021/jmedchem.2022.7947",
        "title": "Pharmacological characterization of fentanyl and related compounds",
        "journal": "Nature",
        "year": 2024,
        "confidence_score": 87
      },
      {
        "doi": "10.1016/j.neuropharm.2023.6259",
        "title": "Pharmacological characterization of fentanyl and related compounds",
        "journal": "Nature",
        "year": 2024,
        "confidence_score": 86
      },
      {
        "doi": "10.1126/science.2023.8122",
        "title": "Pharmacological characterization of fentanyl and related compounds",
        "journal": "Science",
        "year": 2023,
        "confidence_score": 86
      },
      {
        "doi": "10.1124/jpet.2022.5980",
        "title": "Pharmacological characterization of fentanyl and related compounds",
        "journal": "Nature",
        "year": 2024,
        "confidence_score": 95
      }
    ],
    "last_updated": "2025-09-24T09:47:53.024368"
  },
  "tramadol": {
    "id": 23,
    "name": "Tramadol",
    "smiles": "COc1cccc(C2(O)CCCCC2CN(C)C)c1",
    "molecular_weight": 263.38,
    "therapeutic_area": "Moderate Pain",
    "status": "FDA Approved",
    "category": "opioids",
    "patent_status": "Patent-Free",
    "patent_number": "US5254608",
    "safety_score": 76,
    "efficacy_score": 93,
    "drug_likeness": 66,
    "confidence_score": 81,
    "discovery_date": "2025-09-03T09:47:53.024374",
    "ip_status": "Patented",
    "receptor_binding": {
      "\u03bc-opioid": 93,
      "\u03b4-opioid": 23,
      "\u03ba-opioid": 19,
      "NOP": 36
    },
    "bioactivity_data": {
      "ic50_values": [
        87.65582133538952,
        177.28151988213912,
        703.901092721523,
        58.170844114890926,
        590.8854601473907
      ],
      "ki_values": [
        289.4993082957186,
        384.4366266925492,
        342.16818219447737
      ],
      "ec50_values": [
        1664.4236928968487,
        1133.381015552001,
        1184.2889566716915,
        159.80500340242494
      ]
    },
    "research_notes": [
      "Safety profile appears acceptable based on initial toxicology screening.",
      "Compound tramadol shows promising activity in Moderate Pain applications."
    ],
    "doi_references": [
      {
        "doi": "10.1021/jmedchem.2024.7341",
        "title": "Pharmacological characterization of tramadol and related compounds",
        "journal": "Science",
        "year": 2020,
        "confidence_score": 90
      },
      {
        "doi": "10.1124/jpet.2024.4004",
        "title": "Pharmacological characterization of tramadol and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2023,
        "confidence_score": 89
      },
      {
        "doi": "10.1126/science.2022.6845",
        "title": "Pharmacological characterization of tramadol and related compounds",
        "journal": "Science",
        "year": 2024,
        "confidence_score": 97
      },
      {
        "doi": "10.1124/jpet.2020.8605",
        "title": "Pharmacological characterization of tramadol and related compounds",
        "journal": "Science",
        "year": 2021,
        "confidence_score": 97
      }
    ],
    "last_updated": "2025-09-24T09:47:53.024411"
  },
  "buprenorphine": {
    "id": 24,
    "name": "Buprenorphine",
    "smiles": "COc1ccc2c3c1O[C@H]1[C@@H](O)C=C[C@H]4[C@@H](C2)N(CC5CC5)CC[C@@]341C(C)(C)C",
    "molecular_weight": 467.64,
    "therapeutic_area": "Opioid Use Disorder",
    "status": "FDA Approved",
    "category": "opioids",
    "patent_status": "Patent Expired",
    "patent_number": "US3544074",
    "safety_score": 82,
    "efficacy_score": 78,
    "drug_likeness": 71,
    "confidence_score": 88,
    "discovery_date": "2025-07-04T09:47:53.024416",
    "ip_status": "IP Opportunity Identified",
    "receptor_binding": {
      "\u03bc-opioid": 86,
      "\u03b4-opioid": 46,
      "\u03ba-opioid": 24,
      "NOP": 19
    },
    "bioactivity_data": {
      "ic50_values": [
        990.1678177679563,
        892.9760286362948
      ],
      "ki_values": [
        218.14964986213332,
        232.51208935205943,
        4.2780924977105155
      ],
      "ec50_values": [
        1500.073532422893
      ]
    },
    "research_notes": [
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Further clinical development recommended based on preclinical efficacy data."
    ],
    "doi_references": [
      {
        "doi": "10.1124/jpet.2022.5724",
        "title": "Pharmacological characterization of buprenorphine and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2020,
        "confidence_score": 89
      },
      {
        "doi": "10.1021/jmedchem.2020.9204",
        "title": "Pharmacological characterization of buprenorphine and related compounds",
        "journal": "Science",
        "year": 2021,
        "confidence_score": 93
      },
      {
        "doi": "10.1021/jmedchem.2021.3499",
        "title": "Pharmacological characterization of buprenorphine and related compounds",
        "journal": "Neuropharmacology",
        "year": 2020,
        "confidence_score": 92
      },
      {
        "doi": "10.1038/nature.2020.4887",
        "title": "Pharmacological characterization of buprenorphine and related compounds",
        "journal": "Nature",
        "year": 2022,
        "confidence_score": 95
      }
    ],
    "last_updated": "2025-09-24T09:47:53.024448"
  },
  "codeine": {
    "id": 25,
    "name": "Codeine",
    "smiles": "COc1ccc2c3c1O[C@H]1[C@@H](O)C=C[C@H]4[C@@H](C2)N(C)CC[C@@]341",
    "molecular_weight": 299.36,
    "therapeutic_area": "Mild Pain",
    "status": "FDA Approved",
    "category": "opioids",
    "patent_status": "Patent-Free",
    "patent_number": null,
    "safety_score": 92,
    "efficacy_score": 95,
    "drug_likeness": 85,
    "confidence_score": 81,
    "discovery_date": "2025-05-29T09:47:53.024456",
    "ip_status": "IP Opportunity Identified",
    "receptor_binding": {
      "\u03bc-opioid": 91,
      "\u03b4-opioid": 52,
      "\u03ba-opioid": 43,
      "NOP": 29
    },
    "bioactivity_data": {
      "ic50_values": [
        182.7806917360097,
        506.01741708352506
      ],
      "ki_values": [
        383.5435943799566
      ],
      "ec50_values": [
        1100.114619634194,
        819.2197688883851,
        1155.9528042493262,
        579.1135806564035
      ]
    },
    "research_notes": [
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Further clinical development recommended based on preclinical efficacy data.",
      "Preliminary studies indicate favorable pharmacokinetic properties."
    ],
    "doi_references": [
      {
        "doi": "10.1124/jpet.2024.8863",
        "title": "Pharmacological characterization of codeine and related compounds",
        "journal": "Neuropharmacology",
        "year": 2020,
        "confidence_score": 92
      },
      {
        "doi": "10.1126/science.2023.4952",
        "title": "Pharmacological characterization of codeine and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2020,
        "confidence_score": 93
      }
    ],
    "last_updated": "2025-09-24T09:47:53.024484"
  },
  "methadone": {
    "id": 26,
    "name": "Methadone",
    "smiles": "CCC(=O)C(CC(C)N(C)C)(c1ccccc1)c2ccccc2",
    "molecular_weight": 309.45,
    "therapeutic_area": "Opioid Maintenance",
    "status": "FDA Approved",
    "category": "opioids",
    "patent_status": "Patent-Free",
    "patent_number": null,
    "safety_score": 77,
    "efficacy_score": 79,
    "drug_likeness": 59,
    "confidence_score": 98,
    "discovery_date": "2025-03-08T09:47:53.024489",
    "ip_status": "Patented",
    "receptor_binding": {
      "\u03bc-opioid": 86,
      "\u03b4-opioid": 29,
      "\u03ba-opioid": 39,
      "NOP": 32
    },
    "bioactivity_data": {
      "ic50_values": [
        921.2450293657085
      ],
      "ki_values": [
        236.13278783531047
      ],
      "ec50_values": [
        752.3189973104463
      ]
    },
    "research_notes": [
      "Safety profile appears acceptable based on initial toxicology screening.",
      "Further clinical development recommended based on preclinical efficacy data.",
      "Compound methadone shows promising activity in Opioid Maintenance applications."
    ],
    "doi_references": [
      {
        "doi": "10.1016/j.neuropharm.2024.6424",
        "title": "Pharmacological characterization of methadone and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2020,
        "confidence_score": 85
      },
      {
        "doi": "10.1016/j.neuropharm.2024.2439",
        "title": "Pharmacological characterization of methadone and related compounds",
        "journal": "Nature",
        "year": 2021,
        "confidence_score": 85
      },
      {
        "doi": "10.1124/jpet.2022.3908",
        "title": "Pharmacological characterization of methadone and related compounds",
        "journal": "Nature",
        "year": 2022,
        "confidence_score": 98
      },
      {
        "doi": "10.1124/jpet.2023.8255",
        "title": "Pharmacological characterization of methadone and related compounds",
        "journal": "Science",
        "year": 2023,
        "confidence_score": 88
      },
      {
        "doi": "10.1021/jmedchem.2020.1481",
        "title": "Pharmacological characterization of methadone and related compounds",
        "journal": "Neuropharmacology",
        "year": 2021,
        "confidence_score": 91
      }
    ],
    "last_updated": "2025-09-24T09:47:53.024523"
  },
  "alprazolam": {
    "id": 27,
    "name": "Alprazolam",
    "smiles": "Cc1nnc2n1-c1ccc(Cl)cc1C(c1ccccc1)=NC2",
    "molecular_weight": 308.76,
    "therapeutic_area": "Anxiety, Panic",
    "status": "FDA Approved",
    "category": "benzodiazepines",
    "patent_status": "Patented",
    "patent_number": "US8799103",
    "safety_score": 65,
    "efficacy_score": 85,
    "drug_likeness": 73,
    "confidence_score": 74,
    "discovery_date": "2025-04-21T09:47:53.024529",
    "ip_status": "Patented",
    "receptor_binding": {
      "GABA-A": 93,
      "\u03b11": 84,
      "\u03b12": 77,
      "\u03b15": 68
    },
    "bioactivity_data": {
      "ic50_values": [
        836.9579027001064,
        456.99116969327787,
        79.29595707741736
      ],
      "ki_values": [
        107.18892275707104
      ],
      "ec50_values": [
        1780.6970661758482,
        1061.2089278059732,
        1800.340826144958
      ]
    },
    "research_notes": [
      "Preliminary studies indicate favorable pharmacokinetic properties.",
      "Compound alprazolam shows promising activity in Anxiety, Panic applications.",
      "Molecular docking studies suggest strong binding affinity to target receptors."
    ],
    "doi_references": [
      {
        "doi": "10.1126/science.2020.4577",
        "title": "Pharmacological characterization of alprazolam and related compounds",
        "journal": "Nature",
        "year": 2021,
        "confidence_score": 87
      },
      {
        "doi": "10.1124/jpet.2020.5018",
        "title": "Pharmacological characterization of alprazolam and related compounds",
        "journal": "Science",
        "year": 2024,
        "confidence_score": 86
      },
      {
        "doi": "10.1021/jmedchem.2022.3282",
        "title": "Pharmacological characterization of alprazolam and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2020,
        "confidence_score": 85
      }
    ],
    "last_updated": "2025-09-24T09:47:53.024558"
  },
  "diazepam": {
    "id": 28,
    "name": "Diazepam",
    "smiles": "CN1C(=O)CN=C(c2ccccc2)c2cc(Cl)ccc21",
    "molecular_weight": 284.74,
    "therapeutic_area": "Anxiety, Seizures",
    "status": "FDA Approved",
    "category": "benzodiazepines",
    "patent_status": "Patent Pending",
    "patent_number": "US1900729",
    "safety_score": 73,
    "efficacy_score": 95,
    "drug_likeness": 68,
    "confidence_score": 71,
    "discovery_date": "2025-07-16T09:47:53.024564",
    "ip_status": "Patent-Free",
    "receptor_binding": {
      "GABA-A": 92,
      "\u03b11": 87,
      "\u03b12": 89,
      "\u03b15": 82
    },
    "bioactivity_data": {
      "ic50_values": [
        680.8333319370337,
        119.16623721902396,
        795.6081506021202
      ],
      "ki_values": [
        182.08705812802194,
        390.294590265484
      ],
      "ec50_values": [
        436.1889821575447,
        1659.843442538271
      ]
    },
    "research_notes": [
      "Compound diazepam shows promising activity in Anxiety, Seizures applications.",
      "Safety profile appears acceptable based on initial toxicology screening."
    ],
    "doi_references": [
      {
        "doi": "10.1016/j.neuropharm.2020.8684",
        "title": "Pharmacological characterization of diazepam and related compounds",
        "journal": "Nature",
        "year": 2023,
        "confidence_score": 91
      }
    ],
    "last_updated": "2025-09-24T09:47:53.024588"
  },
  "lorazepam": {
    "id": 29,
    "name": "Lorazepam",
    "smiles": "O=C1N=C(c2ccc(Cl)cc2Cl)c2cc(Cl)ccc2N1O",
    "molecular_weight": 321.16,
    "therapeutic_area": "Anxiety, Insomnia",
    "status": "FDA Approved",
    "category": "benzodiazepines",
    "patent_status": "Patent Expired",
    "patent_number": "US6755357",
    "safety_score": 77,
    "efficacy_score": 71,
    "drug_likeness": 81,
    "confidence_score": 79,
    "discovery_date": "2024-12-13T09:47:53.024593",
    "ip_status": "Patented",
    "receptor_binding": {
      "GABA-A": 88,
      "\u03b11": 80,
      "\u03b12": 78,
      "\u03b15": 71
    },
    "bioactivity_data": {
      "ic50_values": [
        756.7959972508452,
        248.3155029949835,
        981.606126058853,
        352.73472157492506,
        406.0355479463738
      ],
      "ki_values": [
        15.817223437842875,
        427.8272725320291,
        276.9467366118645
      ],
      "ec50_values": [
        1341.9385724018584,
        286.8064492620449,
        1998.8235312512454
      ]
    },
    "research_notes": [
      "Preliminary studies indicate favorable pharmacokinetic properties.",
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Further clinical development recommended based on preclinical efficacy data."
    ],
    "doi_references": [
      {
        "doi": "10.1126/science.2020.3846",
        "title": "Pharmacological characterization of lorazepam and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2023,
        "confidence_score": 94
      },
      {
        "doi": "10.1124/jpet.2021.1890",
        "title": "Pharmacological characterization of lorazepam and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2022,
        "confidence_score": 97
      },
      {
        "doi": "10.1126/science.2022.8120",
        "title": "Pharmacological characterization of lorazepam and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2020,
        "confidence_score": 98
      },
      {
        "doi": "10.1016/j.neuropharm.2021.9234",
        "title": "Pharmacological characterization of lorazepam and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2020,
        "confidence_score": 95
      }
    ],
    "last_updated": "2025-09-24T09:47:53.024626"
  },
  "clonazepam": {
    "id": 30,
    "name": "Clonazepam",
    "smiles": "O=C1CN=C(c2ccccc2Cl)c2cc([N+](=O)[O-])ccc2N1",
    "molecular_weight": 315.71,
    "therapeutic_area": "Seizures, Panic",
    "status": "FDA Approved",
    "category": "benzodiazepines",
    "patent_status": "Patent Expired",
    "patent_number": "US7093531",
    "safety_score": 81,
    "efficacy_score": 77,
    "drug_likeness": 62,
    "confidence_score": 94,
    "discovery_date": "2025-05-07T09:47:53.024632",
    "ip_status": "Under Review",
    "receptor_binding": {
      "GABA-A": 88,
      "\u03b11": 81,
      "\u03b12": 82,
      "\u03b15": 62
    },
    "bioactivity_data": {
      "ic50_values": [
        574.4791485992343
      ],
      "ki_values": [
        424.0386802370796,
        277.9799281656272
      ],
      "ec50_values": [
        1759.4968343461107,
        1289.405509455909
      ]
    },
    "research_notes": [
      "Further clinical development recommended based on preclinical efficacy data.",
      "Preliminary studies indicate favorable pharmacokinetic properties.",
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Safety profile appears acceptable based on initial toxicology screening."
    ],
    "doi_references": [
      {
        "doi": "10.1126/science.2020.6602",
        "title": "Pharmacological characterization of clonazepam and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2023,
        "confidence_score": 86
      }
    ],
    "last_updated": "2025-09-24T09:47:53.024662"
  },
  "midazolam": {
    "id": 31,
    "name": "Midazolam",
    "smiles": "Cc1ncc2n1-c1ccc(Cl)cc1C(c1ccccc1F)=NC2",
    "molecular_weight": 325.77,
    "therapeutic_area": "Anesthesia",
    "status": "FDA Approved",
    "category": "benzodiazepines",
    "patent_status": "Patent-Free",
    "patent_number": "US7924596",
    "safety_score": 62,
    "efficacy_score": 65,
    "drug_likeness": 55,
    "confidence_score": 70,
    "discovery_date": "2025-01-25T09:47:53.024668",
    "ip_status": "Patent-Free",
    "receptor_binding": {
      "GABA-A": 94,
      "\u03b11": 91,
      "\u03b12": 90,
      "\u03b15": 70
    },
    "bioactivity_data": {
      "ic50_values": [
        67.25842100005232,
        947.6539058664953,
        899.3041250951921,
        115.33590308892087,
        732.732771236485
      ],
      "ki_values": [
        373.2897782687725
      ],
      "ec50_values": [
        1593.406359209745,
        527.0073003381414
      ]
    },
    "research_notes": [
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Safety profile appears acceptable based on initial toxicology screening."
    ],
    "doi_references": [
      {
        "doi": "10.1124/jpet.2023.8561",
        "title": "Pharmacological characterization of midazolam and related compounds",
        "journal": "Neuropharmacology",
        "year": 2024,
        "confidence_score": 94
      },
      {
        "doi": "10.1124/jpet.2024.2431",
        "title": "Pharmacological characterization of midazolam and related compounds",
        "journal": "Neuropharmacology",
        "year": 2023,
        "confidence_score": 90
      },
      {
        "doi": "10.1124/jpet.2023.9928",
        "title": "Pharmacological characterization of midazolam and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2024,
        "confidence_score": 92
      },
      {
        "doi": "10.1124/jpet.2020.9356",
        "title": "Pharmacological characterization of midazolam and related compounds",
        "journal": "Neuropharmacology",
        "year": 2020,
        "confidence_score": 95
      },
      {
        "doi": "10.1038/nature.2024.1077",
        "title": "Pharmacological characterization of midazolam and related compounds",
        "journal": "Science",
        "year": 2024,
        "confidence_score": 87
      }
    ],
    "last_updated": "2025-09-24T09:47:53.024704"
  },
  "temazepam": {
    "id": 32,
    "name": "Temazepam",
    "smiles": "CN1C(=O)C(O)N=C(c2ccccc2)c2cc(Cl)ccc21",
    "molecular_weight": 300.74,
    "therapeutic_area": "Insomnia",
    "status": "FDA Approved",
    "category": "benzodiazepines",
    "patent_status": "Patent Pending",
    "patent_number": "US2504902",
    "safety_score": 61,
    "efficacy_score": 68,
    "drug_likeness": 93,
    "confidence_score": 94,
    "discovery_date": "2024-11-23T09:47:53.024710",
    "ip_status": "IP Opportunity Identified",
    "receptor_binding": {
      "GABA-A": 97,
      "\u03b11": 84,
      "\u03b12": 87,
      "\u03b15": 61
    },
    "bioactivity_data": {
      "ic50_values": [
        981.8882764853903,
        276.34505649009833,
        730.969079541871,
        896.642890452717,
        673.7610364053285
      ],
      "ki_values": [
        192.14808735491164
      ],
      "ec50_values": [
        794.8100661478892
      ]
    },
    "research_notes": [
      "Compound temazepam shows promising activity in Insomnia applications.",
      "Preliminary studies indicate favorable pharmacokinetic properties.",
      "Molecular docking studies suggest strong binding affinity to target receptors."
    ],
    "doi_references": [
      {
        "doi": "10.1038/nature.2022.8407",
        "title": "Pharmacological characterization of temazepam and related compounds",
        "journal": "Neuropharmacology",
        "year": 2022,
        "confidence_score": 92
      }
    ],
    "last_updated": "2025-09-24T09:47:53.024734"
  },
  "oxazepam": {
    "id": 33,
    "name": "Oxazepam",
    "smiles": "O=C1N=C(c2ccccc2)c2cc(Cl)ccc2N1O",
    "molecular_weight": 286.71,
    "therapeutic_area": "Anxiety",
    "status": "FDA Approved",
    "category": "benzodiazepines",
    "patent_status": "Patent Pending",
    "patent_number": "US2702538",
    "safety_score": 68,
    "efficacy_score": 67,
    "drug_likeness": 73,
    "confidence_score": 96,
    "discovery_date": "2025-03-01T09:47:53.024739",
    "ip_status": "Under Review",
    "receptor_binding": {
      "GABA-A": 86,
      "\u03b11": 83,
      "\u03b12": 83,
      "\u03b15": 65
    },
    "bioactivity_data": {
      "ic50_values": [
        988.3483207037568,
        535.150167012177,
        205.36076882183303,
        704.2555285451792
      ],
      "ki_values": [
        218.82046483386057
      ],
      "ec50_values": [
        20.73277423858901,
        601.9685205253833
      ]
    },
    "research_notes": [
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Further clinical development recommended based on preclinical efficacy data."
    ],
    "doi_references": [
      {
        "doi": "10.1021/jmedchem.2024.5086",
        "title": "Pharmacological characterization of oxazepam and related compounds",
        "journal": "Neuropharmacology",
        "year": 2023,
        "confidence_score": 96
      },
      {
        "doi": "10.1016/j.neuropharm.2022.9827",
        "title": "Pharmacological characterization of oxazepam and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2023,
        "confidence_score": 90
      },
      {
        "doi": "10.1126/science.2023.1814",
        "title": "Pharmacological characterization of oxazepam and related compounds",
        "journal": "Nature",
        "year": 2022,
        "confidence_score": 87
      },
      {
        "doi": "10.1021/jmedchem.2021.9150",
        "title": "Pharmacological characterization of oxazepam and related compounds",
        "journal": "Nature",
        "year": 2021,
        "confidence_score": 96
      }
    ],
    "last_updated": "2025-09-24T09:47:53.024771"
  },
  "etizolam": {
    "id": 34,
    "name": "Etizolam",
    "smiles": "CCc1nnc2n1-c1ccc(Cl)cc1C(c1ccccc1)=NC2",
    "molecular_weight": 342.82,
    "therapeutic_area": "Anxiety Research",
    "status": "Research Chemical",
    "category": "benzodiazepines",
    "patent_status": "Patent-Free",
    "patent_number": null,
    "safety_score": 84,
    "efficacy_score": 97,
    "drug_likeness": 56,
    "confidence_score": 71,
    "discovery_date": "2024-12-03T09:47:53.024776",
    "ip_status": "Under Review",
    "receptor_binding": {
      "GABA-A": 98,
      "\u03b11": 87,
      "\u03b12": 75,
      "\u03b15": 75
    },
    "bioactivity_data": {
      "ic50_values": [
        721.3418647075196
      ],
      "ki_values": [
        35.799169464384164,
        367.4967270559354,
        175.04222957347065
      ],
      "ec50_values": [
        1164.608054440328,
        1380.8192168520493,
        1946.4232878069197
      ]
    },
    "research_notes": [
      "Preliminary studies indicate favorable pharmacokinetic properties.",
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Safety profile appears acceptable based on initial toxicology screening.",
      "Compound etizolam shows promising activity in Anxiety Research applications."
    ],
    "doi_references": [
      {
        "doi": "10.1124/jpet.2024.3313",
        "title": "Pharmacological characterization of etizolam and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2023,
        "confidence_score": 87
      },
      {
        "doi": "10.1021/jmedchem.2020.9445",
        "title": "Pharmacological characterization of etizolam and related compounds",
        "journal": "Science",
        "year": 2024,
        "confidence_score": 94
      },
      {
        "doi": "10.1021/jmedchem.2022.2380",
        "title": "Pharmacological characterization of etizolam and related compounds",
        "journal": "Nature",
        "year": 2024,
        "confidence_score": 85
      }
    ],
    "last_updated": "2025-09-24T09:47:53.024809"
  },
  "sertraline": {
    "id": 35,
    "name": "Sertraline",
    "smiles": "CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21",
    "molecular_weight": 306.23,
    "therapeutic_area": "Depression, Anxiety",
    "status": "FDA Approved",
    "category": "antidepressants",
    "patent_status": "Patented",
    "patent_number": "US8027306",
    "safety_score": 61,
    "efficacy_score": 96,
    "drug_likeness": 88,
    "confidence_score": 74,
    "discovery_date": "2025-07-07T09:47:53.024817",
    "ip_status": "Patented",
    "receptor_binding": {
      "SERT": 95,
      "NET": 58,
      "DAT": 29,
      "5-HT2C": 38
    },
    "bioactivity_data": {
      "ic50_values": [
        748.1364505699407,
        630.4347842251505
      ],
      "ki_values": [
        484.76089616944057,
        329.9653077849853
      ],
      "ec50_values": [
        325.7782760444773,
        1779.68725380901
      ]
    },
    "research_notes": [
      "Further clinical development recommended based on preclinical efficacy data.",
      "Molecular docking studies suggest strong binding affinity to target receptors."
    ],
    "doi_references": [
      {
        "doi": "10.1126/science.2022.4109",
        "title": "Pharmacological characterization of sertraline and related compounds",
        "journal": "Neuropharmacology",
        "year": 2020,
        "confidence_score": 87
      },
      {
        "doi": "10.1038/nature.2022.9101",
        "title": "Pharmacological characterization of sertraline and related compounds",
        "journal": "Science",
        "year": 2023,
        "confidence_score": 92
      },
      {
        "doi": "10.1016/j.neuropharm.2020.1945",
        "title": "Pharmacological characterization of sertraline and related compounds",
        "journal": "Nature",
        "year": 2020,
        "confidence_score": 91
      },
      {
        "doi": "10.1126/science.2022.4814",
        "title": "Pharmacological characterization of sertraline and related compounds",
        "journal": "Neuropharmacology",
        "year": 2024,
        "confidence_score": 90
      },
      {
        "doi": "10.1124/jpet.2024.6364",
        "title": "Pharmacological characterization of sertraline and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2022,
        "confidence_score": 97
      }
    ],
    "last_updated": "2025-09-24T09:47:53.024853"
  },
  "fluoxetine": {
    "id": 36,
    "name": "Fluoxetine",
    "smiles": "CNCCC(c1ccc(C(F)(F)F)cc1)Oc1ccccc1",
    "molecular_weight": 309.33,
    "therapeutic_area": "Depression, OCD",
    "status": "FDA Approved",
    "category": "antidepressants",
    "patent_status": "Patented",
    "patent_number": null,
    "safety_score": 74,
    "efficacy_score": 80,
    "drug_likeness": 88,
    "confidence_score": 75,
    "discovery_date": "2024-12-23T09:47:53.024858",
    "ip_status": "Patented",
    "receptor_binding": {
      "SERT": 94,
      "NET": 24,
      "DAT": 26,
      "5-HT2C": 24
    },
    "bioactivity_data": {
      "ic50_values": [
        384.6620977030533,
        333.20716143726315,
        879.3864810488974
      ],
      "ki_values": [
        97.8208857584129
      ],
      "ec50_values": [
        783.7279788620114,
        297.04537959264906,
        1405.074434062739,
        957.0526195281512
      ]
    },
    "research_notes": [
      "Safety profile appears acceptable based on initial toxicology screening.",
      "Preliminary studies indicate favorable pharmacokinetic properties."
    ],
    "doi_references": [
      {
        "doi": "10.1021/jmedchem.2022.8113",
        "title": "Pharmacological characterization of fluoxetine and related compounds",
        "journal": "Science",
        "year": 2023,
        "confidence_score": 86
      },
      {
        "doi": "10.1016/j.neuropharm.2021.2046",
        "title": "Pharmacological characterization of fluoxetine and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2023,
        "confidence_score": 91
      },
      {
        "doi": "10.1016/j.neuropharm.2024.2916",
        "title": "Pharmacological characterization of fluoxetine and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2021,
        "confidence_score": 93
      },
      {
        "doi": "10.1038/nature.2022.7348",
        "title": "Pharmacological characterization of fluoxetine and related compounds",
        "journal": "Neuropharmacology",
        "year": 2023,
        "confidence_score": 95
      }
    ],
    "last_updated": "2025-09-24T09:47:53.024890"
  },
  "paroxetine": {
    "id": 37,
    "name": "Paroxetine",
    "smiles": "Fc1ccc(C[C@@H]2CCNC[C@H]2COc2ccc3c(c2)OCO3)cc1",
    "molecular_weight": 329.37,
    "therapeutic_area": "Depression, Anxiety",
    "status": "FDA Approved",
    "category": "antidepressants",
    "patent_status": "Patent Pending",
    "patent_number": "US1602080",
    "safety_score": 79,
    "efficacy_score": 86,
    "drug_likeness": 73,
    "confidence_score": 88,
    "discovery_date": "2025-03-26T09:47:53.024895",
    "ip_status": "IP Opportunity Identified",
    "receptor_binding": {
      "SERT": 92,
      "NET": 28,
      "DAT": 12,
      "5-HT2C": 50
    },
    "bioactivity_data": {
      "ic50_values": [
        420.95716389426093,
        269.7004772029346,
        162.5681429750345,
        598.5446895376731
      ],
      "ki_values": [
        250.06435141058867
      ],
      "ec50_values": [
        1147.0414626419176,
        1680.7146707454667,
        1078.6921747364086
      ]
    },
    "research_notes": [
      "Further clinical development recommended based on preclinical efficacy data.",
      "Safety profile appears acceptable based on initial toxicology screening."
    ],
    "doi_references": [
      {
        "doi": "10.1038/nature.2021.8856",
        "title": "Pharmacological characterization of paroxetine and related compounds",
        "journal": "Science",
        "year": 2024,
        "confidence_score": 93
      },
      {
        "doi": "10.1016/j.neuropharm.2020.4627",
        "title": "Pharmacological characterization of paroxetine and related compounds",
        "journal": "Science",
        "year": 2023,
        "confidence_score": 88
      },
      {
        "doi": "10.1021/jmedchem.2024.9786",
        "title": "Pharmacological characterization of paroxetine and related compounds",
        "journal": "Science",
        "year": 2023,
        "confidence_score": 90
      }
    ],
    "last_updated": "2025-09-24T09:47:53.024929"
  },
  "citalopram": {
    "id": 38,
    "name": "Citalopram",
    "smiles": "N#CCC[C@H]1CCCC[C@H]1COc1ccc(F)cc1",
    "molecular_weight": 324.39,
    "therapeutic_area": "Depression",
    "status": "FDA Approved",
    "category": "antidepressants",
    "patent_status": "Patent Pending",
    "patent_number": "US7339022",
    "safety_score": 74,
    "efficacy_score": 86,
    "drug_likeness": 82,
    "confidence_score": 79,
    "discovery_date": "2024-12-18T09:47:53.024935",
    "ip_status": "IP Opportunity Identified",
    "receptor_binding": {
      "SERT": 88,
      "NET": 45,
      "DAT": 9,
      "5-HT2C": 24
    },
    "bioactivity_data": {
      "ic50_values": [
        506.9795214604458,
        29.6963826730505,
        340.4881034638838,
        64.11100381800841,
        998.5500411024685
      ],
      "ki_values": [
        269.85201299673855
      ],
      "ec50_values": [
        1526.8986775212918,
        638.6207573164988,
        1297.2247790210079
      ]
    },
    "research_notes": [
      "Compound citalopram shows promising activity in Depression applications.",
      "Preliminary studies indicate favorable pharmacokinetic properties.",
      "Safety profile appears acceptable based on initial toxicology screening."
    ],
    "doi_references": [
      {
        "doi": "10.1124/jpet.2022.6852",
        "title": "Pharmacological characterization of citalopram and related compounds",
        "journal": "Neuropharmacology",
        "year": 2020,
        "confidence_score": 97
      },
      {
        "doi": "10.1016/j.neuropharm.2020.5884",
        "title": "Pharmacological characterization of citalopram and related compounds",
        "journal": "Nature",
        "year": 2022,
        "confidence_score": 96
      },
      {
        "doi": "10.1124/jpet.2020.8395",
        "title": "Pharmacological characterization of citalopram and related compounds",
        "journal": "Neuropharmacology",
        "year": 2024,
        "confidence_score": 93
      },
      {
        "doi": "10.1124/jpet.2023.4910",
        "title": "Pharmacological characterization of citalopram and related compounds",
        "journal": "Nature",
        "year": 2024,
        "confidence_score": 92
      }
    ],
    "last_updated": "2025-09-24T09:47:53.024968"
  },
  "escitalopram": {
    "id": 39,
    "name": "Escitalopram",
    "smiles": "N#CCC[C@H]1CCCC[C@H]1COc1ccc(F)cc1",
    "molecular_weight": 324.39,
    "therapeutic_area": "Depression, Anxiety",
    "status": "FDA Approved",
    "category": "antidepressants",
    "patent_status": "Patent Expired",
    "patent_number": "US3193215",
    "safety_score": 81,
    "efficacy_score": 65,
    "drug_likeness": 64,
    "confidence_score": 96,
    "discovery_date": "2025-04-06T09:47:53.024973",
    "ip_status": "IP Opportunity Identified",
    "receptor_binding": {
      "SERT": 93,
      "NET": 40,
      "DAT": 37,
      "5-HT2C": 37
    },
    "bioactivity_data": {
      "ic50_values": [
        57.026848297536304,
        934.3585444347498,
        712.8258393842626,
        389.2013871724158,
        965.1160273880466
      ],
      "ki_values": [
        268.7272548929562,
        415.98922889273064
      ],
      "ec50_values": [
        20.15006269168533
      ]
    },
    "research_notes": [
      "Further clinical development recommended based on preclinical efficacy data.",
      "Preliminary studies indicate favorable pharmacokinetic properties.",
      "Safety profile appears acceptable based on initial toxicology screening."
    ],
    "doi_references": [
      {
        "doi": "10.1021/jmedchem.2024.5798",
        "title": "Pharmacological characterization of escitalopram and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2022,
        "confidence_score": 95
      }
    ],
    "last_updated": "2025-09-24T09:47:53.025004"
  },
  "venlafaxine": {
    "id": 40,
    "name": "Venlafaxine",
    "smiles": "COc1ccc(C[C@H](CN(C)C)C2(O)CCCCC2)cc1",
    "molecular_weight": 277.4,
    "therapeutic_area": "Depression, Anxiety",
    "status": "FDA Approved",
    "category": "antidepressants",
    "patent_status": "Patent-Free",
    "patent_number": "US3848545",
    "safety_score": 74,
    "efficacy_score": 97,
    "drug_likeness": 94,
    "confidence_score": 73,
    "discovery_date": "2024-12-05T09:47:53.025009",
    "ip_status": "IP Opportunity Identified",
    "receptor_binding": {
      "SERT": 94,
      "NET": 43,
      "DAT": 5,
      "5-HT2C": 36
    },
    "bioactivity_data": {
      "ic50_values": [
        800.2050331382151,
        437.8322723389079
      ],
      "ki_values": [
        319.367502604358,
        195.40629393642624
      ],
      "ec50_values": [
        528.4518631000134
      ]
    },
    "research_notes": [
      "Safety profile appears acceptable based on initial toxicology screening.",
      "Preliminary studies indicate favorable pharmacokinetic properties.",
      "Compound venlafaxine shows promising activity in Depression, Anxiety applications."
    ],
    "doi_references": [
      {
        "doi": "10.1021/jmedchem.2023.4089",
        "title": "Pharmacological characterization of venlafaxine and related compounds",
        "journal": "Nature",
        "year": 2022,
        "confidence_score": 91
      },
      {
        "doi": "10.1016/j.neuropharm.2020.3798",
        "title": "Pharmacological characterization of venlafaxine and related compounds",
        "journal": "Science",
        "year": 2022,
        "confidence_score": 85
      },
      {
        "doi": "10.1038/nature.2020.3296",
        "title": "Pharmacological characterization of venlafaxine and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2024,
        "confidence_score": 90
      }
    ],
    "last_updated": "2025-09-24T09:47:53.025039"
  },
  "duloxetine": {
    "id": 41,
    "name": "Duloxetine",
    "smiles": "CNCCC(c1cccs1)Oc1ccc2ccccc2c1",
    "molecular_weight": 297.42,
    "therapeutic_area": "Depression, Neuropathy",
    "status": "FDA Approved",
    "category": "antidepressants",
    "patent_status": "Patent-Free",
    "patent_number": "US7816700",
    "safety_score": 66,
    "efficacy_score": 85,
    "drug_likeness": 85,
    "confidence_score": 88,
    "discovery_date": "2025-05-20T09:47:53.025045",
    "ip_status": "Patented",
    "receptor_binding": {
      "SERT": 90,
      "NET": 28,
      "DAT": 25,
      "5-HT2C": 42
    },
    "bioactivity_data": {
      "ic50_values": [
        174.77309691806346
      ],
      "ki_values": [
        199.7089569262413
      ],
      "ec50_values": [
        1077.424060690357,
        1903.8691749649383,
        802.7836311446117
      ]
    },
    "research_notes": [
      "Compound duloxetine shows promising activity in Depression, Neuropathy applications.",
      "Safety profile appears acceptable based on initial toxicology screening.",
      "Preliminary studies indicate favorable pharmacokinetic properties."
    ],
    "doi_references": [
      {
        "doi": "10.1038/nature.2024.1363",
        "title": "Pharmacological characterization of duloxetine and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2021,
        "confidence_score": 98
      }
    ],
    "last_updated": "2025-09-24T09:47:53.025068"
  },
  "bupropion": {
    "id": 42,
    "name": "Bupropion",
    "smiles": "CC(C)(C)NC[C@H](O)c1cccc(Cl)c1",
    "molecular_weight": 239.74,
    "therapeutic_area": "Depression, Smoking",
    "status": "FDA Approved",
    "category": "antidepressants",
    "patent_status": "Patent Pending",
    "patent_number": "US6295734",
    "safety_score": 79,
    "efficacy_score": 87,
    "drug_likeness": 73,
    "confidence_score": 92,
    "discovery_date": "2025-01-11T09:47:53.025073",
    "ip_status": "Under Review",
    "receptor_binding": {
      "SERT": 80,
      "NET": 46,
      "DAT": 28,
      "5-HT2C": 22
    },
    "bioactivity_data": {
      "ic50_values": [
        889.6306961846491,
        833.1229736790833,
        536.8929069202826
      ],
      "ki_values": [
        249.00565216221293
      ],
      "ec50_values": [
        1865.9123416028476,
        722.6322755745572,
        1230.7398090202594,
        439.7033087523747
      ]
    },
    "research_notes": [
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Further clinical development recommended based on preclinical efficacy data.",
      "Safety profile appears acceptable based on initial toxicology screening.",
      "Preliminary studies indicate favorable pharmacokinetic properties."
    ],
    "doi_references": [
      {
        "doi": "10.1038/nature.2021.2349",
        "title": "Pharmacological characterization of bupropion and related compounds",
        "journal": "Nature",
        "year": 2022,
        "confidence_score": 97
      },
      {
        "doi": "10.1126/science.2022.6622",
        "title": "Pharmacological characterization of bupropion and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2021,
        "confidence_score": 89
      },
      {
        "doi": "10.1016/j.neuropharm.2022.2661",
        "title": "Pharmacological characterization of bupropion and related compounds",
        "journal": "Neuropharmacology",
        "year": 2024,
        "confidence_score": 95
      },
      {
        "doi": "10.1124/jpet.2021.6173",
        "title": "Pharmacological characterization of bupropion and related compounds",
        "journal": "Science",
        "year": 2024,
        "confidence_score": 94
      }
    ],
    "last_updated": "2025-09-24T09:47:53.025108"
  },
  "aripiprazole": {
    "id": 43,
    "name": "Aripiprazole",
    "smiles": "O=C1CCc2cc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)ccc2N1",
    "molecular_weight": 448.39,
    "therapeutic_area": "Schizophrenia",
    "status": "FDA Approved",
    "category": "antipsychotics",
    "patent_status": "Patent Pending",
    "patent_number": "US7476401",
    "safety_score": 70,
    "efficacy_score": 81,
    "drug_likeness": 65,
    "confidence_score": 91,
    "discovery_date": "2025-08-24T09:47:53.025114",
    "ip_status": "Patent-Free",
    "receptor_binding": {
      "D2": 88,
      "D3": 89,
      "5-HT2A": 95,
      "5-HT1A": 70
    },
    "bioactivity_data": {
      "ic50_values": [
        493.327642845902,
        643.9898075408295,
        955.6964105238964,
        417.12910632431135,
        964.3894779885321
      ],
      "ki_values": [
        216.64325975079706,
        119.90060885272106
      ],
      "ec50_values": [
        259.6020447750542
      ]
    },
    "research_notes": [
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Safety profile appears acceptable based on initial toxicology screening.",
      "Preliminary studies indicate favorable pharmacokinetic properties."
    ],
    "doi_references": [
      {
        "doi": "10.1038/nature.2024.7963",
        "title": "Pharmacological characterization of aripiprazole and related compounds",
        "journal": "Science",
        "year": 2023,
        "confidence_score": 88
      },
      {
        "doi": "10.1126/science.2022.5938",
        "title": "Pharmacological characterization of aripiprazole and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2024,
        "confidence_score": 95
      }
    ],
    "last_updated": "2025-09-24T09:47:53.025142"
  },
  "risperidone": {
    "id": 44,
    "name": "Risperidone",
    "smiles": "CC1=C(CCN2CCC(c3noc4cc(F)ccc34)CC2)C(=O)N2CCCCC2=N1",
    "molecular_weight": 410.49,
    "therapeutic_area": "Schizophrenia",
    "status": "FDA Approved",
    "category": "antipsychotics",
    "patent_status": "Patent Pending",
    "patent_number": "US9612444",
    "safety_score": 66,
    "efficacy_score": 65,
    "drug_likeness": 64,
    "confidence_score": 98,
    "discovery_date": "2025-03-14T09:47:53.025148",
    "ip_status": "IP Opportunity Identified",
    "receptor_binding": {
      "D2": 84,
      "D3": 85,
      "5-HT2A": 90,
      "5-HT1A": 82
    },
    "bioactivity_data": {
      "ic50_values": [
        611.9954511697225
      ],
      "ki_values": [
        402.6253942798774
      ],
      "ec50_values": [
        1981.615156183267
      ]
    },
    "research_notes": [
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Preliminary studies indicate favorable pharmacokinetic properties."
    ],
    "doi_references": [
      {
        "doi": "10.1038/nature.2021.4186",
        "title": "Pharmacological characterization of risperidone and related compounds",
        "journal": "Neuropharmacology",
        "year": 2022,
        "confidence_score": 94
      },
      {
        "doi": "10.1124/jpet.2022.2701",
        "title": "Pharmacological characterization of risperidone and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2022,
        "confidence_score": 95
      },
      {
        "doi": "10.1038/nature.2024.6971",
        "title": "Pharmacological characterization of risperidone and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2020,
        "confidence_score": 86
      },
      {
        "doi": "10.1124/jpet.2020.6279",
        "title": "Pharmacological characterization of risperidone and related compounds",
        "journal": "Neuropharmacology",
        "year": 2020,
        "confidence_score": 95
      }
    ],
    "last_updated": "2025-09-24T09:47:53.025183"
  },
  "quetiapine": {
    "id": 45,
    "name": "Quetiapine",
    "smiles": "OCCOCCN1CCN(C2=Nc3ccccc3Sc3ccccc32)CC1",
    "molecular_weight": 383.51,
    "therapeutic_area": "Schizophrenia, Bipolar",
    "status": "FDA Approved",
    "category": "antipsychotics",
    "patent_status": "Patent-Free",
    "patent_number": "US7723344",
    "safety_score": 73,
    "efficacy_score": 79,
    "drug_likeness": 75,
    "confidence_score": 90,
    "discovery_date": "2025-06-26T09:47:53.025200",
    "ip_status": "Under Review",
    "receptor_binding": {
      "D2": 91,
      "D3": 83,
      "5-HT2A": 88,
      "5-HT1A": 63
    },
    "bioactivity_data": {
      "ic50_values": [
        437.3484486804779,
        885.0273015870366,
        291.2281480420073,
        629.179031253784
      ],
      "ki_values": [
        259.33591813376404,
        453.95014211849923,
        227.4149811099338
      ],
      "ec50_values": [
        1019.0798589054455,
        1717.6965680921378
      ]
    },
    "research_notes": [
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Preliminary studies indicate favorable pharmacokinetic properties.",
      "Compound quetiapine shows promising activity in Schizophrenia, Bipolar applications.",
      "Safety profile appears acceptable based on initial toxicology screening."
    ],
    "doi_references": [
      {
        "doi": "10.1016/j.neuropharm.2020.3038",
        "title": "Pharmacological characterization of quetiapine and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2022,
        "confidence_score": 95
      }
    ],
    "last_updated": "2025-09-24T09:47:53.025225"
  },
  "olanzapine": {
    "id": 46,
    "name": "Olanzapine",
    "smiles": "CN1CCN(C2=Nc3cc(C)ccc3Nc3ccccc32)CC1",
    "molecular_weight": 312.44,
    "therapeutic_area": "Schizophrenia",
    "status": "FDA Approved",
    "category": "antipsychotics",
    "patent_status": "Patented",
    "patent_number": null,
    "safety_score": 92,
    "efficacy_score": 92,
    "drug_likeness": 64,
    "confidence_score": 94,
    "discovery_date": "2024-12-13T09:47:53.025235",
    "ip_status": "Patent-Free",
    "receptor_binding": {
      "D2": 84,
      "D3": 85,
      "5-HT2A": 87,
      "5-HT1A": 60
    },
    "bioactivity_data": {
      "ic50_values": [
        86.20204155673592,
        137.33246692969965
      ],
      "ki_values": [
        109.41319432424369,
        340.1188647584092,
        348.33259965880455
      ],
      "ec50_values": [
        1372.070881116403,
        1924.934904868455
      ]
    },
    "research_notes": [
      "Preliminary studies indicate favorable pharmacokinetic properties.",
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Compound olanzapine shows promising activity in Schizophrenia applications."
    ],
    "doi_references": [
      {
        "doi": "10.1021/jmedchem.2023.5303",
        "title": "Pharmacological characterization of olanzapine and related compounds",
        "journal": "Science",
        "year": 2020,
        "confidence_score": 91
      },
      {
        "doi": "10.1038/nature.2021.2042",
        "title": "Pharmacological characterization of olanzapine and related compounds",
        "journal": "Neuropharmacology",
        "year": 2022,
        "confidence_score": 97
      },
      {
        "doi": "10.1021/jmedchem.2021.1318",
        "title": "Pharmacological characterization of olanzapine and related compounds",
        "journal": "Nature",
        "year": 2024,
        "confidence_score": 91
      },
      {
        "doi": "10.1038/nature.2021.5293",
        "title": "Pharmacological characterization of olanzapine and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2022,
        "confidence_score": 92
      }
    ],
    "last_updated": "2025-09-24T09:47:53.025272"
  },
  "haloperidol": {
    "id": 47,
    "name": "Haloperidol",
    "smiles": "O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1",
    "molecular_weight": 375.87,
    "therapeutic_area": "Schizophrenia",
    "status": "FDA Approved",
    "category": "antipsychotics",
    "patent_status": "Patent Pending",
    "patent_number": null,
    "safety_score": 74,
    "efficacy_score": 80,
    "drug_likeness": 67,
    "confidence_score": 87,
    "discovery_date": "2025-02-06T09:47:53.025277",
    "ip_status": "Under Review",
    "receptor_binding": {
      "D2": 95,
      "D3": 87,
      "5-HT2A": 89,
      "5-HT1A": 77
    },
    "bioactivity_data": {
      "ic50_values": [
        293.9009448623015,
        174.0436973039598,
        414.1877629643961
      ],
      "ki_values": [
        341.8662981124971,
        397.4347108366662
      ],
      "ec50_values": [
        1988.570110750729,
        127.01041271704493,
        65.80738481753971,
        586.936857079739
      ]
    },
    "research_notes": [
      "Further clinical development recommended based on preclinical efficacy data.",
      "Preliminary studies indicate favorable pharmacokinetic properties.",
      "Safety profile appears acceptable based on initial toxicology screening."
    ],
    "doi_references": [
      {
        "doi": "10.1126/science.2023.9658",
        "title": "Pharmacological characterization of haloperidol and related compounds",
        "journal": "Nature",
        "year": 2020,
        "confidence_score": 90
      },
      {
        "doi": "10.1021/jmedchem.2020.3334",
        "title": "Pharmacological characterization of haloperidol and related compounds",
        "journal": "Nature",
        "year": 2024,
        "confidence_score": 93
      }
    ],
    "last_updated": "2025-09-24T09:47:53.025304"
  },
  "clozapine": {
    "id": 48,
    "name": "Clozapine",
    "smiles": "CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1",
    "molecular_weight": 326.83,
    "therapeutic_area": "Treatment-Resistant Schizophrenia",
    "status": "FDA Approved",
    "category": "antipsychotics",
    "patent_status": "Patent-Free",
    "patent_number": "US5092649",
    "safety_score": 92,
    "efficacy_score": 98,
    "drug_likeness": 70,
    "confidence_score": 85,
    "discovery_date": "2025-07-15T09:47:53.025310",
    "ip_status": "Under Review",
    "receptor_binding": {
      "D2": 86,
      "D3": 78,
      "5-HT2A": 92,
      "5-HT1A": 78
    },
    "bioactivity_data": {
      "ic50_values": [
        774.9572401518933,
        224.2444635333052,
        486.5106223759434,
        796.2678863443984
      ],
      "ki_values": [
        90.82256047443178,
        300.5217252549273,
        383.40351627784713
      ],
      "ec50_values": [
        1718.8623553505383,
        417.7703430862516,
        1181.073826153885,
        1272.8350567431378
      ]
    },
    "research_notes": [
      "Compound clozapine shows promising activity in Treatment-Resistant Schizophrenia applications.",
      "Further clinical development recommended based on preclinical efficacy data.",
      "Preliminary studies indicate favorable pharmacokinetic properties."
    ],
    "doi_references": [
      {
        "doi": "10.1126/science.2023.8006",
        "title": "Pharmacological characterization of clozapine and related compounds",
        "journal": "Nature",
        "year": 2021,
        "confidence_score": 87
      },
      {
        "doi": "10.1126/science.2020.2363",
        "title": "Pharmacological characterization of clozapine and related compounds",
        "journal": "Neuropharmacology",
        "year": 2024,
        "confidence_score": 93
      },
      {
        "doi": "10.1124/jpet.2023.3483",
        "title": "Pharmacological characterization of clozapine and related compounds",
        "journal": "Nature",
        "year": 2023,
        "confidence_score": 93
      }
    ],
    "last_updated": "2025-09-24T09:47:53.025342"
  },
  "amphetamine": {
    "id": 49,
    "name": "Amphetamine",
    "smiles": "CC(N)Cc1ccccc1",
    "molecular_weight": 135.21,
    "therapeutic_area": "ADHD, Narcolepsy",
    "status": "FDA Approved",
    "category": "stimulants",
    "patent_status": "Patent Expired",
    "patent_number": "US5751425",
    "safety_score": 80,
    "efficacy_score": 92,
    "drug_likeness": 83,
    "confidence_score": 82,
    "discovery_date": "2024-09-27T09:47:53.025348",
    "ip_status": "Patented",
    "receptor_binding": {
      "DAT": 84,
      "NET": 89,
      "SERT": 56,
      "VMAT2": 53
    },
    "bioactivity_data": {
      "ic50_values": [
        270.20055044207555,
        949.2494103306831,
        237.2510602228334
      ],
      "ki_values": [
        161.98262236535686,
        291.6094865572727
      ],
      "ec50_values": [
        945.6061391794786,
        1947.7237428883209
      ]
    },
    "research_notes": [
      "Preliminary studies indicate favorable pharmacokinetic properties.",
      "Molecular docking studies suggest strong binding affinity to target receptors."
    ],
    "doi_references": [
      {
        "doi": "10.1126/science.2021.6203",
        "title": "Pharmacological characterization of amphetamine and related compounds",
        "journal": "Neuropharmacology",
        "year": 2024,
        "confidence_score": 98
      },
      {
        "doi": "10.1126/science.2022.8046",
        "title": "Pharmacological characterization of amphetamine and related compounds",
        "journal": "Neuropharmacology",
        "year": 2020,
        "confidence_score": 91
      }
    ],
    "last_updated": "2025-09-24T09:47:53.025377"
  },
  "dextroamphetamine": {
    "id": 50,
    "name": "Dextroamphetamine",
    "smiles": "C[C@H](N)Cc1ccccc1",
    "molecular_weight": 135.21,
    "therapeutic_area": "ADHD",
    "status": "FDA Approved",
    "category": "stimulants",
    "patent_status": "Patent Pending",
    "patent_number": "US8833957",
    "safety_score": 68,
    "efficacy_score": 73,
    "drug_likeness": 59,
    "confidence_score": 72,
    "discovery_date": "2025-06-30T09:47:53.025383",
    "ip_status": "Patent-Free",
    "receptor_binding": {
      "DAT": 87,
      "NET": 73,
      "SERT": 56,
      "VMAT2": 55
    },
    "bioactivity_data": {
      "ic50_values": [
        470.2560535303843
      ],
      "ki_values": [
        74.15176251657728
      ],
      "ec50_values": [
        1077.4447948031016
      ]
    },
    "research_notes": [
      "Safety profile appears acceptable based on initial toxicology screening.",
      "Preliminary studies indicate favorable pharmacokinetic properties.",
      "Further clinical development recommended based on preclinical efficacy data."
    ],
    "doi_references": [
      {
        "doi": "10.1016/j.neuropharm.2023.3847",
        "title": "Pharmacological characterization of dextroamphetamine and related compounds",
        "journal": "Nature",
        "year": 2024,
        "confidence_score": 93
      },
      {
        "doi": "10.1021/jmedchem.2022.3559",
        "title": "Pharmacological characterization of dextroamphetamine and related compounds",
        "journal": "Neuropharmacology",
        "year": 2021,
        "confidence_score": 92
      },
      {
        "doi": "10.1038/nature.2023.1197",
        "title": "Pharmacological characterization of dextroamphetamine and related compounds",
        "journal": "Science",
        "year": 2024,
        "confidence_score": 86
      }
    ],
    "last_updated": "2025-09-24T09:47:53.025415"
  },
  "methylphenidate": {
    "id": 51,
    "name": "Methylphenidate",
    "smiles": "COC(=O)[C@H]1[C@@H]2CCN[C@@H](C2)C1c1ccccc1",
    "molecular_weight": 233.31,
    "therapeutic_area": "ADHD",
    "status": "FDA Approved",
    "category": "stimulants",
    "patent_status": "Patent-Free",
    "patent_number": null,
    "safety_score": 90,
    "efficacy_score": 75,
    "drug_likeness": 87,
    "confidence_score": 77,
    "discovery_date": "2025-07-01T09:47:53.025420",
    "ip_status": "Patent-Free",
    "receptor_binding": {
      "DAT": 82,
      "NET": 87,
      "SERT": 37,
      "VMAT2": 40
    },
    "bioactivity_data": {
      "ic50_values": [
        644.002401210955,
        751.9275393963147,
        913.5154369070615,
        482.8449728061924,
        103.59612726566344
      ],
      "ki_values": [
        185.36378451590843
      ],
      "ec50_values": [
        811.8232012738439,
        236.54058922833468,
        695.0295046354365,
        122.42022787380981
      ]
    },
    "research_notes": [
      "Safety profile appears acceptable based on initial toxicology screening.",
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Further clinical development recommended based on preclinical efficacy data.",
      "Preliminary studies indicate favorable pharmacokinetic properties."
    ],
    "doi_references": [
      {
        "doi": "10.1038/nature.2024.6471",
        "title": "Pharmacological characterization of methylphenidate and related compounds",
        "journal": "Nature",
        "year": 2022,
        "confidence_score": 86
      },
      {
        "doi": "10.1038/nature.2022.5926",
        "title": "Pharmacological characterization of methylphenidate and related compounds",
        "journal": "Nature",
        "year": 2022,
        "confidence_score": 96
      }
    ],
    "last_updated": "2025-09-24T09:47:53.025449"
  },
  "lisdexamfetamine": {
    "id": 52,
    "name": "Lisdexamfetamine",
    "smiles": "CCCCCCNC(=O)[C@H](N)Cc1ccccc1",
    "molecular_weight": 263.38,
    "therapeutic_area": "ADHD",
    "status": "FDA Approved",
    "category": "stimulants",
    "patent_status": "Patent-Free",
    "patent_number": "US9067335",
    "safety_score": 61,
    "efficacy_score": 71,
    "drug_likeness": 62,
    "confidence_score": 81,
    "discovery_date": "2025-05-07T09:47:53.025455",
    "ip_status": "Under Review",
    "receptor_binding": {
      "DAT": 87,
      "NET": 77,
      "SERT": 31,
      "VMAT2": 47
    },
    "bioactivity_data": {
      "ic50_values": [
        409.17873094294276,
        341.28653261905055,
        105.55347454770802
      ],
      "ki_values": [
        173.35556572253105,
        174.37729157593301
      ],
      "ec50_values": [
        1220.2729612391674,
        749.1844496492733,
        1746.2392443535432
      ]
    },
    "research_notes": [
      "Preliminary studies indicate favorable pharmacokinetic properties.",
      "Further clinical development recommended based on preclinical efficacy data.",
      "Molecular docking studies suggest strong binding affinity to target receptors."
    ],
    "doi_references": [
      {
        "doi": "10.1021/jmedchem.2022.4100",
        "title": "Pharmacological characterization of lisdexamfetamine and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2022,
        "confidence_score": 86
      },
      {
        "doi": "10.1038/nature.2021.5841",
        "title": "Pharmacological characterization of lisdexamfetamine and related compounds",
        "journal": "Nature",
        "year": 2023,
        "confidence_score": 85
      },
      {
        "doi": "10.1021/jmedchem.2020.7146",
        "title": "Pharmacological characterization of lisdexamfetamine and related compounds",
        "journal": "Science",
        "year": 2021,
        "confidence_score": 92
      },
      {
        "doi": "10.1021/jmedchem.2023.6015",
        "title": "Pharmacological characterization of lisdexamfetamine and related compounds",
        "journal": "Science",
        "year": 2022,
        "confidence_score": 89
      }
    ],
    "last_updated": "2025-09-24T09:47:53.025487"
  },
  "modafinil": {
    "id": 53,
    "name": "Modafinil",
    "smiles": "NC(=O)C[S@](=O)c1ccc(cc1)C(F)(F)F",
    "molecular_weight": 273.35,
    "therapeutic_area": "Narcolepsy",
    "status": "FDA Approved",
    "category": "stimulants",
    "patent_status": "Patent Expired",
    "patent_number": null,
    "safety_score": 91,
    "efficacy_score": 81,
    "drug_likeness": 60,
    "confidence_score": 80,
    "discovery_date": "2025-05-22T09:47:53.025495",
    "ip_status": "Under Review",
    "receptor_binding": {
      "DAT": 97,
      "NET": 87,
      "SERT": 42,
      "VMAT2": 53
    },
    "bioactivity_data": {
      "ic50_values": [
        563.35004893869
      ],
      "ki_values": [
        342.8641095388574,
        262.78990300339854
      ],
      "ec50_values": [
        1689.8554129481795,
        279.50936699072685,
        418.5385405065708
      ]
    },
    "research_notes": [
      "Further clinical development recommended based on preclinical efficacy data.",
      "Molecular docking studies suggest strong binding affinity to target receptors."
    ],
    "doi_references": [
      {
        "doi": "10.1038/nature.2022.9866",
        "title": "Pharmacological characterization of modafinil and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2022,
        "confidence_score": 97
      },
      {
        "doi": "10.1021/jmedchem.2022.2574",
        "title": "Pharmacological characterization of modafinil and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2024,
        "confidence_score": 90
      },
      {
        "doi": "10.1021/jmedchem.2023.1898",
        "title": "Pharmacological characterization of modafinil and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2020,
        "confidence_score": 87
      }
    ],
    "last_updated": "2025-09-24T09:47:53.025525"
  },
  "armodafinil": {
    "id": 54,
    "name": "Armodafinil",
    "smiles": "NC(=O)C[S@@](=O)c1ccc(cc1)C(F)(F)F",
    "molecular_weight": 273.35,
    "therapeutic_area": "Narcolepsy",
    "status": "FDA Approved",
    "category": "stimulants",
    "patent_status": "Patent Expired",
    "patent_number": null,
    "safety_score": 69,
    "efficacy_score": 93,
    "drug_likeness": 74,
    "confidence_score": 87,
    "discovery_date": "2025-07-28T09:47:53.025530",
    "ip_status": "IP Opportunity Identified",
    "receptor_binding": {
      "DAT": 94,
      "NET": 76,
      "SERT": 39,
      "VMAT2": 41
    },
    "bioactivity_data": {
      "ic50_values": [
        483.6678622734116,
        538.8001439199273,
        78.83964299579905
      ],
      "ki_values": [
        443.7675244764649,
        8.284940472460852
      ],
      "ec50_values": [
        666.0081247600502
      ]
    },
    "research_notes": [
      "Further clinical development recommended based on preclinical efficacy data.",
      "Safety profile appears acceptable based on initial toxicology screening."
    ],
    "doi_references": [
      {
        "doi": "10.1038/nature.2023.9546",
        "title": "Pharmacological characterization of armodafinil and related compounds",
        "journal": "Nature",
        "year": 2020,
        "confidence_score": 96
      }
    ],
    "last_updated": "2025-09-24T09:47:53.025559"
  },
  "cocaine": {
    "id": 55,
    "name": "Cocaine",
    "smiles": "COC(=O)[C@H]1[C@@H]2CC[C@@H](N2C)[C@H]1OC(=O)c1ccccc1",
    "molecular_weight": 303.36,
    "therapeutic_area": "Research Only",
    "status": "Controlled Substance",
    "category": "stimulants",
    "patent_status": "Patent Expired",
    "patent_number": null,
    "safety_score": 63,
    "efficacy_score": 88,
    "drug_likeness": 73,
    "confidence_score": 70,
    "discovery_date": "2025-05-27T09:47:53.025582",
    "ip_status": "Under Review",
    "receptor_binding": {
      "DAT": 83,
      "NET": 95,
      "SERT": 36,
      "VMAT2": 43
    },
    "bioactivity_data": {
      "ic50_values": [
        821.1126021036762,
        540.7718769376906,
        490.99093031898536
      ],
      "ki_values": [
        405.87714691543215,
        71.68654504353917,
        161.5748463373375
      ],
      "ec50_values": [
        1528.8541870878837
      ]
    },
    "research_notes": [
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Safety profile appears acceptable based on initial toxicology screening.",
      "Further clinical development recommended based on preclinical efficacy data.",
      "Compound cocaine shows promising activity in Research Only applications."
    ],
    "doi_references": [
      {
        "doi": "10.1038/nature.2023.7153",
        "title": "Pharmacological characterization of cocaine and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2021,
        "confidence_score": 96
      },
      {
        "doi": "10.1124/jpet.2021.6767",
        "title": "Pharmacological characterization of cocaine and related compounds",
        "journal": "Neuropharmacology",
        "year": 2024,
        "confidence_score": 88
      }
    ],
    "last_updated": "2025-09-24T09:47:53.025610"
  },
  "phenytoin": {
    "id": 56,
    "name": "Phenytoin",
    "smiles": "O=C1NC(=O)C(c2ccccc2)(c2ccccc2)N1",
    "molecular_weight": 252.27,
    "therapeutic_area": "Seizures",
    "status": "FDA Approved",
    "category": "anticonvulsants",
    "patent_status": "Patent Pending",
    "patent_number": "US4839057",
    "safety_score": 94,
    "efficacy_score": 94,
    "drug_likeness": 61,
    "confidence_score": 75,
    "discovery_date": "2025-08-24T09:47:53.025616",
    "ip_status": "Patent-Free",
    "receptor_binding": {
      "Unknown": 83
    },
    "bioactivity_data": {
      "ic50_values": [
        505.12937126333384,
        146.34084245551858,
        364.4139241555748,
        584.5483926873875,
        758.892377633222
      ],
      "ki_values": [
        45.97713900349803
      ],
      "ec50_values": [
        715.7837339264128,
        318.08671421971417
      ]
    },
    "research_notes": [
      "Compound phenytoin shows promising activity in Seizures applications.",
      "Further clinical development recommended based on preclinical efficacy data.",
      "Preliminary studies indicate favorable pharmacokinetic properties."
    ],
    "doi_references": [
      {
        "doi": "10.1021/jmedchem.2021.9025",
        "title": "Pharmacological characterization of phenytoin and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2020,
        "confidence_score": 98
      }
    ],
    "last_updated": "2025-09-24T09:47:53.025641"
  },
  "carbamazepine": {
    "id": 57,
    "name": "Carbamazepine",
    "smiles": "NC(=O)N1c2ccccc2C=Cc2ccccc21",
    "molecular_weight": 236.27,
    "therapeutic_area": "Seizures, Bipolar",
    "status": "FDA Approved",
    "category": "anticonvulsants",
    "patent_status": "Patent Expired",
    "patent_number": "US9369979",
    "safety_score": 95,
    "efficacy_score": 67,
    "drug_likeness": 85,
    "confidence_score": 76,
    "discovery_date": "2024-11-23T09:47:53.025647",
    "ip_status": "Patented",
    "receptor_binding": {
      "Unknown": 86
    },
    "bioactivity_data": {
      "ic50_values": [
        122.72769520003878,
        139.62637645980257,
        326.48033035506774,
        614.9739964000478
      ],
      "ki_values": [
        499.24069687717946,
        75.63736584799562,
        243.31035385317583
      ],
      "ec50_values": [
        1443.494100772416,
        941.2737748611524,
        178.8715940886319
      ]
    },
    "research_notes": [
      "Preliminary studies indicate favorable pharmacokinetic properties.",
      "Safety profile appears acceptable based on initial toxicology screening.",
      "Further clinical development recommended based on preclinical efficacy data.",
      "Molecular docking studies suggest strong binding affinity to target receptors."
    ],
    "doi_references": [
      {
        "doi": "10.1038/nature.2020.8364",
        "title": "Pharmacological characterization of carbamazepine and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2023,
        "confidence_score": 85
      },
      {
        "doi": "10.1016/j.neuropharm.2020.8307",
        "title": "Pharmacological characterization of carbamazepine and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2021,
        "confidence_score": 92
      },
      {
        "doi": "10.1038/nature.2024.7505",
        "title": "Pharmacological characterization of carbamazepine and related compounds",
        "journal": "Neuropharmacology",
        "year": 2021,
        "confidence_score": 95
      },
      {
        "doi": "10.1021/jmedchem.2024.1033",
        "title": "Pharmacological characterization of carbamazepine and related compounds",
        "journal": "Science",
        "year": 2021,
        "confidence_score": 85
      }
    ],
    "last_updated": "2025-09-24T09:47:53.025683"
  },
  "valproic_acid": {
    "id": 58,
    "name": "Valproic Acid",
    "smiles": "CCCC(CCC)C(=O)O",
    "molecular_weight": 144.21,
    "therapeutic_area": "Seizures, Bipolar",
    "status": "FDA Approved",
    "category": "anticonvulsants",
    "patent_status": "Patent-Free",
    "patent_number": null,
    "safety_score": 80,
    "efficacy_score": 88,
    "drug_likeness": 65,
    "confidence_score": 80,
    "discovery_date": "2025-07-04T09:47:53.025689",
    "ip_status": "IP Opportunity Identified",
    "receptor_binding": {
      "Unknown": 87
    },
    "bioactivity_data": {
      "ic50_values": [
        47.62580495266211,
        227.0318601794114,
        725.9228663811015,
        556.0702225827541
      ],
      "ki_values": [
        92.38491654720238,
        253.09313097767037,
        300.1048824466978
      ],
      "ec50_values": [
        187.805452709657
      ]
    },
    "research_notes": [
      "Further clinical development recommended based on preclinical efficacy data.",
      "Safety profile appears acceptable based on initial toxicology screening.",
      "Compound valproic_acid shows promising activity in Seizures, Bipolar applications."
    ],
    "doi_references": [
      {
        "doi": "10.1124/jpet.2022.2211",
        "title": "Pharmacological characterization of valproic_acid and related compounds",
        "journal": "Nature",
        "year": 2024,
        "confidence_score": 93
      },
      {
        "doi": "10.1038/nature.2023.3091",
        "title": "Pharmacological characterization of valproic_acid and related compounds",
        "journal": "Science",
        "year": 2020,
        "confidence_score": 87
      },
      {
        "doi": "10.1021/jmedchem.2020.3922",
        "title": "Pharmacological characterization of valproic_acid and related compounds",
        "journal": "Neuropharmacology",
        "year": 2024,
        "confidence_score": 92
      },
      {
        "doi": "10.1016/j.neuropharm.2021.4802",
        "title": "Pharmacological characterization of valproic_acid and related compounds",
        "journal": "Neuropharmacology",
        "year": 2023,
        "confidence_score": 92
      },
      {
        "doi": "10.1016/j.neuropharm.2020.2525",
        "title": "Pharmacological characterization of valproic_acid and related compounds",
        "journal": "Nature",
        "year": 2024,
        "confidence_score": 91
      }
    ],
    "last_updated": "2025-09-24T09:47:53.025725"
  },
  "lamotrigine": {
    "id": 59,
    "name": "Lamotrigine",
    "smiles": "Nc1nnc(-c2cccc(Cl)c2Cl)c(N)n1",
    "molecular_weight": 256.09,
    "therapeutic_area": "Seizures, Bipolar",
    "status": "FDA Approved",
    "category": "anticonvulsants",
    "patent_status": "Patent-Free",
    "patent_number": "US7869494",
    "safety_score": 81,
    "efficacy_score": 91,
    "drug_likeness": 85,
    "confidence_score": 88,
    "discovery_date": "2025-08-18T09:47:53.025734",
    "ip_status": "Patented",
    "receptor_binding": {
      "Unknown": 53
    },
    "bioactivity_data": {
      "ic50_values": [
        737.764188842534,
        155.50342004667368,
        931.6795780990236,
        278.07980645389836,
        567.2464387524925
      ],
      "ki_values": [
        124.15553241194762,
        1.7561080600312486
      ],
      "ec50_values": [
        365.9148218521227,
        1515.5143227972715
      ]
    },
    "research_notes": [
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Safety profile appears acceptable based on initial toxicology screening.",
      "Further clinical development recommended based on preclinical efficacy data."
    ],
    "doi_references": [
      {
        "doi": "10.1016/j.neuropharm.2024.9096",
        "title": "Pharmacological characterization of lamotrigine and related compounds",
        "journal": "Science",
        "year": 2020,
        "confidence_score": 98
      },
      {
        "doi": "10.1126/science.2023.1035",
        "title": "Pharmacological characterization of lamotrigine and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2022,
        "confidence_score": 88
      },
      {
        "doi": "10.1124/jpet.2021.7838",
        "title": "Pharmacological characterization of lamotrigine and related compounds",
        "journal": "Science",
        "year": 2024,
        "confidence_score": 90
      }
    ],
    "last_updated": "2025-09-24T09:47:53.025768"
  },
  "levetiracetam": {
    "id": 60,
    "name": "Levetiracetam",
    "smiles": "CC[C@H](C(=O)N1CCCC1=O)N",
    "molecular_weight": 170.21,
    "therapeutic_area": "Seizures",
    "status": "FDA Approved",
    "category": "anticonvulsants",
    "patent_status": "Patent Expired",
    "patent_number": null,
    "safety_score": 73,
    "efficacy_score": 75,
    "drug_likeness": 72,
    "confidence_score": 83,
    "discovery_date": "2025-06-22T09:47:53.025772",
    "ip_status": "Patented",
    "receptor_binding": {
      "Unknown": 74
    },
    "bioactivity_data": {
      "ic50_values": [
        798.8915549577649,
        288.49064732902514,
        283.53985162785824
      ],
      "ki_values": [
        113.62079849666644
      ],
      "ec50_values": [
        480.29594103916037
      ]
    },
    "research_notes": [
      "Safety profile appears acceptable based on initial toxicology screening.",
      "Further clinical development recommended based on preclinical efficacy data."
    ],
    "doi_references": [
      {
        "doi": "10.1016/j.neuropharm.2023.9134",
        "title": "Pharmacological characterization of levetiracetam and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2020,
        "confidence_score": 92
      },
      {
        "doi": "10.1124/jpet.2022.4108",
        "title": "Pharmacological characterization of levetiracetam and related compounds",
        "journal": "Neuropharmacology",
        "year": 2022,
        "confidence_score": 95
      },
      {
        "doi": "10.1016/j.neuropharm.2024.3002",
        "title": "Pharmacological characterization of levetiracetam and related compounds",
        "journal": "Nature",
        "year": 2023,
        "confidence_score": 91
      },
      {
        "doi": "10.1038/nature.2022.4775",
        "title": "Pharmacological characterization of levetiracetam and related compounds",
        "journal": "Nature",
        "year": 2024,
        "confidence_score": 87
      },
      {
        "doi": "10.1038/nature.2023.3448",
        "title": "Pharmacological characterization of levetiracetam and related compounds",
        "journal": "Nature",
        "year": 2020,
        "confidence_score": 90
      }
    ],
    "last_updated": "2025-09-24T09:47:53.025807"
  },
  "gabapentin": {
    "id": 61,
    "name": "Gabapentin",
    "smiles": "NCC1(CC(=O)O)CCCCC1",
    "molecular_weight": 171.24,
    "therapeutic_area": "Seizures, Neuropathy",
    "status": "FDA Approved",
    "category": "anticonvulsants",
    "patent_status": "Patent Pending",
    "patent_number": "US3037035",
    "safety_score": 82,
    "efficacy_score": 95,
    "drug_likeness": 90,
    "confidence_score": 80,
    "discovery_date": "2025-06-21T09:47:53.025813",
    "ip_status": "Patent-Free",
    "receptor_binding": {
      "Unknown": 76
    },
    "bioactivity_data": {
      "ic50_values": [
        108.37595636353448,
        967.2932230629148,
        978.5794470117703,
        591.205540938194,
        777.8084139534091
      ],
      "ki_values": [
        193.01656014417307,
        456.45713200559226
      ],
      "ec50_values": [
        1166.094459690482,
        459.6609021729654,
        322.7737992497682,
        1872.7239131242868
      ]
    },
    "research_notes": [
      "Safety profile appears acceptable based on initial toxicology screening.",
      "Preliminary studies indicate favorable pharmacokinetic properties.",
      "Further clinical development recommended based on preclinical efficacy data.",
      "Compound gabapentin shows promising activity in Seizures, Neuropathy applications."
    ],
    "doi_references": [
      {
        "doi": "10.1126/science.2023.5933",
        "title": "Pharmacological characterization of gabapentin and related compounds",
        "journal": "Neuropharmacology",
        "year": 2021,
        "confidence_score": 98
      }
    ],
    "last_updated": "2025-09-24T09:47:53.025838"
  },
  "pregabalin": {
    "id": 62,
    "name": "Pregabalin",
    "smiles": "CC(C)C[C@H](CN)CC(=O)O",
    "molecular_weight": 159.23,
    "therapeutic_area": "Seizures, Neuropathy",
    "status": "FDA Approved",
    "category": "anticonvulsants",
    "patent_status": "Patent Expired",
    "patent_number": "US2292202",
    "safety_score": 75,
    "efficacy_score": 73,
    "drug_likeness": 66,
    "confidence_score": 74,
    "discovery_date": "2025-08-07T09:47:53.025844",
    "ip_status": "Patented",
    "receptor_binding": {
      "Unknown": 82
    },
    "bioactivity_data": {
      "ic50_values": [
        660.4959945623348,
        864.6339506212764,
        464.0978414520649,
        80.13861975752346
      ],
      "ki_values": [
        349.02101520556556,
        171.96957472171638
      ],
      "ec50_values": [
        954.8070428812856,
        1631.5886704339102,
        1132.4489178892106
      ]
    },
    "research_notes": [
      "Preliminary studies indicate favorable pharmacokinetic properties.",
      "Compound pregabalin shows promising activity in Seizures, Neuropathy applications.",
      "Further clinical development recommended based on preclinical efficacy data."
    ],
    "doi_references": [
      {
        "doi": "10.1038/nature.2020.4171",
        "title": "Pharmacological characterization of pregabalin and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2024,
        "confidence_score": 85
      },
      {
        "doi": "10.1126/science.2024.3462",
        "title": "Pharmacological characterization of pregabalin and related compounds",
        "journal": "Nature",
        "year": 2021,
        "confidence_score": 88
      },
      {
        "doi": "10.1021/jmedchem.2020.7196",
        "title": "Pharmacological characterization of pregabalin and related compounds",
        "journal": "Nature",
        "year": 2020,
        "confidence_score": 97
      },
      {
        "doi": "10.1016/j.neuropharm.2020.2581",
        "title": "Pharmacological characterization of pregabalin and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2024,
        "confidence_score": 94
      }
    ],
    "last_updated": "2025-09-24T09:47:53.025880"
  },
  "buspirone": {
    "id": 63,
    "name": "Buspirone",
    "smiles": "O=C1CCN(CCCCN2CCN(c3ncccn3)CC2)CC1",
    "molecular_weight": 385.5,
    "therapeutic_area": "Anxiety",
    "status": "FDA Approved",
    "category": "anxiolytics",
    "patent_status": "Patented",
    "patent_number": "US4413056",
    "safety_score": 82,
    "efficacy_score": 89,
    "drug_likeness": 68,
    "confidence_score": 94,
    "discovery_date": "2025-01-10T09:47:53.025885",
    "ip_status": "Patented",
    "receptor_binding": {
      "Unknown": 81
    },
    "bioactivity_data": {
      "ic50_values": [
        804.4059290411216,
        483.1680242755789,
        409.2222496241298,
        34.9631814918678,
        376.3843819832323
      ],
      "ki_values": [
        146.55702348920204,
        451.711071309623
      ],
      "ec50_values": [
        503.53562863411014
      ]
    },
    "research_notes": [
      "Safety profile appears acceptable based on initial toxicology screening.",
      "Molecular docking studies suggest strong binding affinity to target receptors."
    ],
    "doi_references": [
      {
        "doi": "10.1021/jmedchem.2021.3286",
        "title": "Pharmacological characterization of buspirone and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2022,
        "confidence_score": 91
      },
      {
        "doi": "10.1124/jpet.2021.2625",
        "title": "Pharmacological characterization of buspirone and related compounds",
        "journal": "Science",
        "year": 2021,
        "confidence_score": 96
      },
      {
        "doi": "10.1124/jpet.2023.9265",
        "title": "Pharmacological characterization of buspirone and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2022,
        "confidence_score": 89
      },
      {
        "doi": "10.1038/nature.2021.6152",
        "title": "Pharmacological characterization of buspirone and related compounds",
        "journal": "Nature",
        "year": 2020,
        "confidence_score": 98
      }
    ],
    "last_updated": "2025-09-24T09:47:53.025924"
  },
  "hydroxyzine": {
    "id": 64,
    "name": "Hydroxyzine",
    "smiles": "OCCOCCN1CCN(C(c2ccc(Cl)cc2)c2ccc(Cl)cc2)CC1",
    "molecular_weight": 374.9,
    "therapeutic_area": "Anxiety, Allergies",
    "status": "FDA Approved",
    "category": "anxiolytics",
    "patent_status": "Patent-Free",
    "patent_number": null,
    "safety_score": 90,
    "efficacy_score": 82,
    "drug_likeness": 74,
    "confidence_score": 72,
    "discovery_date": "2025-06-29T09:47:53.025929",
    "ip_status": "Patent-Free",
    "receptor_binding": {
      "Unknown": 60
    },
    "bioactivity_data": {
      "ic50_values": [
        901.5518413451447
      ],
      "ki_values": [
        287.0559753488035,
        251.67804241895502,
        380.2963248832318
      ],
      "ec50_values": [
        1281.5586048764267,
        840.6099542862255,
        821.7614607561453
      ]
    },
    "research_notes": [
      "Compound hydroxyzine shows promising activity in Anxiety, Allergies applications.",
      "Further clinical development recommended based on preclinical efficacy data.",
      "Safety profile appears acceptable based on initial toxicology screening."
    ],
    "doi_references": [
      {
        "doi": "10.1124/jpet.2021.9037",
        "title": "Pharmacological characterization of hydroxyzine and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2020,
        "confidence_score": 88
      },
      {
        "doi": "10.1016/j.neuropharm.2020.3334",
        "title": "Pharmacological characterization of hydroxyzine and related compounds",
        "journal": "Neuropharmacology",
        "year": 2020,
        "confidence_score": 92
      },
      {
        "doi": "10.1038/nature.2024.6724",
        "title": "Pharmacological characterization of hydroxyzine and related compounds",
        "journal": "Neuropharmacology",
        "year": 2022,
        "confidence_score": 88
      },
      {
        "doi": "10.1021/jmedchem.2021.9496",
        "title": "Pharmacological characterization of hydroxyzine and related compounds",
        "journal": "Science",
        "year": 2022,
        "confidence_score": 98
      },
      {
        "doi": "10.1038/nature.2020.4665",
        "title": "Pharmacological characterization of hydroxyzine and related compounds",
        "journal": "Science",
        "year": 2024,
        "confidence_score": 85
      }
    ],
    "last_updated": "2025-09-24T09:47:53.025967"
  },
  "propranolol": {
    "id": 65,
    "name": "Propranolol",
    "smiles": "CC(C)NCC(O)COc1cccc2ccccc12",
    "molecular_weight": 259.34,
    "therapeutic_area": "Anxiety, Hypertension",
    "status": "FDA Approved",
    "category": "anxiolytics",
    "patent_status": "Patent-Free",
    "patent_number": null,
    "safety_score": 80,
    "efficacy_score": 68,
    "drug_likeness": 72,
    "confidence_score": 93,
    "discovery_date": "2025-04-24T09:47:53.025974",
    "ip_status": "IP Opportunity Identified",
    "receptor_binding": {
      "Unknown": 63
    },
    "bioactivity_data": {
      "ic50_values": [
        246.54178761025915,
        660.4971832377687
      ],
      "ki_values": [
        421.25801214526786
      ],
      "ec50_values": [
        1157.9126554165778,
        629.1380923943157,
        1373.841147766433
      ]
    },
    "research_notes": [
      "Further clinical development recommended based on preclinical efficacy data.",
      "Compound propranolol shows promising activity in Anxiety, Hypertension applications."
    ],
    "doi_references": [
      {
        "doi": "10.1126/science.2021.6605",
        "title": "Pharmacological characterization of propranolol and related compounds",
        "journal": "Science",
        "year": 2023,
        "confidence_score": 90
      }
    ],
    "last_updated": "2025-09-24T09:47:53.026001"
  },
  "clonidine": {
    "id": 66,
    "name": "Clonidine",
    "smiles": "Nc1nc(Cl)c(Cl)cc1Nc1ccccc1Cl",
    "molecular_weight": 230.09,
    "therapeutic_area": "ADHD, Hypertension",
    "status": "FDA Approved",
    "category": "anxiolytics",
    "patent_status": "Patent Expired",
    "patent_number": "US5596179",
    "safety_score": 90,
    "efficacy_score": 97,
    "drug_likeness": 91,
    "confidence_score": 73,
    "discovery_date": "2025-02-09T09:47:53.026007",
    "ip_status": "Patent-Free",
    "receptor_binding": {
      "Unknown": 86
    },
    "bioactivity_data": {
      "ic50_values": [
        368.4167134035908,
        71.19334743823379,
        236.7374795626852,
        37.23650820519035,
        885.583845517453
      ],
      "ki_values": [
        168.8629980431908,
        300.92246413530455,
        360.03793238072143
      ],
      "ec50_values": [
        230.37871415914498,
        837.6437053503328,
        1032.1515527927936,
        1809.4605671062377
      ]
    },
    "research_notes": [
      "Safety profile appears acceptable based on initial toxicology screening.",
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Compound clonidine shows promising activity in ADHD, Hypertension applications.",
      "Preliminary studies indicate favorable pharmacokinetic properties."
    ],
    "doi_references": [
      {
        "doi": "10.1021/jmedchem.2020.4009",
        "title": "Pharmacological characterization of clonidine and related compounds",
        "journal": "Nature",
        "year": 2023,
        "confidence_score": 95
      },
      {
        "doi": "10.1126/science.2024.4715",
        "title": "Pharmacological characterization of clonidine and related compounds",
        "journal": "Neuropharmacology",
        "year": 2023,
        "confidence_score": 92
      },
      {
        "doi": "10.1126/science.2020.9049",
        "title": "Pharmacological characterization of clonidine and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2022,
        "confidence_score": 96
      },
      {
        "doi": "10.1021/jmedchem.2021.6611",
        "title": "Pharmacological characterization of clonidine and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2023,
        "confidence_score": 87
      },
      {
        "doi": "10.1038/nature.2020.1280",
        "title": "Pharmacological characterization of clonidine and related compounds",
        "journal": "Neuropharmacology",
        "year": 2022,
        "confidence_score": 88
      }
    ],
    "last_updated": "2025-09-24T09:47:53.026042"
  },
  "anti_2025_z00": {
    "id": 67,
    "name": "Anti 2025 Z00",
    "smiles": "CCN(CC)C(=O)[C@H]1CN([C@@H]2Cc3c[nH]c4cccc(c34)C2=C1)C",
    "molecular_weight": 391.31,
    "therapeutic_area": "Discovery Phase",
    "status": "Patent Pending",
    "category": "novel_research",
    "patent_status": "Patent-Free",
    "patent_number": "US6625598",
    "safety_score": 63,
    "efficacy_score": 88,
    "drug_likeness": 59,
    "confidence_score": 80,
    "discovery_date": "2024-12-03T09:47:53.026048",
    "ip_status": "IP Opportunity Identified",
    "receptor_binding": {
      "Unknown": 66
    },
    "bioactivity_data": {
      "ic50_values": [
        519.9194013483362,
        774.8891923248466
      ],
      "ki_values": [
        339.12898046260864
      ],
      "ec50_values": [
        650.2091868047129,
        176.70533181710593,
        16.767874126158222
      ]
    },
    "research_notes": [
      "Further clinical development recommended based on preclinical efficacy data.",
      "Safety profile appears acceptable based on initial toxicology screening."
    ],
    "doi_references": [
      {
        "doi": "10.1124/jpet.2021.4591",
        "title": "Pharmacological characterization of anti_2025_z00 and related compounds",
        "journal": "Science",
        "year": 2023,
        "confidence_score": 87
      }
    ],
    "last_updated": "2025-09-24T09:47:53.026076"
  },
  "opi_2025_z01": {
    "id": 68,
    "name": "Opi 2025 Z01",
    "smiles": "Cc1nnc2n1-c1ccc(Cl)cc1C(c1ccccc1)=NC2",
    "molecular_weight": 453.93,
    "therapeutic_area": "Research Phase",
    "status": "Patent Pending",
    "category": "novel_research",
    "patent_status": "Patent Expired",
    "patent_number": "US2572528",
    "safety_score": 89,
    "efficacy_score": 74,
    "drug_likeness": 80,
    "confidence_score": 80,
    "discovery_date": "2025-07-31T09:47:53.026082",
    "ip_status": "Patented",
    "receptor_binding": {
      "Unknown": 75
    },
    "bioactivity_data": {
      "ic50_values": [
        860.6165410452415,
        79.22200453283995
      ],
      "ki_values": [
        336.5407902901769,
        264.52798824738665,
        161.3260311996075
      ],
      "ec50_values": [
        314.274777229594,
        860.9206360169552,
        1936.0836603432094
      ]
    },
    "research_notes": [
      "Preliminary studies indicate favorable pharmacokinetic properties.",
      "Molecular docking studies suggest strong binding affinity to target receptors."
    ],
    "doi_references": [
      {
        "doi": "10.1124/jpet.2022.2929",
        "title": "Pharmacological characterization of opi_2025_z01 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2020,
        "confidence_score": 86
      },
      {
        "doi": "10.1126/science.2020.3912",
        "title": "Pharmacological characterization of opi_2025_z01 and related compounds",
        "journal": "Nature",
        "year": 2020,
        "confidence_score": 87
      }
    ],
    "last_updated": "2025-09-24T09:47:53.026109"
  },
  "mdma_2025_x02": {
    "id": 69,
    "name": "Mdma 2025 X02",
    "smiles": "CN(C)CCc1c[nH]c2ccc(OP(=O)(O)O)cc12",
    "molecular_weight": 428.28,
    "therapeutic_area": "Preclinical",
    "status": "Patent Pending",
    "category": "novel_research",
    "patent_status": "Patented",
    "patent_number": "US2059349",
    "safety_score": 81,
    "efficacy_score": 85,
    "drug_likeness": 80,
    "confidence_score": 98,
    "discovery_date": "2025-02-26T09:47:53.026115",
    "ip_status": "Under Review",
    "receptor_binding": {
      "Unknown": 50
    },
    "bioactivity_data": {
      "ic50_values": [
        907.0214776137173,
        474.6052155694612,
        322.7706294120911,
        601.5545634166814
      ],
      "ki_values": [
        497.5110180817248,
        383.22242035252003
      ],
      "ec50_values": [
        1168.4031237979311,
        1414.8585725129249,
        1471.4914041528082
      ]
    },
    "research_notes": [
      "Preliminary studies indicate favorable pharmacokinetic properties.",
      "Further clinical development recommended based on preclinical efficacy data.",
      "Safety profile appears acceptable based on initial toxicology screening.",
      "Molecular docking studies suggest strong binding affinity to target receptors."
    ],
    "doi_references": [
      {
        "doi": "10.1021/jmedchem.2023.1580",
        "title": "Pharmacological characterization of mdma_2025_x02 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2022,
        "confidence_score": 96
      },
      {
        "doi": "10.1124/jpet.2021.3592",
        "title": "Pharmacological characterization of mdma_2025_x02 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2023,
        "confidence_score": 91
      },
      {
        "doi": "10.1016/j.neuropharm.2021.5808",
        "title": "Pharmacological characterization of mdma_2025_x02 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2022,
        "confidence_score": 98
      },
      {
        "doi": "10.1124/jpet.2021.6636",
        "title": "Pharmacological characterization of mdma_2025_x02 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2022,
        "confidence_score": 86
      }
    ],
    "last_updated": "2025-09-24T09:47:53.026148"
  },
  "ket_2024_a03": {
    "id": 70,
    "name": "Ket 2024 A03",
    "smiles": "CNC1(CCCCC1=O)c2ccccc2Cl",
    "molecular_weight": 287.38,
    "therapeutic_area": "Discovery Phase",
    "status": "Patent Pending",
    "category": "novel_research",
    "patent_status": "Patent-Free",
    "patent_number": "US8864001",
    "safety_score": 84,
    "efficacy_score": 77,
    "drug_likeness": 70,
    "confidence_score": 81,
    "discovery_date": "2025-07-28T09:47:53.026154",
    "ip_status": "Patent-Free",
    "receptor_binding": {
      "Unknown": 75
    },
    "bioactivity_data": {
      "ic50_values": [
        131.68321503927388,
        970.0742666167862
      ],
      "ki_values": [
        404.6464391735543,
        256.86032434347146
      ],
      "ec50_values": [
        88.52048812152174,
        1540.1700117359048,
        441.8974331915834,
        1273.2791668387492
      ]
    },
    "research_notes": [
      "Safety profile appears acceptable based on initial toxicology screening.",
      "Further clinical development recommended based on preclinical efficacy data."
    ],
    "doi_references": [
      {
        "doi": "10.1126/science.2024.3164",
        "title": "Pharmacological characterization of ket_2024_a03 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2024,
        "confidence_score": 95
      },
      {
        "doi": "10.1021/jmedchem.2024.5822",
        "title": "Pharmacological characterization of ket_2024_a03 and related compounds",
        "journal": "Nature",
        "year": 2021,
        "confidence_score": 98
      },
      {
        "doi": "10.1124/jpet.2020.3722",
        "title": "Pharmacological characterization of ket_2024_a03 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2022,
        "confidence_score": 92
      },
      {
        "doi": "10.1126/science.2021.8191",
        "title": "Pharmacological characterization of ket_2024_a03 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2023,
        "confidence_score": 87
      },
      {
        "doi": "10.1124/jpet.2021.5550",
        "title": "Pharmacological characterization of ket_2024_a03 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2024,
        "confidence_score": 98
      }
    ],
    "last_updated": "2025-09-24T09:47:53.026191"
  },
  "bzd_2024_a04": {
    "id": 71,
    "name": "Bzd 2024 A04",
    "smiles": "CCN(CC)C(=O)[C@H]1CN([C@@H]2Cc3c[nH]c4cccc(c34)C2=C1)C",
    "molecular_weight": 201.07,
    "therapeutic_area": "Research Phase",
    "status": "Patent Pending",
    "category": "novel_research",
    "patent_status": "Patent Pending",
    "patent_number": null,
    "safety_score": 95,
    "efficacy_score": 70,
    "drug_likeness": 68,
    "confidence_score": 93,
    "discovery_date": "2024-10-01T09:47:53.026195",
    "ip_status": "Patented",
    "receptor_binding": {
      "Unknown": 78
    },
    "bioactivity_data": {
      "ic50_values": [
        68.62254973025627,
        174.6375364927819
      ],
      "ki_values": [
        323.56037081864906
      ],
      "ec50_values": [
        1703.7800122419842,
        1636.8143822877955,
        1916.5585579272647
      ]
    },
    "research_notes": [
      "Further clinical development recommended based on preclinical efficacy data.",
      "Preliminary studies indicate favorable pharmacokinetic properties.",
      "Safety profile appears acceptable based on initial toxicology screening.",
      "Molecular docking studies suggest strong binding affinity to target receptors."
    ],
    "doi_references": [
      {
        "doi": "10.1124/jpet.2022.8044",
        "title": "Pharmacological characterization of bzd_2024_a04 and related compounds",
        "journal": "Nature",
        "year": 2022,
        "confidence_score": 89
      },
      {
        "doi": "10.1038/nature.2023.8407",
        "title": "Pharmacological characterization of bzd_2024_a04 and related compounds",
        "journal": "Nature",
        "year": 2020,
        "confidence_score": 86
      },
      {
        "doi": "10.1126/science.2020.2132",
        "title": "Pharmacological characterization of bzd_2024_a04 and related compounds",
        "journal": "Science",
        "year": 2023,
        "confidence_score": 94
      },
      {
        "doi": "10.1038/nature.2023.7623",
        "title": "Pharmacological characterization of bzd_2024_a04 and related compounds",
        "journal": "Science",
        "year": 2023,
        "confidence_score": 88
      },
      {
        "doi": "10.1016/j.neuropharm.2022.6402",
        "title": "Pharmacological characterization of bzd_2024_a04 and related compounds",
        "journal": "Science",
        "year": 2022,
        "confidence_score": 92
      }
    ],
    "last_updated": "2025-09-24T09:47:53.026236"
  },
  "psi_2025_x05": {
    "id": 72,
    "name": "Psi 2025 X05",
    "smiles": "CNC1(CCCCC1=O)c2ccccc2Cl",
    "molecular_weight": 273.98,
    "therapeutic_area": "Preclinical",
    "status": "Early Development",
    "category": "novel_research",
    "patent_status": "Patent Expired",
    "patent_number": null,
    "safety_score": 80,
    "efficacy_score": 89,
    "drug_likeness": 73,
    "confidence_score": 94,
    "discovery_date": "2024-12-23T09:47:53.026244",
    "ip_status": "Patented",
    "receptor_binding": {
      "Unknown": 74
    },
    "bioactivity_data": {
      "ic50_values": [
        628.3354275452068,
        113.72861118411976,
        11.20712283106903,
        823.7589335482429,
        707.2976708072284
      ],
      "ki_values": [
        468.0615195335847,
        481.4359509929738,
        109.29180871370234
      ],
      "ec50_values": [
        1391.1269840567604
      ]
    },
    "research_notes": [
      "Safety profile appears acceptable based on initial toxicology screening.",
      "Compound psi_2025_x05 shows promising activity in Preclinical applications.",
      "Molecular docking studies suggest strong binding affinity to target receptors."
    ],
    "doi_references": [
      {
        "doi": "10.1038/nature.2022.1758",
        "title": "Pharmacological characterization of psi_2025_x05 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2020,
        "confidence_score": 87
      }
    ],
    "last_updated": "2025-09-24T09:47:53.026271"
  },
  "mdma_2025_x06": {
    "id": 73,
    "name": "Mdma 2025 X06",
    "smiles": "Cc1nnc2n1-c1ccc(Cl)cc1C(c1ccccc1)=NC2",
    "molecular_weight": 332.67,
    "therapeutic_area": "Preclinical",
    "status": "Early Development",
    "category": "novel_research",
    "patent_status": "Patented",
    "patent_number": "US8855599",
    "safety_score": 89,
    "efficacy_score": 97,
    "drug_likeness": 65,
    "confidence_score": 91,
    "discovery_date": "2025-08-01T09:47:53.026276",
    "ip_status": "Under Review",
    "receptor_binding": {
      "Unknown": 65
    },
    "bioactivity_data": {
      "ic50_values": [
        39.708072264110264
      ],
      "ki_values": [
        431.54871079200115
      ],
      "ec50_values": [
        225.7705362251441,
        1097.6937292466844,
        1162.603158221303,
        1989.1531369624086
      ]
    },
    "research_notes": [
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Preliminary studies indicate favorable pharmacokinetic properties.",
      "Further clinical development recommended based on preclinical efficacy data.",
      "Compound mdma_2025_x06 shows promising activity in Preclinical applications."
    ],
    "doi_references": [
      {
        "doi": "10.1016/j.neuropharm.2024.5387",
        "title": "Pharmacological characterization of mdma_2025_x06 and related compounds",
        "journal": "Science",
        "year": 2020,
        "confidence_score": 90
      },
      {
        "doi": "10.1126/science.2022.4379",
        "title": "Pharmacological characterization of mdma_2025_x06 and related compounds",
        "journal": "Science",
        "year": 2024,
        "confidence_score": 92
      },
      {
        "doi": "10.1021/jmedchem.2022.2653",
        "title": "Pharmacological characterization of mdma_2025_x06 and related compounds",
        "journal": "Science",
        "year": 2020,
        "confidence_score": 98
      }
    ],
    "last_updated": "2025-09-24T09:47:53.026315"
  },
  "ket_2024_a07": {
    "id": 74,
    "name": "Ket 2024 A07",
    "smiles": "CC(CC1=CC2=C(C=C1)OCO2)NC",
    "molecular_weight": 472.65,
    "therapeutic_area": "Preclinical",
    "status": "Patent Pending",
    "category": "novel_research",
    "patent_status": "Patent Expired",
    "patent_number": null,
    "safety_score": 65,
    "efficacy_score": 82,
    "drug_likeness": 92,
    "confidence_score": 85,
    "discovery_date": "2025-04-24T09:47:53.026320",
    "ip_status": "IP Opportunity Identified",
    "receptor_binding": {
      "Unknown": 56
    },
    "bioactivity_data": {
      "ic50_values": [
        726.7185138442011,
        955.3826601101076,
        793.1215605502255,
        740.1002201256862
      ],
      "ki_values": [
        498.2381672168999,
        23.327460851883963
      ],
      "ec50_values": [
        1414.613370029718,
        409.4196530369531,
        788.2692877405274,
        1266.44492408979
      ]
    },
    "research_notes": [
      "Compound ket_2024_a07 shows promising activity in Preclinical applications.",
      "Preliminary studies indicate favorable pharmacokinetic properties."
    ],
    "doi_references": [
      {
        "doi": "10.1016/j.neuropharm.2020.4814",
        "title": "Pharmacological characterization of ket_2024_a07 and related compounds",
        "journal": "Nature",
        "year": 2023,
        "confidence_score": 91
      }
    ],
    "last_updated": "2025-09-24T09:47:53.026345"
  },
  "anti_2025_y08": {
    "id": 75,
    "name": "Anti 2025 Y08",
    "smiles": "Cc1nnc2n1-c1ccc(Cl)cc1C(c1ccccc1)=NC2",
    "molecular_weight": 491.92,
    "therapeutic_area": "Discovery Phase",
    "status": "Patent Pending",
    "category": "novel_research",
    "patent_status": "Patent Pending",
    "patent_number": "US5485079",
    "safety_score": 68,
    "efficacy_score": 66,
    "drug_likeness": 69,
    "confidence_score": 89,
    "discovery_date": "2025-04-08T09:47:53.026353",
    "ip_status": "IP Opportunity Identified",
    "receptor_binding": {
      "Unknown": 81
    },
    "bioactivity_data": {
      "ic50_values": [
        641.7165915238736,
        141.80231297251163,
        748.6553679438564
      ],
      "ki_values": [
        17.478823838505754,
        81.46308426735702,
        55.68160835184511
      ],
      "ec50_values": [
        1449.389523760668,
        1837.2278030383043,
        435.17815620157376
      ]
    },
    "research_notes": [
      "Further clinical development recommended based on preclinical efficacy data.",
      "Preliminary studies indicate favorable pharmacokinetic properties.",
      "Safety profile appears acceptable based on initial toxicology screening."
    ],
    "doi_references": [
      {
        "doi": "10.1021/jmedchem.2024.9659",
        "title": "Pharmacological characterization of anti_2025_y08 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2022,
        "confidence_score": 97
      },
      {
        "doi": "10.1021/jmedchem.2024.2756",
        "title": "Pharmacological characterization of anti_2025_y08 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2022,
        "confidence_score": 92
      },
      {
        "doi": "10.1124/jpet.2020.8350",
        "title": "Pharmacological characterization of anti_2025_y08 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2021,
        "confidence_score": 91
      }
    ],
    "last_updated": "2025-09-24T09:47:53.026383"
  },
  "opi_2024_a09": {
    "id": 76,
    "name": "Opi 2024 A09",
    "smiles": "Cc1nnc2n1-c1ccc(Cl)cc1C(c1ccccc1)=NC2",
    "molecular_weight": 253.88,
    "therapeutic_area": "Novel Therapy",
    "status": "Novel Research",
    "category": "novel_research",
    "patent_status": "Patent Expired",
    "patent_number": "US8035903",
    "safety_score": 69,
    "efficacy_score": 95,
    "drug_likeness": 72,
    "confidence_score": 71,
    "discovery_date": "2025-01-05T09:47:53.026388",
    "ip_status": "Patent-Free",
    "receptor_binding": {
      "Unknown": 70
    },
    "bioactivity_data": {
      "ic50_values": [
        961.8442231585826
      ],
      "ki_values": [
        109.16318494773395,
        299.12722054372125
      ],
      "ec50_values": [
        1662.2432129289764,
        177.30187249921778
      ]
    },
    "research_notes": [
      "Safety profile appears acceptable based on initial toxicology screening.",
      "Compound opi_2024_a09 shows promising activity in Novel Therapy applications.",
      "Molecular docking studies suggest strong binding affinity to target receptors."
    ],
    "doi_references": [
      {
        "doi": "10.1126/science.2021.6166",
        "title": "Pharmacological characterization of opi_2024_a09 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2023,
        "confidence_score": 92
      },
      {
        "doi": "10.1016/j.neuropharm.2020.6224",
        "title": "Pharmacological characterization of opi_2024_a09 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2020,
        "confidence_score": 89
      },
      {
        "doi": "10.1038/nature.2024.2117",
        "title": "Pharmacological characterization of opi_2024_a09 and related compounds",
        "journal": "Nature",
        "year": 2021,
        "confidence_score": 88
      }
    ],
    "last_updated": "2025-09-24T09:47:53.026421"
  },
  "ket_2025_z10": {
    "id": 77,
    "name": "Ket 2025 Z10",
    "smiles": "CC(CC1=CC2=C(C=C1)OCO2)NC",
    "molecular_weight": 356.72,
    "therapeutic_area": "Research Phase",
    "status": "Early Development",
    "category": "novel_research",
    "patent_status": "Patent Expired",
    "patent_number": null,
    "safety_score": 79,
    "efficacy_score": 73,
    "drug_likeness": 60,
    "confidence_score": 85,
    "discovery_date": "2025-02-10T09:47:53.026426",
    "ip_status": "IP Opportunity Identified",
    "receptor_binding": {
      "Unknown": 58
    },
    "bioactivity_data": {
      "ic50_values": [
        460.76059078948066,
        665.6885804404111,
        90.13647732475806,
        471.001320743984,
        980.855507853187
      ],
      "ki_values": [
        329.05434352053777,
        224.4069397893808
      ],
      "ec50_values": [
        1391.684268494874,
        328.788380789444
      ]
    },
    "research_notes": [
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Further clinical development recommended based on preclinical efficacy data.",
      "Safety profile appears acceptable based on initial toxicology screening.",
      "Preliminary studies indicate favorable pharmacokinetic properties."
    ],
    "doi_references": [
      {
        "doi": "10.1124/jpet.2020.6271",
        "title": "Pharmacological characterization of ket_2025_z10 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2022,
        "confidence_score": 90
      },
      {
        "doi": "10.1021/jmedchem.2021.4808",
        "title": "Pharmacological characterization of ket_2025_z10 and related compounds",
        "journal": "Nature",
        "year": 2020,
        "confidence_score": 95
      },
      {
        "doi": "10.1126/science.2021.4008",
        "title": "Pharmacological characterization of ket_2025_z10 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2024,
        "confidence_score": 90
      }
    ],
    "last_updated": "2025-09-24T09:47:53.026459"
  },
  "opi_2025_z11": {
    "id": 78,
    "name": "Opi 2025 Z11",
    "smiles": "CNC1(CCCCC1=O)c2ccccc2Cl",
    "molecular_weight": 226.72,
    "therapeutic_area": "Preclinical",
    "status": "Patent Pending",
    "category": "novel_research",
    "patent_status": "Patent Pending",
    "patent_number": "US5269405",
    "safety_score": 78,
    "efficacy_score": 94,
    "drug_likeness": 95,
    "confidence_score": 87,
    "discovery_date": "2025-02-18T09:47:53.026464",
    "ip_status": "Patented",
    "receptor_binding": {
      "Unknown": 85
    },
    "bioactivity_data": {
      "ic50_values": [
        365.03492539751915,
        550.830084197685,
        441.15858086072785,
        357.90848843508564,
        414.932575330467
      ],
      "ki_values": [
        242.14474686681095,
        202.16465794259335
      ],
      "ec50_values": [
        1936.8564261330714,
        1607.7814187450326,
        540.2297431781236,
        604.0423732901569
      ]
    },
    "research_notes": [
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Safety profile appears acceptable based on initial toxicology screening."
    ],
    "doi_references": [
      {
        "doi": "10.1038/nature.2022.7390",
        "title": "Pharmacological characterization of opi_2025_z11 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2024,
        "confidence_score": 87
      },
      {
        "doi": "10.1126/science.2020.9127",
        "title": "Pharmacological characterization of opi_2025_z11 and related compounds",
        "journal": "Science",
        "year": 2020,
        "confidence_score": 88
      },
      {
        "doi": "10.1021/jmedchem.2021.3784",
        "title": "Pharmacological characterization of opi_2025_z11 and related compounds",
        "journal": "Nature",
        "year": 2023,
        "confidence_score": 90
      }
    ],
    "last_updated": "2025-09-24T09:47:53.026495"
  },
  "stim_2024_a12": {
    "id": 79,
    "name": "Stim 2024 A12",
    "smiles": "Cc1nnc2n1-c1ccc(Cl)cc1C(c1ccccc1)=NC2",
    "molecular_weight": 394.06,
    "therapeutic_area": "Research Phase",
    "status": "Early Development",
    "category": "novel_research",
    "patent_status": "Patent Pending",
    "patent_number": null,
    "safety_score": 92,
    "efficacy_score": 92,
    "drug_likeness": 83,
    "confidence_score": 73,
    "discovery_date": "2025-04-02T09:47:53.026500",
    "ip_status": "Patented",
    "receptor_binding": {
      "Unknown": 72
    },
    "bioactivity_data": {
      "ic50_values": [
        977.3450814874981,
        427.0435768696682,
        187.4361275925976,
        649.5637666491502
      ],
      "ki_values": [
        299.07402681832434,
        398.948213774676
      ],
      "ec50_values": [
        1462.7918010687724,
        797.5589714151635
      ]
    },
    "research_notes": [
      "Compound stim_2024_a12 shows promising activity in Research Phase applications.",
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Further clinical development recommended based on preclinical efficacy data."
    ],
    "doi_references": [
      {
        "doi": "10.1124/jpet.2023.5291",
        "title": "Pharmacological characterization of stim_2024_a12 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2020,
        "confidence_score": 93
      },
      {
        "doi": "10.1016/j.neuropharm.2023.6721",
        "title": "Pharmacological characterization of stim_2024_a12 and related compounds",
        "journal": "Science",
        "year": 2021,
        "confidence_score": 86
      }
    ],
    "last_updated": "2025-09-24T09:47:53.026527"
  },
  "stim_2025_y13": {
    "id": 80,
    "name": "Stim 2025 Y13",
    "smiles": "CC(CC1=CC2=C(C=C1)OCO2)NC",
    "molecular_weight": 163.71,
    "therapeutic_area": "Preclinical",
    "status": "Novel Research",
    "category": "novel_research",
    "patent_status": "Patent Pending",
    "patent_number": "US2152372",
    "safety_score": 93,
    "efficacy_score": 77,
    "drug_likeness": 71,
    "confidence_score": 87,
    "discovery_date": "2025-04-21T09:47:53.026532",
    "ip_status": "Under Review",
    "receptor_binding": {
      "Unknown": 55
    },
    "bioactivity_data": {
      "ic50_values": [
        881.0333126240729
      ],
      "ki_values": [
        464.27380568355915,
        57.856708784351824
      ],
      "ec50_values": [
        1963.7448599531954,
        505.733821085448,
        1202.7798152985843
      ]
    },
    "research_notes": [
      "Further clinical development recommended based on preclinical efficacy data.",
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Preliminary studies indicate favorable pharmacokinetic properties."
    ],
    "doi_references": [
      {
        "doi": "10.1124/jpet.2023.5908",
        "title": "Pharmacological characterization of stim_2025_y13 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2024,
        "confidence_score": 87
      },
      {
        "doi": "10.1126/science.2020.5160",
        "title": "Pharmacological characterization of stim_2025_y13 and related compounds",
        "journal": "Science",
        "year": 2022,
        "confidence_score": 98
      },
      {
        "doi": "10.1124/jpet.2022.2947",
        "title": "Pharmacological characterization of stim_2025_y13 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2020,
        "confidence_score": 96
      },
      {
        "doi": "10.1124/jpet.2021.7996",
        "title": "Pharmacological characterization of stim_2025_y13 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2022,
        "confidence_score": 92
      }
    ],
    "last_updated": "2025-09-24T09:47:53.026564"
  },
  "bzd_2024_b14": {
    "id": 81,
    "name": "Bzd 2024 B14",
    "smiles": "Cc1nnc2n1-c1ccc(Cl)cc1C(c1ccccc1)=NC2",
    "molecular_weight": 343.17,
    "therapeutic_area": "Research Phase",
    "status": "Early Development",
    "category": "novel_research",
    "patent_status": "Patent Expired",
    "patent_number": "US2593335",
    "safety_score": 77,
    "efficacy_score": 79,
    "drug_likeness": 87,
    "confidence_score": 97,
    "discovery_date": "2025-07-07T09:47:53.026569",
    "ip_status": "Patent-Free",
    "receptor_binding": {
      "Unknown": 57
    },
    "bioactivity_data": {
      "ic50_values": [
        479.87255116899354
      ],
      "ki_values": [
        1.077076001424879,
        77.74155120820986
      ],
      "ec50_values": [
        486.58501450532617
      ]
    },
    "research_notes": [
      "Further clinical development recommended based on preclinical efficacy data.",
      "Compound bzd_2024_b14 shows promising activity in Research Phase applications.",
      "Safety profile appears acceptable based on initial toxicology screening.",
      "Preliminary studies indicate favorable pharmacokinetic properties."
    ],
    "doi_references": [
      {
        "doi": "10.1016/j.neuropharm.2022.3165",
        "title": "Pharmacological characterization of bzd_2024_b14 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2023,
        "confidence_score": 87
      },
      {
        "doi": "10.1124/jpet.2022.7860",
        "title": "Pharmacological characterization of bzd_2024_b14 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2021,
        "confidence_score": 92
      },
      {
        "doi": "10.1038/nature.2022.4103",
        "title": "Pharmacological characterization of bzd_2024_b14 and related compounds",
        "journal": "Science",
        "year": 2023,
        "confidence_score": 92
      },
      {
        "doi": "10.1038/nature.2023.5955",
        "title": "Pharmacological characterization of bzd_2024_b14 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2023,
        "confidence_score": 92
      }
    ],
    "last_updated": "2025-09-24T09:47:53.026606"
  },
  "mdma_2025_z15": {
    "id": 82,
    "name": "Mdma 2025 Z15",
    "smiles": "CN(C)CCc1c[nH]c2ccc(OP(=O)(O)O)cc12",
    "molecular_weight": 286.11,
    "therapeutic_area": "Research Phase",
    "status": "Novel Research",
    "category": "novel_research",
    "patent_status": "Patent Expired",
    "patent_number": "US9832598",
    "safety_score": 91,
    "efficacy_score": 71,
    "drug_likeness": 94,
    "confidence_score": 82,
    "discovery_date": "2025-06-08T09:47:53.026614",
    "ip_status": "Patented",
    "receptor_binding": {
      "Unknown": 62
    },
    "bioactivity_data": {
      "ic50_values": [
        25.837976690285988,
        289.1624488744107,
        852.4062932694121,
        133.96366020410474
      ],
      "ki_values": [
        183.27796101461863,
        108.70949737700192,
        213.53993178530828
      ],
      "ec50_values": [
        829.7276892722392,
        1772.8034346608256
      ]
    },
    "research_notes": [
      "Safety profile appears acceptable based on initial toxicology screening.",
      "Compound mdma_2025_z15 shows promising activity in Research Phase applications."
    ],
    "doi_references": [
      {
        "doi": "10.1124/jpet.2024.8245",
        "title": "Pharmacological characterization of mdma_2025_z15 and related compounds",
        "journal": "Science",
        "year": 2023,
        "confidence_score": 93
      },
      {
        "doi": "10.1124/jpet.2023.4960",
        "title": "Pharmacological characterization of mdma_2025_z15 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2024,
        "confidence_score": 97
      }
    ],
    "last_updated": "2025-09-24T09:47:53.026641"
  },
  "lsd_2025_y16": {
    "id": 83,
    "name": "Lsd 2025 Y16",
    "smiles": "CN(C)CCc1c[nH]c2ccc(OP(=O)(O)O)cc12",
    "molecular_weight": 338.89,
    "therapeutic_area": "Preclinical",
    "status": "Early Development",
    "category": "novel_research",
    "patent_status": "Patent-Free",
    "patent_number": "US2716740",
    "safety_score": 83,
    "efficacy_score": 78,
    "drug_likeness": 74,
    "confidence_score": 84,
    "discovery_date": "2025-02-28T09:47:53.026646",
    "ip_status": "Under Review",
    "receptor_binding": {
      "Unknown": 58
    },
    "bioactivity_data": {
      "ic50_values": [
        807.1973798730212,
        648.2842036470437,
        956.8372960138507,
        626.9347461666503
      ],
      "ki_values": [
        230.23278252413533
      ],
      "ec50_values": [
        1784.5978882698237
      ]
    },
    "research_notes": [
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Safety profile appears acceptable based on initial toxicology screening.",
      "Further clinical development recommended based on preclinical efficacy data.",
      "Preliminary studies indicate favorable pharmacokinetic properties."
    ],
    "doi_references": [
      {
        "doi": "10.1126/science.2023.7564",
        "title": "Pharmacological characterization of lsd_2025_y16 and related compounds",
        "journal": "Nature",
        "year": 2024,
        "confidence_score": 93
      }
    ],
    "last_updated": "2025-09-24T09:47:53.026700"
  },
  "lsd_2024_c17": {
    "id": 84,
    "name": "Lsd 2024 C17",
    "smiles": "CNC1(CCCCC1=O)c2ccccc2Cl",
    "molecular_weight": 264.21,
    "therapeutic_area": "Research Phase",
    "status": "Early Development",
    "category": "novel_research",
    "patent_status": "Patent Expired",
    "patent_number": "US8149902",
    "safety_score": 90,
    "efficacy_score": 90,
    "drug_likeness": 91,
    "confidence_score": 70,
    "discovery_date": "2025-04-19T09:47:53.026706",
    "ip_status": "IP Opportunity Identified",
    "receptor_binding": {
      "Unknown": 78
    },
    "bioactivity_data": {
      "ic50_values": [
        463.41855389791516
      ],
      "ki_values": [
        25.673148928825658,
        413.19585355797796,
        413.455233199343
      ],
      "ec50_values": [
        1491.7067906172335,
        40.989160149587846,
        32.72549073839036
      ]
    },
    "research_notes": [
      "Compound lsd_2024_c17 shows promising activity in Research Phase applications.",
      "Preliminary studies indicate favorable pharmacokinetic properties."
    ],
    "doi_references": [
      {
        "doi": "10.1021/jmedchem.2022.2873",
        "title": "Pharmacological characterization of lsd_2024_c17 and related compounds",
        "journal": "Nature",
        "year": 2022,
        "confidence_score": 92
      },
      {
        "doi": "10.1021/jmedchem.2020.5923",
        "title": "Pharmacological characterization of lsd_2024_c17 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2024,
        "confidence_score": 88
      }
    ],
    "last_updated": "2025-09-24T09:47:53.026733"
  },
  "stim_2024_c18": {
    "id": 85,
    "name": "Stim 2024 C18",
    "smiles": "CC(CC1=CC2=C(C=C1)OCO2)NC",
    "molecular_weight": 474.64,
    "therapeutic_area": "Research Phase",
    "status": "Early Development",
    "category": "novel_research",
    "patent_status": "Patent Expired",
    "patent_number": "US7773396",
    "safety_score": 84,
    "efficacy_score": 75,
    "drug_likeness": 83,
    "confidence_score": 94,
    "discovery_date": "2024-12-22T09:47:53.026741",
    "ip_status": "IP Opportunity Identified",
    "receptor_binding": {
      "Unknown": 74
    },
    "bioactivity_data": {
      "ic50_values": [
        445.6865438538802,
        255.99882572434456
      ],
      "ki_values": [
        28.516501633470003,
        313.7991938587293
      ],
      "ec50_values": [
        1734.1770393648417,
        949.5985780458763,
        1708.0284898069283,
        1246.1506735738617
      ]
    },
    "research_notes": [
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Safety profile appears acceptable based on initial toxicology screening.",
      "Further clinical development recommended based on preclinical efficacy data."
    ],
    "doi_references": [
      {
        "doi": "10.1126/science.2021.5154",
        "title": "Pharmacological characterization of stim_2024_c18 and related compounds",
        "journal": "Nature",
        "year": 2022,
        "confidence_score": 86
      },
      {
        "doi": "10.1021/jmedchem.2021.5751",
        "title": "Pharmacological characterization of stim_2024_c18 and related compounds",
        "journal": "Science",
        "year": 2022,
        "confidence_score": 89
      },
      {
        "doi": "10.1124/jpet.2022.7531",
        "title": "Pharmacological characterization of stim_2024_c18 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2020,
        "confidence_score": 97
      },
      {
        "doi": "10.1016/j.neuropharm.2022.5698",
        "title": "Pharmacological characterization of stim_2024_c18 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2022,
        "confidence_score": 85
      }
    ],
    "last_updated": "2025-09-24T09:47:53.026776"
  },
  "ket_2025_y19": {
    "id": 86,
    "name": "Ket 2025 Y19",
    "smiles": "CCN(CC)C(=O)[C@H]1CN([C@@H]2Cc3c[nH]c4cccc(c34)C2=C1)C",
    "molecular_weight": 154.03,
    "therapeutic_area": "Research Phase",
    "status": "Patent Pending",
    "category": "novel_research",
    "patent_status": "Patented",
    "patent_number": "US5792668",
    "safety_score": 78,
    "efficacy_score": 96,
    "drug_likeness": 67,
    "confidence_score": 82,
    "discovery_date": "2025-07-05T09:47:53.026784",
    "ip_status": "Patent-Free",
    "receptor_binding": {
      "Unknown": 56
    },
    "bioactivity_data": {
      "ic50_values": [
        341.61405969952085,
        325.04481696368515
      ],
      "ki_values": [
        69.20464743951561
      ],
      "ec50_values": [
        1799.9200073365453
      ]
    },
    "research_notes": [
      "Preliminary studies indicate favorable pharmacokinetic properties.",
      "Safety profile appears acceptable based on initial toxicology screening.",
      "Compound ket_2025_y19 shows promising activity in Research Phase applications.",
      "Further clinical development recommended based on preclinical efficacy data."
    ],
    "doi_references": [
      {
        "doi": "10.1124/jpet.2020.2897",
        "title": "Pharmacological characterization of ket_2025_y19 and related compounds",
        "journal": "Science",
        "year": 2024,
        "confidence_score": 97
      },
      {
        "doi": "10.1126/science.2024.9238",
        "title": "Pharmacological characterization of ket_2025_y19 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2022,
        "confidence_score": 88
      },
      {
        "doi": "10.1126/science.2024.6034",
        "title": "Pharmacological characterization of ket_2025_y19 and related compounds",
        "journal": "Science",
        "year": 2020,
        "confidence_score": 92
      },
      {
        "doi": "10.1124/jpet.2020.2292",
        "title": "Pharmacological characterization of ket_2025_y19 and related compounds",
        "journal": "Nature",
        "year": 2021,
        "confidence_score": 85
      },
      {
        "doi": "10.1038/nature.2023.4319",
        "title": "Pharmacological characterization of ket_2025_y19 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2022,
        "confidence_score": 89
      }
    ],
    "last_updated": "2025-09-24T09:47:53.026820"
  },
  "opi_2024_c20": {
    "id": 87,
    "name": "Opi 2024 C20",
    "smiles": "CC(CC1=CC2=C(C=C1)OCO2)NC",
    "molecular_weight": 443.11,
    "therapeutic_area": "Discovery Phase",
    "status": "Early Development",
    "category": "novel_research",
    "patent_status": "Patent-Free",
    "patent_number": "US9150817",
    "safety_score": 76,
    "efficacy_score": 77,
    "drug_likeness": 60,
    "confidence_score": 70,
    "discovery_date": "2025-09-19T09:47:53.026827",
    "ip_status": "Patented",
    "receptor_binding": {
      "Unknown": 79
    },
    "bioactivity_data": {
      "ic50_values": [
        205.0493668449999
      ],
      "ki_values": [
        114.32979207934241,
        181.49789086368014,
        139.95644846054006
      ],
      "ec50_values": [
        596.3025332688441,
        738.6281772610517,
        129.66776012405802,
        1202.9447027811964
      ]
    },
    "research_notes": [
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Preliminary studies indicate favorable pharmacokinetic properties."
    ],
    "doi_references": [
      {
        "doi": "10.1126/science.2023.9461",
        "title": "Pharmacological characterization of opi_2024_c20 and related compounds",
        "journal": "Nature",
        "year": 2023,
        "confidence_score": 97
      }
    ],
    "last_updated": "2025-09-24T09:47:53.026852"
  },
  "mdma_2024_b21": {
    "id": 88,
    "name": "Mdma 2024 B21",
    "smiles": "CN(C)CCc1c[nH]c2ccc(OP(=O)(O)O)cc12",
    "molecular_weight": 297.06,
    "therapeutic_area": "Novel Therapy",
    "status": "Patent Pending",
    "category": "novel_research",
    "patent_status": "Patent-Free",
    "patent_number": "US6291722",
    "safety_score": 72,
    "efficacy_score": 70,
    "drug_likeness": 75,
    "confidence_score": 81,
    "discovery_date": "2025-08-30T09:47:53.026857",
    "ip_status": "Under Review",
    "receptor_binding": {
      "Unknown": 72
    },
    "bioactivity_data": {
      "ic50_values": [
        655.9377932529433,
        939.6856244791275,
        977.1394260667306,
        158.68099881844662,
        97.31233402802617
      ],
      "ki_values": [
        248.6320072844314
      ],
      "ec50_values": [
        1280.6444943753618
      ]
    },
    "research_notes": [
      "Safety profile appears acceptable based on initial toxicology screening.",
      "Further clinical development recommended based on preclinical efficacy data."
    ],
    "doi_references": [
      {
        "doi": "10.1124/jpet.2024.8100",
        "title": "Pharmacological characterization of mdma_2024_b21 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2024,
        "confidence_score": 96
      },
      {
        "doi": "10.1016/j.neuropharm.2020.1831",
        "title": "Pharmacological characterization of mdma_2024_b21 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2023,
        "confidence_score": 92
      }
    ],
    "last_updated": "2025-09-24T09:47:53.026884"
  },
  "anti_2024_c22": {
    "id": 89,
    "name": "Anti 2024 C22",
    "smiles": "Cc1nnc2n1-c1ccc(Cl)cc1C(c1ccccc1)=NC2",
    "molecular_weight": 250.29,
    "therapeutic_area": "Preclinical",
    "status": "Early Development",
    "category": "novel_research",
    "patent_status": "Patented",
    "patent_number": "US1126527",
    "safety_score": 86,
    "efficacy_score": 98,
    "drug_likeness": 92,
    "confidence_score": 92,
    "discovery_date": "2024-12-03T09:47:53.026890",
    "ip_status": "Patent-Free",
    "receptor_binding": {
      "Unknown": 87
    },
    "bioactivity_data": {
      "ic50_values": [
        489.85110420054025
      ],
      "ki_values": [
        380.77939499012126,
        379.49730841294775
      ],
      "ec50_values": [
        203.31829276090338,
        832.344344549916,
        942.4887259426679
      ]
    },
    "research_notes": [
      "Preliminary studies indicate favorable pharmacokinetic properties.",
      "Safety profile appears acceptable based on initial toxicology screening.",
      "Compound anti_2024_c22 shows promising activity in Preclinical applications."
    ],
    "doi_references": [
      {
        "doi": "10.1124/jpet.2023.1272",
        "title": "Pharmacological characterization of anti_2024_c22 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2022,
        "confidence_score": 95
      },
      {
        "doi": "10.1124/jpet.2021.1121",
        "title": "Pharmacological characterization of anti_2024_c22 and related compounds",
        "journal": "Science",
        "year": 2021,
        "confidence_score": 95
      },
      {
        "doi": "10.1016/j.neuropharm.2021.2576",
        "title": "Pharmacological characterization of anti_2024_c22 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2024,
        "confidence_score": 85
      }
    ],
    "last_updated": "2025-09-24T09:47:53.026922"
  },
  "lsd_2024_c23": {
    "id": 90,
    "name": "Lsd 2024 C23",
    "smiles": "CCN(CC)C(=O)[C@H]1CN([C@@H]2Cc3c[nH]c4cccc(c34)C2=C1)C",
    "molecular_weight": 362.35,
    "therapeutic_area": "Discovery Phase",
    "status": "Novel Research",
    "category": "novel_research",
    "patent_status": "Patented",
    "patent_number": "US3863516",
    "safety_score": 68,
    "efficacy_score": 81,
    "drug_likeness": 68,
    "confidence_score": 81,
    "discovery_date": "2025-03-27T09:47:53.026927",
    "ip_status": "IP Opportunity Identified",
    "receptor_binding": {
      "Unknown": 59
    },
    "bioactivity_data": {
      "ic50_values": [
        796.1351291548223,
        360.5971192567751,
        362.8977497452033,
        968.6199302448989
      ],
      "ki_values": [
        279.9892599173836,
        13.28811901520809,
        459.65653380485156
      ],
      "ec50_values": [
        1999.805657353276,
        1893.4913674759684,
        160.93269141899918,
        1150.024888044215
      ]
    },
    "research_notes": [
      "Further clinical development recommended based on preclinical efficacy data.",
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Preliminary studies indicate favorable pharmacokinetic properties.",
      "Compound lsd_2024_c23 shows promising activity in Discovery Phase applications."
    ],
    "doi_references": [
      {
        "doi": "10.1016/j.neuropharm.2024.1437",
        "title": "Pharmacological characterization of lsd_2024_c23 and related compounds",
        "journal": "Nature",
        "year": 2024,
        "confidence_score": 97
      },
      {
        "doi": "10.1021/jmedchem.2020.8039",
        "title": "Pharmacological characterization of lsd_2024_c23 and related compounds",
        "journal": "Nature",
        "year": 2023,
        "confidence_score": 85
      },
      {
        "doi": "10.1016/j.neuropharm.2021.5403",
        "title": "Pharmacological characterization of lsd_2024_c23 and related compounds",
        "journal": "Nature",
        "year": 2022,
        "confidence_score": 98
      },
      {
        "doi": "10.1126/science.2022.3334",
        "title": "Pharmacological characterization of lsd_2024_c23 and related compounds",
        "journal": "Science",
        "year": 2022,
        "confidence_score": 87
      }
    ],
    "last_updated": "2025-09-24T09:47:53.026965"
  },
  "mdma_2024_b24": {
    "id": 91,
    "name": "Mdma 2024 B24",
    "smiles": "CCN(CC)C(=O)[C@H]1CN([C@@H]2Cc3c[nH]c4cccc(c34)C2=C1)C",
    "molecular_weight": 174.42,
    "therapeutic_area": "Discovery Phase",
    "status": "Novel Research",
    "category": "novel_research",
    "patent_status": "Patent Pending",
    "patent_number": "US7150116",
    "safety_score": 82,
    "efficacy_score": 74,
    "drug_likeness": 62,
    "confidence_score": 75,
    "discovery_date": "2025-06-23T09:47:53.026971",
    "ip_status": "Under Review",
    "receptor_binding": {
      "Unknown": 72
    },
    "bioactivity_data": {
      "ic50_values": [
        129.33266893375517,
        903.6462987387738
      ],
      "ki_values": [
        352.58288775009186,
        469.77454280303425,
        499.04918792268904
      ],
      "ec50_values": [
        280.28853185016214,
        1180.913002170054,
        188.59311351509842
      ]
    },
    "research_notes": [
      "Preliminary studies indicate favorable pharmacokinetic properties.",
      "Further clinical development recommended based on preclinical efficacy data."
    ],
    "doi_references": [
      {
        "doi": "10.1021/jmedchem.2023.8947",
        "title": "Pharmacological characterization of mdma_2024_b24 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2023,
        "confidence_score": 90
      },
      {
        "doi": "10.1038/nature.2020.3036",
        "title": "Pharmacological characterization of mdma_2024_b24 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2020,
        "confidence_score": 88
      },
      {
        "doi": "10.1021/jmedchem.2022.9011",
        "title": "Pharmacological characterization of mdma_2024_b24 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2022,
        "confidence_score": 98
      },
      {
        "doi": "10.1016/j.neuropharm.2021.1644",
        "title": "Pharmacological characterization of mdma_2024_b24 and related compounds",
        "journal": "Science",
        "year": 2022,
        "confidence_score": 98
      }
    ],
    "last_updated": "2025-09-24T09:47:53.027003"
  },
  "mdma_2024_a25": {
    "id": 92,
    "name": "Mdma 2024 A25",
    "smiles": "CNC1(CCCCC1=O)c2ccccc2Cl",
    "molecular_weight": 153.16,
    "therapeutic_area": "Research Phase",
    "status": "Early Development",
    "category": "novel_research",
    "patent_status": "Patented",
    "patent_number": "US6314297",
    "safety_score": 69,
    "efficacy_score": 73,
    "drug_likeness": 93,
    "confidence_score": 84,
    "discovery_date": "2025-05-12T09:47:53.027008",
    "ip_status": "IP Opportunity Identified",
    "receptor_binding": {
      "Unknown": 57
    },
    "bioactivity_data": {
      "ic50_values": [
        28.896291931636313
      ],
      "ki_values": [
        221.9600101973812
      ],
      "ec50_values": [
        783.415214666105
      ]
    },
    "research_notes": [
      "Compound mdma_2024_a25 shows promising activity in Research Phase applications.",
      "Safety profile appears acceptable based on initial toxicology screening."
    ],
    "doi_references": [
      {
        "doi": "10.1124/jpet.2021.9550",
        "title": "Pharmacological characterization of mdma_2024_a25 and related compounds",
        "journal": "Science",
        "year": 2024,
        "confidence_score": 90
      },
      {
        "doi": "10.1124/jpet.2021.7228",
        "title": "Pharmacological characterization of mdma_2024_a25 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2024,
        "confidence_score": 89
      },
      {
        "doi": "10.1124/jpet.2023.1410",
        "title": "Pharmacological characterization of mdma_2024_a25 and related compounds",
        "journal": "Science",
        "year": 2020,
        "confidence_score": 91
      },
      {
        "doi": "10.1021/jmedchem.2023.1755",
        "title": "Pharmacological characterization of mdma_2024_a25 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2021,
        "confidence_score": 93
      },
      {
        "doi": "10.1021/jmedchem.2024.7601",
        "title": "Pharmacological characterization of mdma_2024_a25 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2023,
        "confidence_score": 88
      }
    ],
    "last_updated": "2025-09-24T09:47:53.027045"
  },
  "opi_2024_a26": {
    "id": 93,
    "name": "Opi 2024 A26",
    "smiles": "Cc1nnc2n1-c1ccc(Cl)cc1C(c1ccccc1)=NC2",
    "molecular_weight": 412.91,
    "therapeutic_area": "Preclinical",
    "status": "Novel Research",
    "category": "novel_research",
    "patent_status": "Patent-Free",
    "patent_number": "US2282335",
    "safety_score": 91,
    "efficacy_score": 75,
    "drug_likeness": 59,
    "confidence_score": 80,
    "discovery_date": "2024-10-31T09:47:53.027050",
    "ip_status": "Patent-Free",
    "receptor_binding": {
      "Unknown": 81
    },
    "bioactivity_data": {
      "ic50_values": [
        380.2868959682623
      ],
      "ki_values": [
        476.7328786531621
      ],
      "ec50_values": [
        951.4318429888176,
        1507.782855310176
      ]
    },
    "research_notes": [
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Preliminary studies indicate favorable pharmacokinetic properties.",
      "Compound opi_2024_a26 shows promising activity in Preclinical applications.",
      "Safety profile appears acceptable based on initial toxicology screening."
    ],
    "doi_references": [
      {
        "doi": "10.1126/science.2022.6102",
        "title": "Pharmacological characterization of opi_2024_a26 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2020,
        "confidence_score": 98
      }
    ],
    "last_updated": "2025-09-24T09:47:53.027077"
  },
  "mdma_2024_c27": {
    "id": 94,
    "name": "Mdma 2024 C27",
    "smiles": "Cc1nnc2n1-c1ccc(Cl)cc1C(c1ccccc1)=NC2",
    "molecular_weight": 455.35,
    "therapeutic_area": "Research Phase",
    "status": "Novel Research",
    "category": "novel_research",
    "patent_status": "Patent Pending",
    "patent_number": "US1132256",
    "safety_score": 83,
    "efficacy_score": 90,
    "drug_likeness": 76,
    "confidence_score": 78,
    "discovery_date": "2025-08-16T09:47:53.027082",
    "ip_status": "Patent-Free",
    "receptor_binding": {
      "Unknown": 54
    },
    "bioactivity_data": {
      "ic50_values": [
        183.65502925866895
      ],
      "ki_values": [
        430.5683958899387,
        77.71663496871068
      ],
      "ec50_values": [
        1468.566566636143
      ]
    },
    "research_notes": [
      "Preliminary studies indicate favorable pharmacokinetic properties.",
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Compound mdma_2024_c27 shows promising activity in Research Phase applications.",
      "Safety profile appears acceptable based on initial toxicology screening."
    ],
    "doi_references": [
      {
        "doi": "10.1124/jpet.2021.2730",
        "title": "Pharmacological characterization of mdma_2024_c27 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2022,
        "confidence_score": 88
      },
      {
        "doi": "10.1124/jpet.2020.3100",
        "title": "Pharmacological characterization of mdma_2024_c27 and related compounds",
        "journal": "Nature",
        "year": 2021,
        "confidence_score": 96
      },
      {
        "doi": "10.1126/science.2020.4122",
        "title": "Pharmacological characterization of mdma_2024_c27 and related compounds",
        "journal": "Science",
        "year": 2022,
        "confidence_score": 91
      },
      {
        "doi": "10.1038/nature.2020.6392",
        "title": "Pharmacological characterization of mdma_2024_c27 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2022,
        "confidence_score": 90
      }
    ],
    "last_updated": "2025-09-24T09:47:53.027117"
  },
  "stim_2025_z28": {
    "id": 95,
    "name": "Stim 2025 Z28",
    "smiles": "CC(CC1=CC2=C(C=C1)OCO2)NC",
    "molecular_weight": 216.97,
    "therapeutic_area": "Research Phase",
    "status": "Novel Research",
    "category": "novel_research",
    "patent_status": "Patent Pending",
    "patent_number": null,
    "safety_score": 87,
    "efficacy_score": 74,
    "drug_likeness": 65,
    "confidence_score": 82,
    "discovery_date": "2025-07-24T09:47:53.027126",
    "ip_status": "IP Opportunity Identified",
    "receptor_binding": {
      "Unknown": 87
    },
    "bioactivity_data": {
      "ic50_values": [
        102.73061167892395,
        870.4937119475601
      ],
      "ki_values": [
        179.54904508703163,
        245.369942366098
      ],
      "ec50_values": [
        491.34789301041775,
        1274.1551811061531,
        200.9640174957827
      ]
    },
    "research_notes": [
      "Preliminary studies indicate favorable pharmacokinetic properties.",
      "Further clinical development recommended based on preclinical efficacy data.",
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Safety profile appears acceptable based on initial toxicology screening."
    ],
    "doi_references": [
      {
        "doi": "10.1124/jpet.2021.8213",
        "title": "Pharmacological characterization of stim_2025_z28 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2023,
        "confidence_score": 95
      },
      {
        "doi": "10.1124/jpet.2024.8492",
        "title": "Pharmacological characterization of stim_2025_z28 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2024,
        "confidence_score": 94
      }
    ],
    "last_updated": "2025-09-24T09:47:53.027153"
  },
  "ket_2024_a29": {
    "id": 96,
    "name": "Ket 2024 A29",
    "smiles": "CN(C)CCc1c[nH]c2ccc(OP(=O)(O)O)cc12",
    "molecular_weight": 223.65,
    "therapeutic_area": "Preclinical",
    "status": "Early Development",
    "category": "novel_research",
    "patent_status": "Patent-Free",
    "patent_number": null,
    "safety_score": 67,
    "efficacy_score": 91,
    "drug_likeness": 73,
    "confidence_score": 83,
    "discovery_date": "2025-09-08T09:47:53.027158",
    "ip_status": "Under Review",
    "receptor_binding": {
      "Unknown": 80
    },
    "bioactivity_data": {
      "ic50_values": [
        213.385175123718,
        457.331860695005,
        982.6965786833712,
        884.0707584657412,
        323.7137153817523
      ],
      "ki_values": [
        427.2741208663861,
        402.48911321251
      ],
      "ec50_values": [
        901.2975981711838,
        1446.4770395566034
      ]
    },
    "research_notes": [
      "Preliminary studies indicate favorable pharmacokinetic properties.",
      "Safety profile appears acceptable based on initial toxicology screening."
    ],
    "doi_references": [
      {
        "doi": "10.1038/nature.2021.3780",
        "title": "Pharmacological characterization of ket_2024_a29 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2024,
        "confidence_score": 88
      },
      {
        "doi": "10.1016/j.neuropharm.2020.2574",
        "title": "Pharmacological characterization of ket_2024_a29 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2022,
        "confidence_score": 96
      }
    ],
    "last_updated": "2025-09-24T09:47:53.027188"
  },
  "opi_2024_c30": {
    "id": 97,
    "name": "Opi 2024 C30",
    "smiles": "CCN(CC)C(=O)[C@H]1CN([C@@H]2Cc3c[nH]c4cccc(c34)C2=C1)C",
    "molecular_weight": 359.9,
    "therapeutic_area": "Research Phase",
    "status": "Patent Pending",
    "category": "novel_research",
    "patent_status": "Patent Pending",
    "patent_number": "US2420749",
    "safety_score": 64,
    "efficacy_score": 94,
    "drug_likeness": 75,
    "confidence_score": 82,
    "discovery_date": "2024-12-24T09:47:53.027193",
    "ip_status": "Patent-Free",
    "receptor_binding": {
      "Unknown": 81
    },
    "bioactivity_data": {
      "ic50_values": [
        166.8904974081503,
        334.78447496563615,
        937.4503261713028
      ],
      "ki_values": [
        11.183299085338678,
        380.1954616836758,
        389.19744152659723
      ],
      "ec50_values": [
        1332.1017648103032,
        1139.4072397862292,
        364.82540268841814
      ]
    },
    "research_notes": [
      "Safety profile appears acceptable based on initial toxicology screening.",
      "Preliminary studies indicate favorable pharmacokinetic properties."
    ],
    "doi_references": [
      {
        "doi": "10.1126/science.2021.2514",
        "title": "Pharmacological characterization of opi_2024_c30 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2024,
        "confidence_score": 93
      },
      {
        "doi": "10.1021/jmedchem.2022.1320",
        "title": "Pharmacological characterization of opi_2024_c30 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2023,
        "confidence_score": 93
      },
      {
        "doi": "10.1016/j.neuropharm.2022.5410",
        "title": "Pharmacological characterization of opi_2024_c30 and related compounds",
        "journal": "Nature",
        "year": 2021,
        "confidence_score": 90
      },
      {
        "doi": "10.1124/jpet.2024.3068",
        "title": "Pharmacological characterization of opi_2024_c30 and related compounds",
        "journal": "Nature",
        "year": 2020,
        "confidence_score": 95
      },
      {
        "doi": "10.1021/jmedchem.2022.8383",
        "title": "Pharmacological characterization of opi_2024_c30 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2022,
        "confidence_score": 93
      }
    ],
    "last_updated": "2025-09-24T09:47:53.027233"
  },
  "anti_2025_x31": {
    "id": 98,
    "name": "Anti 2025 X31",
    "smiles": "CCN(CC)C(=O)[C@H]1CN([C@@H]2Cc3c[nH]c4cccc(c34)C2=C1)C",
    "molecular_weight": 339.56,
    "therapeutic_area": "Discovery Phase",
    "status": "Novel Research",
    "category": "novel_research",
    "patent_status": "Patented",
    "patent_number": "US2984787",
    "safety_score": 93,
    "efficacy_score": 95,
    "drug_likeness": 76,
    "confidence_score": 86,
    "discovery_date": "2025-04-24T09:47:53.027238",
    "ip_status": "Under Review",
    "receptor_binding": {
      "Unknown": 83
    },
    "bioactivity_data": {
      "ic50_values": [
        628.0686605767756,
        423.9761208334273,
        927.625584951312
      ],
      "ki_values": [
        150.12453791141806
      ],
      "ec50_values": [
        1964.578573984035,
        1117.896261729886,
        1492.676556098838
      ]
    },
    "research_notes": [
      "Further clinical development recommended based on preclinical efficacy data.",
      "Molecular docking studies suggest strong binding affinity to target receptors."
    ],
    "doi_references": [
      {
        "doi": "10.1038/nature.2021.4257",
        "title": "Pharmacological characterization of anti_2025_x31 and related compounds",
        "journal": "Nature",
        "year": 2024,
        "confidence_score": 98
      },
      {
        "doi": "10.1126/science.2024.6113",
        "title": "Pharmacological characterization of anti_2025_x31 and related compounds",
        "journal": "Science",
        "year": 2024,
        "confidence_score": 86
      },
      {
        "doi": "10.1038/nature.2022.5102",
        "title": "Pharmacological characterization of anti_2025_x31 and related compounds",
        "journal": "Science",
        "year": 2022,
        "confidence_score": 95
      },
      {
        "doi": "10.1126/science.2020.8004",
        "title": "Pharmacological characterization of anti_2025_x31 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2024,
        "confidence_score": 85
      }
    ],
    "last_updated": "2025-09-24T09:47:53.027271"
  },
  "mdma_2025_y32": {
    "id": 99,
    "name": "Mdma 2025 Y32",
    "smiles": "CNC1(CCCCC1=O)c2ccccc2Cl",
    "molecular_weight": 296.56,
    "therapeutic_area": "Novel Therapy",
    "status": "Novel Research",
    "category": "novel_research",
    "patent_status": "Patented",
    "patent_number": "US1730733",
    "safety_score": 70,
    "efficacy_score": 84,
    "drug_likeness": 61,
    "confidence_score": 93,
    "discovery_date": "2025-09-12T09:47:53.027276",
    "ip_status": "Patented",
    "receptor_binding": {
      "Unknown": 85
    },
    "bioactivity_data": {
      "ic50_values": [
        844.046338622703
      ],
      "ki_values": [
        364.28658348513994
      ],
      "ec50_values": [
        156.86253258055442
      ]
    },
    "research_notes": [
      "Compound mdma_2025_y32 shows promising activity in Novel Therapy applications.",
      "Safety profile appears acceptable based on initial toxicology screening.",
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Preliminary studies indicate favorable pharmacokinetic properties."
    ],
    "doi_references": [
      {
        "doi": "10.1021/jmedchem.2024.9295",
        "title": "Pharmacological characterization of mdma_2025_y32 and related compounds",
        "journal": "Nature",
        "year": 2021,
        "confidence_score": 88
      },
      {
        "doi": "10.1126/science.2021.7122",
        "title": "Pharmacological characterization of mdma_2025_y32 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2023,
        "confidence_score": 93
      }
    ],
    "last_updated": "2025-09-24T09:47:53.027308"
  },
  "anti_2024_c33": {
    "id": 100,
    "name": "Anti 2024 C33",
    "smiles": "CCN(CC)C(=O)[C@H]1CN([C@@H]2Cc3c[nH]c4cccc(c34)C2=C1)C",
    "molecular_weight": 459.39,
    "therapeutic_area": "Research Phase",
    "status": "Early Development",
    "category": "novel_research",
    "patent_status": "Patented",
    "patent_number": null,
    "safety_score": 69,
    "efficacy_score": 98,
    "drug_likeness": 85,
    "confidence_score": 82,
    "discovery_date": "2025-08-06T09:47:53.027313",
    "ip_status": "IP Opportunity Identified",
    "receptor_binding": {
      "Unknown": 88
    },
    "bioactivity_data": {
      "ic50_values": [
        917.1074663986952,
        129.2362382866634,
        778.8776706427801,
        574.5983004915665,
        870.9885023884556
      ],
      "ki_values": [
        121.02448850830115,
        293.5445501500077
      ],
      "ec50_values": [
        993.6381778747603,
        883.4524040260578,
        1240.1563092921865,
        364.8552023633371
      ]
    },
    "research_notes": [
      "Further clinical development recommended based on preclinical efficacy data.",
      "Preliminary studies indicate favorable pharmacokinetic properties."
    ],
    "doi_references": [
      {
        "doi": "10.1038/nature.2020.1509",
        "title": "Pharmacological characterization of anti_2024_c33 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2023,
        "confidence_score": 90
      },
      {
        "doi": "10.1021/jmedchem.2024.2972",
        "title": "Pharmacological characterization of anti_2024_c33 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2024,
        "confidence_score": 87
      },
      {
        "doi": "10.1016/j.neuropharm.2022.3284",
        "title": "Pharmacological characterization of anti_2024_c33 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2022,
        "confidence_score": 90
      },
      {
        "doi": "10.1038/nature.2020.6938",
        "title": "Pharmacological characterization of anti_2024_c33 and related compounds",
        "journal": "Nature",
        "year": 2023,
        "confidence_score": 94
      },
      {
        "doi": "10.1021/jmedchem.2024.3643",
        "title": "Pharmacological characterization of anti_2024_c33 and related compounds",
        "journal": "Science",
        "year": 2023,
        "confidence_score": 95
      }
    ],
    "last_updated": "2025-09-24T09:47:53.027350"
  },
  "psi_2025_x34": {
    "id": 101,
    "name": "Psi 2025 X34",
    "smiles": "Cc1nnc2n1-c1ccc(Cl)cc1C(c1ccccc1)=NC2",
    "molecular_weight": 456.8,
    "therapeutic_area": "Preclinical",
    "status": "Novel Research",
    "category": "novel_research",
    "patent_status": "Patent-Free",
    "patent_number": "US3082403",
    "safety_score": 77,
    "efficacy_score": 71,
    "drug_likeness": 95,
    "confidence_score": 81,
    "discovery_date": "2025-08-28T09:47:53.027356",
    "ip_status": "IP Opportunity Identified",
    "receptor_binding": {
      "Unknown": 63
    },
    "bioactivity_data": {
      "ic50_values": [
        477.7572846670755
      ],
      "ki_values": [
        365.6360495389017
      ],
      "ec50_values": [
        1159.5214172577996,
        543.7779264749572,
        142.89019354132338,
        1844.6762569152734
      ]
    },
    "research_notes": [
      "Compound psi_2025_x34 shows promising activity in Preclinical applications.",
      "Preliminary studies indicate favorable pharmacokinetic properties.",
      "Further clinical development recommended based on preclinical efficacy data."
    ],
    "doi_references": [
      {
        "doi": "10.1126/science.2024.7573",
        "title": "Pharmacological characterization of psi_2025_x34 and related compounds",
        "journal": "Science",
        "year": 2024,
        "confidence_score": 94
      },
      {
        "doi": "10.1124/jpet.2020.4488",
        "title": "Pharmacological characterization of psi_2025_x34 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2024,
        "confidence_score": 89
      },
      {
        "doi": "10.1126/science.2022.8315",
        "title": "Pharmacological characterization of psi_2025_x34 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2022,
        "confidence_score": 85
      }
    ],
    "last_updated": "2025-09-24T09:47:53.027385"
  },
  "psi_2024_b35": {
    "id": 102,
    "name": "Psi 2024 B35",
    "smiles": "CNC1(CCCCC1=O)c2ccccc2Cl",
    "molecular_weight": 340.43,
    "therapeutic_area": "Preclinical",
    "status": "Novel Research",
    "category": "novel_research",
    "patent_status": "Patented",
    "patent_number": "US1484276",
    "safety_score": 81,
    "efficacy_score": 94,
    "drug_likeness": 64,
    "confidence_score": 76,
    "discovery_date": "2025-07-20T09:47:53.027390",
    "ip_status": "Patent-Free",
    "receptor_binding": {
      "Unknown": 81
    },
    "bioactivity_data": {
      "ic50_values": [
        891.539776978538
      ],
      "ki_values": [
        295.59886619077,
        76.86265915055472,
        252.9962069384267
      ],
      "ec50_values": [
        1688.944966921205,
        1078.6472199538748,
        1847.6962760728247
      ]
    },
    "research_notes": [
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Preliminary studies indicate favorable pharmacokinetic properties.",
      "Compound psi_2024_b35 shows promising activity in Preclinical applications."
    ],
    "doi_references": [
      {
        "doi": "10.1016/j.neuropharm.2024.3749",
        "title": "Pharmacological characterization of psi_2024_b35 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2022,
        "confidence_score": 89
      },
      {
        "doi": "10.1124/jpet.2022.8130",
        "title": "Pharmacological characterization of psi_2024_b35 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2023,
        "confidence_score": 98
      },
      {
        "doi": "10.1021/jmedchem.2020.2726",
        "title": "Pharmacological characterization of psi_2024_b35 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2024,
        "confidence_score": 98
      }
    ],
    "last_updated": "2025-09-24T09:47:53.027419"
  },
  "psi_2024_c36": {
    "id": 103,
    "name": "Psi 2024 C36",
    "smiles": "Cc1nnc2n1-c1ccc(Cl)cc1C(c1ccccc1)=NC2",
    "molecular_weight": 235.41,
    "therapeutic_area": "Novel Therapy",
    "status": "Novel Research",
    "category": "novel_research",
    "patent_status": "Patent Pending",
    "patent_number": null,
    "safety_score": 89,
    "efficacy_score": 66,
    "drug_likeness": 81,
    "confidence_score": 93,
    "discovery_date": "2025-06-03T09:47:53.027424",
    "ip_status": "Under Review",
    "receptor_binding": {
      "Unknown": 54
    },
    "bioactivity_data": {
      "ic50_values": [
        334.5992380204346,
        881.6398182614573,
        821.8640752408111,
        749.3501663340337,
        407.3570324104318
      ],
      "ki_values": [
        38.550825540798186,
        369.38883816603425
      ],
      "ec50_values": [
        1410.6081062475441,
        384.93775044890975
      ]
    },
    "research_notes": [
      "Further clinical development recommended based on preclinical efficacy data.",
      "Compound psi_2024_c36 shows promising activity in Novel Therapy applications.",
      "Safety profile appears acceptable based on initial toxicology screening."
    ],
    "doi_references": [
      {
        "doi": "10.1021/jmedchem.2023.5780",
        "title": "Pharmacological characterization of psi_2024_c36 and related compounds",
        "journal": "Nature",
        "year": 2020,
        "confidence_score": 89
      },
      {
        "doi": "10.1126/science.2021.8082",
        "title": "Pharmacological characterization of psi_2024_c36 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2023,
        "confidence_score": 88
      },
      {
        "doi": "10.1124/jpet.2024.1530",
        "title": "Pharmacological characterization of psi_2024_c36 and related compounds",
        "journal": "Science",
        "year": 2021,
        "confidence_score": 88
      },
      {
        "doi": "10.1124/jpet.2024.1634",
        "title": "Pharmacological characterization of psi_2024_c36 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2020,
        "confidence_score": 95
      },
      {
        "doi": "10.1124/jpet.2022.5075",
        "title": "Pharmacological characterization of psi_2024_c36 and related compounds",
        "journal": "Science",
        "year": 2022,
        "confidence_score": 95
      }
    ],
    "last_updated": "2025-09-24T09:47:53.027466"
  },
  "psi_2024_c37": {
    "id": 104,
    "name": "Psi 2024 C37",
    "smiles": "CC(CC1=CC2=C(C=C1)OCO2)NC",
    "molecular_weight": 165.09,
    "therapeutic_area": "Research Phase",
    "status": "Early Development",
    "category": "novel_research",
    "patent_status": "Patented",
    "patent_number": "US8972349",
    "safety_score": 86,
    "efficacy_score": 94,
    "drug_likeness": 74,
    "confidence_score": 96,
    "discovery_date": "2025-09-13T09:47:53.027472",
    "ip_status": "IP Opportunity Identified",
    "receptor_binding": {
      "Unknown": 75
    },
    "bioactivity_data": {
      "ic50_values": [
        613.4143564172201,
        818.3299371036438,
        462.4567422478992,
        188.87667691483855,
        205.11634492080793
      ],
      "ki_values": [
        133.5618210471548,
        305.34661292450494,
        260.3920041548902
      ],
      "ec50_values": [
        388.81950256427126,
        1072.471797316338
      ]
    },
    "research_notes": [
      "Safety profile appears acceptable based on initial toxicology screening.",
      "Compound psi_2024_c37 shows promising activity in Research Phase applications.",
      "Preliminary studies indicate favorable pharmacokinetic properties.",
      "Molecular docking studies suggest strong binding affinity to target receptors."
    ],
    "doi_references": [
      {
        "doi": "10.1038/nature.2023.2272",
        "title": "Pharmacological characterization of psi_2024_c37 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2023,
        "confidence_score": 89
      },
      {
        "doi": "10.1021/jmedchem.2024.3702",
        "title": "Pharmacological characterization of psi_2024_c37 and related compounds",
        "journal": "Science",
        "year": 2023,
        "confidence_score": 93
      },
      {
        "doi": "10.1016/j.neuropharm.2020.7969",
        "title": "Pharmacological characterization of psi_2024_c37 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2022,
        "confidence_score": 98
      }
    ],
    "last_updated": "2025-09-24T09:47:53.027502"
  },
  "bzd_2024_b38": {
    "id": 105,
    "name": "Bzd 2024 B38",
    "smiles": "CC(CC1=CC2=C(C=C1)OCO2)NC",
    "molecular_weight": 425.44,
    "therapeutic_area": "Discovery Phase",
    "status": "Novel Research",
    "category": "novel_research",
    "patent_status": "Patent-Free",
    "patent_number": "US3900187",
    "safety_score": 88,
    "efficacy_score": 91,
    "drug_likeness": 77,
    "confidence_score": 91,
    "discovery_date": "2024-10-13T09:47:53.027510",
    "ip_status": "IP Opportunity Identified",
    "receptor_binding": {
      "Unknown": 53
    },
    "bioactivity_data": {
      "ic50_values": [
        669.7853114295535,
        926.214450137523,
        993.517173523207,
        36.92103049455796
      ],
      "ki_values": [
        179.1022997163336
      ],
      "ec50_values": [
        186.99139191316442,
        386.04624901132325
      ]
    },
    "research_notes": [
      "Preliminary studies indicate favorable pharmacokinetic properties.",
      "Further clinical development recommended based on preclinical efficacy data.",
      "Safety profile appears acceptable based on initial toxicology screening."
    ],
    "doi_references": [
      {
        "doi": "10.1124/jpet.2022.5082",
        "title": "Pharmacological characterization of bzd_2024_b38 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2020,
        "confidence_score": 85
      },
      {
        "doi": "10.1124/jpet.2020.2503",
        "title": "Pharmacological characterization of bzd_2024_b38 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2024,
        "confidence_score": 98
      },
      {
        "doi": "10.1038/nature.2024.8352",
        "title": "Pharmacological characterization of bzd_2024_b38 and related compounds",
        "journal": "Science",
        "year": 2023,
        "confidence_score": 96
      },
      {
        "doi": "10.1016/j.neuropharm.2024.8097",
        "title": "Pharmacological characterization of bzd_2024_b38 and related compounds",
        "journal": "Science",
        "year": 2021,
        "confidence_score": 92
      },
      {
        "doi": "10.1038/nature.2024.4735",
        "title": "Pharmacological characterization of bzd_2024_b38 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2020,
        "confidence_score": 89
      }
    ],
    "last_updated": "2025-09-24T09:47:53.027546"
  },
  "anti_2025_x39": {
    "id": 106,
    "name": "Anti 2025 X39",
    "smiles": "CC(CC1=CC2=C(C=C1)OCO2)NC",
    "molecular_weight": 408.18,
    "therapeutic_area": "Discovery Phase",
    "status": "Early Development",
    "category": "novel_research",
    "patent_status": "Patent Expired",
    "patent_number": "US1852991",
    "safety_score": 64,
    "efficacy_score": 92,
    "drug_likeness": 56,
    "confidence_score": 95,
    "discovery_date": "2025-04-16T09:47:53.027551",
    "ip_status": "IP Opportunity Identified",
    "receptor_binding": {
      "Unknown": 75
    },
    "bioactivity_data": {
      "ic50_values": [
        641.0820802530473,
        915.6727919362471,
        940.7387643780153
      ],
      "ki_values": [
        373.23521875286696
      ],
      "ec50_values": [
        513.7685444640839,
        1372.435048269682,
        1600.6818037201922
      ]
    },
    "research_notes": [
      "Preliminary studies indicate favorable pharmacokinetic properties.",
      "Further clinical development recommended based on preclinical efficacy data.",
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Safety profile appears acceptable based on initial toxicology screening."
    ],
    "doi_references": [
      {
        "doi": "10.1038/nature.2024.3843",
        "title": "Pharmacological characterization of anti_2025_x39 and related compounds",
        "journal": "Science",
        "year": 2024,
        "confidence_score": 91
      },
      {
        "doi": "10.1124/jpet.2020.9261",
        "title": "Pharmacological characterization of anti_2025_x39 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2022,
        "confidence_score": 95
      },
      {
        "doi": "10.1038/nature.2021.9820",
        "title": "Pharmacological characterization of anti_2025_x39 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2021,
        "confidence_score": 95
      },
      {
        "doi": "10.1124/jpet.2020.9348",
        "title": "Pharmacological characterization of anti_2025_x39 and related compounds",
        "journal": "Nature",
        "year": 2020,
        "confidence_score": 98
      }
    ],
    "last_updated": "2025-09-24T09:47:53.027587"
  },
  "lsd_2025_x40": {
    "id": 107,
    "name": "Lsd 2025 X40",
    "smiles": "Cc1nnc2n1-c1ccc(Cl)cc1C(c1ccccc1)=NC2",
    "molecular_weight": 437.22,
    "therapeutic_area": "Discovery Phase",
    "status": "Early Development",
    "category": "novel_research",
    "patent_status": "Patent Expired",
    "patent_number": null,
    "safety_score": 95,
    "efficacy_score": 67,
    "drug_likeness": 73,
    "confidence_score": 75,
    "discovery_date": "2025-06-26T09:47:53.027592",
    "ip_status": "Patent-Free",
    "receptor_binding": {
      "Unknown": 88
    },
    "bioactivity_data": {
      "ic50_values": [
        332.72652582827766,
        241.16347941031043,
        405.5092904108865,
        907.9346869099642
      ],
      "ki_values": [
        95.24172891097967,
        111.8380686739759,
        205.34227889488582
      ],
      "ec50_values": [
        1960.813348796661,
        1889.716560580668,
        1010.6366069874359
      ]
    },
    "research_notes": [
      "Further clinical development recommended based on preclinical efficacy data.",
      "Compound lsd_2025_x40 shows promising activity in Discovery Phase applications.",
      "Safety profile appears acceptable based on initial toxicology screening."
    ],
    "doi_references": [
      {
        "doi": "10.1038/nature.2021.5371",
        "title": "Pharmacological characterization of lsd_2025_x40 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2023,
        "confidence_score": 98
      },
      {
        "doi": "10.1021/jmedchem.2022.8543",
        "title": "Pharmacological characterization of lsd_2025_x40 and related compounds",
        "journal": "Nature",
        "year": 2023,
        "confidence_score": 91
      }
    ],
    "last_updated": "2025-09-24T09:47:53.027632"
  },
  "ket_2025_x41": {
    "id": 108,
    "name": "Ket 2025 X41",
    "smiles": "CCN(CC)C(=O)[C@H]1CN([C@@H]2Cc3c[nH]c4cccc(c34)C2=C1)C",
    "molecular_weight": 484.21,
    "therapeutic_area": "Research Phase",
    "status": "Patent Pending",
    "category": "novel_research",
    "patent_status": "Patent Pending",
    "patent_number": "US7121535",
    "safety_score": 95,
    "efficacy_score": 95,
    "drug_likeness": 77,
    "confidence_score": 83,
    "discovery_date": "2025-05-09T09:47:53.027638",
    "ip_status": "IP Opportunity Identified",
    "receptor_binding": {
      "Unknown": 70
    },
    "bioactivity_data": {
      "ic50_values": [
        586.1334529922747,
        72.51366442444784,
        12.465921410971893,
        929.8673825252125
      ],
      "ki_values": [
        316.2200217164441,
        213.2528984499912,
        390.9543406479503
      ],
      "ec50_values": [
        647.6023887121036,
        1334.9559541008987,
        282.9973285459218
      ]
    },
    "research_notes": [
      "Further clinical development recommended based on preclinical efficacy data.",
      "Safety profile appears acceptable based on initial toxicology screening."
    ],
    "doi_references": [
      {
        "doi": "10.1126/science.2021.3164",
        "title": "Pharmacological characterization of ket_2025_x41 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2020,
        "confidence_score": 87
      }
    ],
    "last_updated": "2025-09-24T09:47:53.027664"
  },
  "mdma_2025_z42": {
    "id": 109,
    "name": "Mdma 2025 Z42",
    "smiles": "CN(C)CCc1c[nH]c2ccc(OP(=O)(O)O)cc12",
    "molecular_weight": 235.98,
    "therapeutic_area": "Novel Therapy",
    "status": "Novel Research",
    "category": "novel_research",
    "patent_status": "Patent Pending",
    "patent_number": "US5676726",
    "safety_score": 84,
    "efficacy_score": 88,
    "drug_likeness": 57,
    "confidence_score": 94,
    "discovery_date": "2025-07-07T09:47:53.027669",
    "ip_status": "Patent-Free",
    "receptor_binding": {
      "Unknown": 81
    },
    "bioactivity_data": {
      "ic50_values": [
        13.618144939519249,
        417.0848262845246,
        701.8568866386889,
        604.6270000483854,
        685.0946796299618
      ],
      "ki_values": [
        431.5146396314861,
        249.99216397180726
      ],
      "ec50_values": [
        860.0090267030151,
        634.7525886444073,
        453.52815197800845,
        1127.0505943940404
      ]
    },
    "research_notes": [
      "Further clinical development recommended based on preclinical efficacy data.",
      "Molecular docking studies suggest strong binding affinity to target receptors."
    ],
    "doi_references": [
      {
        "doi": "10.1021/jmedchem.2020.2623",
        "title": "Pharmacological characterization of mdma_2025_z42 and related compounds",
        "journal": "Science",
        "year": 2022,
        "confidence_score": 90
      },
      {
        "doi": "10.1038/nature.2022.6918",
        "title": "Pharmacological characterization of mdma_2025_z42 and related compounds",
        "journal": "Science",
        "year": 2024,
        "confidence_score": 90
      },
      {
        "doi": "10.1124/jpet.2023.3696",
        "title": "Pharmacological characterization of mdma_2025_z42 and related compounds",
        "journal": "Science",
        "year": 2020,
        "confidence_score": 88
      },
      {
        "doi": "10.1021/jmedchem.2021.4376",
        "title": "Pharmacological characterization of mdma_2025_z42 and related compounds",
        "journal": "Science",
        "year": 2023,
        "confidence_score": 95
      }
    ],
    "last_updated": "2025-09-24T09:47:53.027701"
  },
  "mdma_2025_y43": {
    "id": 110,
    "name": "Mdma 2025 Y43",
    "smiles": "CCN(CC)C(=O)[C@H]1CN([C@@H]2Cc3c[nH]c4cccc(c34)C2=C1)C",
    "molecular_weight": 438.68,
    "therapeutic_area": "Research Phase",
    "status": "Early Development",
    "category": "novel_research",
    "patent_status": "Patent-Free",
    "patent_number": null,
    "safety_score": 87,
    "efficacy_score": 80,
    "drug_likeness": 76,
    "confidence_score": 91,
    "discovery_date": "2025-05-20T09:47:53.027706",
    "ip_status": "IP Opportunity Identified",
    "receptor_binding": {
      "Unknown": 61
    },
    "bioactivity_data": {
      "ic50_values": [
        617.6260868577255
      ],
      "ki_values": [
        208.41652792414604,
        206.8445649255411
      ],
      "ec50_values": [
        1865.9221368455696,
        217.61851708322558,
        1320.9588142746784,
        213.25669280372762
      ]
    },
    "research_notes": [
      "Compound mdma_2025_y43 shows promising activity in Research Phase applications.",
      "Further clinical development recommended based on preclinical efficacy data."
    ],
    "doi_references": [
      {
        "doi": "10.1016/j.neuropharm.2023.6699",
        "title": "Pharmacological characterization of mdma_2025_y43 and related compounds",
        "journal": "Science",
        "year": 2022,
        "confidence_score": 88
      }
    ],
    "last_updated": "2025-09-24T09:47:53.027731"
  },
  "bzd_2024_c44": {
    "id": 111,
    "name": "Bzd 2024 C44",
    "smiles": "CC(CC1=CC2=C(C=C1)OCO2)NC",
    "molecular_weight": 222.7,
    "therapeutic_area": "Preclinical",
    "status": "Early Development",
    "category": "novel_research",
    "patent_status": "Patent Pending",
    "patent_number": "US1500456",
    "safety_score": 60,
    "efficacy_score": 95,
    "drug_likeness": 95,
    "confidence_score": 91,
    "discovery_date": "2025-05-01T09:47:53.027736",
    "ip_status": "Patented",
    "receptor_binding": {
      "Unknown": 74
    },
    "bioactivity_data": {
      "ic50_values": [
        911.0235886425871
      ],
      "ki_values": [
        440.95065545813156,
        216.28331390391494,
        325.8681824357844
      ],
      "ec50_values": [
        642.1182484756534,
        1341.878857852718
      ]
    },
    "research_notes": [
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Compound bzd_2024_c44 shows promising activity in Preclinical applications.",
      "Preliminary studies indicate favorable pharmacokinetic properties."
    ],
    "doi_references": [
      {
        "doi": "10.1021/jmedchem.2020.9071",
        "title": "Pharmacological characterization of bzd_2024_c44 and related compounds",
        "journal": "Science",
        "year": 2020,
        "confidence_score": 94
      },
      {
        "doi": "10.1021/jmedchem.2021.7584",
        "title": "Pharmacological characterization of bzd_2024_c44 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2024,
        "confidence_score": 85
      },
      {
        "doi": "10.1016/j.neuropharm.2023.2155",
        "title": "Pharmacological characterization of bzd_2024_c44 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2021,
        "confidence_score": 89
      },
      {
        "doi": "10.1016/j.neuropharm.2021.8522",
        "title": "Pharmacological characterization of bzd_2024_c44 and related compounds",
        "journal": "Science",
        "year": 2020,
        "confidence_score": 87
      }
    ],
    "last_updated": "2025-09-24T09:47:53.027768"
  },
  "stim_2025_z45": {
    "id": 112,
    "name": "Stim 2025 Z45",
    "smiles": "CNC1(CCCCC1=O)c2ccccc2Cl",
    "molecular_weight": 157.14,
    "therapeutic_area": "Preclinical",
    "status": "Novel Research",
    "category": "novel_research",
    "patent_status": "Patent Pending",
    "patent_number": null,
    "safety_score": 79,
    "efficacy_score": 75,
    "drug_likeness": 77,
    "confidence_score": 98,
    "discovery_date": "2025-05-07T09:47:53.027773",
    "ip_status": "Patented",
    "receptor_binding": {
      "Unknown": 76
    },
    "bioactivity_data": {
      "ic50_values": [
        315.8239048602489
      ],
      "ki_values": [
        197.94168809572076,
        403.5612928283905
      ],
      "ec50_values": [
        819.828656674068,
        1396.7963675067565,
        1616.2329696620689,
        1823.1778684524616
      ]
    },
    "research_notes": [
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Preliminary studies indicate favorable pharmacokinetic properties.",
      "Compound stim_2025_z45 shows promising activity in Preclinical applications."
    ],
    "doi_references": [
      {
        "doi": "10.1038/nature.2024.9661",
        "title": "Pharmacological characterization of stim_2025_z45 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2021,
        "confidence_score": 97
      },
      {
        "doi": "10.1124/jpet.2024.6649",
        "title": "Pharmacological characterization of stim_2025_z45 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2020,
        "confidence_score": 88
      },
      {
        "doi": "10.1126/science.2020.7988",
        "title": "Pharmacological characterization of stim_2025_z45 and related compounds",
        "journal": "Nature",
        "year": 2023,
        "confidence_score": 91
      },
      {
        "doi": "10.1021/jmedchem.2024.8027",
        "title": "Pharmacological characterization of stim_2025_z45 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2020,
        "confidence_score": 97
      },
      {
        "doi": "10.1126/science.2024.7035",
        "title": "Pharmacological characterization of stim_2025_z45 and related compounds",
        "journal": "Nature",
        "year": 2021,
        "confidence_score": 97
      }
    ],
    "last_updated": "2025-09-24T09:47:53.027811"
  },
  "opi_2024_c46": {
    "id": 113,
    "name": "Opi 2024 C46",
    "smiles": "CN(C)CCc1c[nH]c2ccc(OP(=O)(O)O)cc12",
    "molecular_weight": 381.91,
    "therapeutic_area": "Research Phase",
    "status": "Novel Research",
    "category": "novel_research",
    "patent_status": "Patented",
    "patent_number": "US8482881",
    "safety_score": 88,
    "efficacy_score": 74,
    "drug_likeness": 93,
    "confidence_score": 78,
    "discovery_date": "2025-04-08T09:47:53.027817",
    "ip_status": "Under Review",
    "receptor_binding": {
      "Unknown": 69
    },
    "bioactivity_data": {
      "ic50_values": [
        136.05011084929316
      ],
      "ki_values": [
        484.6653123766104
      ],
      "ec50_values": [
        99.38292782712844,
        1249.3135365708185,
        943.7541230746378,
        912.1666321534294
      ]
    },
    "research_notes": [
      "Preliminary studies indicate favorable pharmacokinetic properties.",
      "Compound opi_2024_c46 shows promising activity in Research Phase applications."
    ],
    "doi_references": [
      {
        "doi": "10.1016/j.neuropharm.2021.5150",
        "title": "Pharmacological characterization of opi_2024_c46 and related compounds",
        "journal": "Science",
        "year": 2023,
        "confidence_score": 96
      },
      {
        "doi": "10.1016/j.neuropharm.2024.3473",
        "title": "Pharmacological characterization of opi_2024_c46 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2022,
        "confidence_score": 98
      },
      {
        "doi": "10.1016/j.neuropharm.2021.6670",
        "title": "Pharmacological characterization of opi_2024_c46 and related compounds",
        "journal": "Nature",
        "year": 2022,
        "confidence_score": 89
      },
      {
        "doi": "10.1126/science.2021.7435",
        "title": "Pharmacological characterization of opi_2024_c46 and related compounds",
        "journal": "Nature",
        "year": 2022,
        "confidence_score": 94
      }
    ],
    "last_updated": "2025-09-24T09:47:53.027851"
  },
  "ket_2025_z47": {
    "id": 114,
    "name": "Ket 2025 Z47",
    "smiles": "CC(CC1=CC2=C(C=C1)OCO2)NC",
    "molecular_weight": 345.29,
    "therapeutic_area": "Novel Therapy",
    "status": "Novel Research",
    "category": "novel_research",
    "patent_status": "Patented",
    "patent_number": "US9920782",
    "safety_score": 71,
    "efficacy_score": 69,
    "drug_likeness": 55,
    "confidence_score": 98,
    "discovery_date": "2025-02-15T09:47:53.027856",
    "ip_status": "Under Review",
    "receptor_binding": {
      "Unknown": 84
    },
    "bioactivity_data": {
      "ic50_values": [
        175.5444372363556,
        265.754349471978
      ],
      "ki_values": [
        119.18851137433825,
        295.48751026214757,
        98.03383654232766
      ],
      "ec50_values": [
        164.09740891126378,
        1222.099247784685,
        207.25961728851055,
        894.6637289128788
      ]
    },
    "research_notes": [
      "Further clinical development recommended based on preclinical efficacy data.",
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Preliminary studies indicate favorable pharmacokinetic properties.",
      "Compound ket_2025_z47 shows promising activity in Novel Therapy applications."
    ],
    "doi_references": [
      {
        "doi": "10.1038/nature.2022.8366",
        "title": "Pharmacological characterization of ket_2025_z47 and related compounds",
        "journal": "Nature",
        "year": 2024,
        "confidence_score": 90
      },
      {
        "doi": "10.1126/science.2022.8953",
        "title": "Pharmacological characterization of ket_2025_z47 and related compounds",
        "journal": "Science",
        "year": 2023,
        "confidence_score": 95
      },
      {
        "doi": "10.1126/science.2020.6410",
        "title": "Pharmacological characterization of ket_2025_z47 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2021,
        "confidence_score": 93
      }
    ],
    "last_updated": "2025-09-24T09:47:53.027885"
  },
  "anti_2025_z48": {
    "id": 115,
    "name": "Anti 2025 Z48",
    "smiles": "Cc1nnc2n1-c1ccc(Cl)cc1C(c1ccccc1)=NC2",
    "molecular_weight": 494.17,
    "therapeutic_area": "Preclinical",
    "status": "Early Development",
    "category": "novel_research",
    "patent_status": "Patent Expired",
    "patent_number": "US4994204",
    "safety_score": 67,
    "efficacy_score": 96,
    "drug_likeness": 87,
    "confidence_score": 83,
    "discovery_date": "2025-05-04T09:47:53.027892",
    "ip_status": "IP Opportunity Identified",
    "receptor_binding": {
      "Unknown": 82
    },
    "bioactivity_data": {
      "ic50_values": [
        959.1007607542133,
        264.9701120397052,
        398.05425347639584,
        784.5034358392373,
        824.3648118510025
      ],
      "ki_values": [
        289.3776752704171
      ],
      "ec50_values": [
        1841.666855395008,
        1452.1037884834373,
        757.7839412243754
      ]
    },
    "research_notes": [
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Further clinical development recommended based on preclinical efficacy data."
    ],
    "doi_references": [
      {
        "doi": "10.1124/jpet.2021.6744",
        "title": "Pharmacological characterization of anti_2025_z48 and related compounds",
        "journal": "Nature",
        "year": 2023,
        "confidence_score": 93
      }
    ],
    "last_updated": "2025-09-24T09:47:53.027916"
  },
  "psi_2024_a49": {
    "id": 116,
    "name": "Psi 2024 A49",
    "smiles": "Cc1nnc2n1-c1ccc(Cl)cc1C(c1ccccc1)=NC2",
    "molecular_weight": 243.75,
    "therapeutic_area": "Discovery Phase",
    "status": "Early Development",
    "category": "novel_research",
    "patent_status": "Patent Pending",
    "patent_number": "US5750696",
    "safety_score": 70,
    "efficacy_score": 89,
    "drug_likeness": 60,
    "confidence_score": 81,
    "discovery_date": "2025-01-19T09:47:53.027921",
    "ip_status": "IP Opportunity Identified",
    "receptor_binding": {
      "Unknown": 54
    },
    "bioactivity_data": {
      "ic50_values": [
        660.7553075619045,
        758.2483860842564,
        288.0450451597911
      ],
      "ki_values": [
        151.77086847197032
      ],
      "ec50_values": [
        568.1112857874159,
        812.1718730427555,
        1965.102123304782,
        1636.1700568467695
      ]
    },
    "research_notes": [
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Compound psi_2024_a49 shows promising activity in Discovery Phase applications.",
      "Further clinical development recommended based on preclinical efficacy data."
    ],
    "doi_references": [
      {
        "doi": "10.1016/j.neuropharm.2023.9589",
        "title": "Pharmacological characterization of psi_2024_a49 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2021,
        "confidence_score": 90
      },
      {
        "doi": "10.1124/jpet.2024.1203",
        "title": "Pharmacological characterization of psi_2024_a49 and related compounds",
        "journal": "Science",
        "year": 2020,
        "confidence_score": 92
      },
      {
        "doi": "10.1124/jpet.2024.9918",
        "title": "Pharmacological characterization of psi_2024_a49 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2023,
        "confidence_score": 89
      },
      {
        "doi": "10.1126/science.2024.8992",
        "title": "Pharmacological characterization of psi_2024_a49 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2023,
        "confidence_score": 95
      },
      {
        "doi": "10.1126/science.2024.5363",
        "title": "Pharmacological characterization of psi_2024_a49 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2021,
        "confidence_score": 85
      }
    ],
    "last_updated": "2025-09-24T09:47:53.027963"
  },
  "bzd_2025_y50": {
    "id": 117,
    "name": "Bzd 2025 Y50",
    "smiles": "CN(C)CCc1c[nH]c2ccc(OP(=O)(O)O)cc12",
    "molecular_weight": 164.63,
    "therapeutic_area": "Preclinical",
    "status": "Novel Research",
    "category": "novel_research",
    "patent_status": "Patented",
    "patent_number": "US3081529",
    "safety_score": 88,
    "efficacy_score": 87,
    "drug_likeness": 92,
    "confidence_score": 98,
    "discovery_date": "2025-02-08T09:47:53.027968",
    "ip_status": "Patented",
    "receptor_binding": {
      "Unknown": 86
    },
    "bioactivity_data": {
      "ic50_values": [
        908.1258545921756
      ],
      "ki_values": [
        43.940801295521396,
        467.57340642621676,
        349.75108873597543
      ],
      "ec50_values": [
        1053.396065427047
      ]
    },
    "research_notes": [
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Safety profile appears acceptable based on initial toxicology screening."
    ],
    "doi_references": [
      {
        "doi": "10.1016/j.neuropharm.2020.5729",
        "title": "Pharmacological characterization of bzd_2025_y50 and related compounds",
        "journal": "Science",
        "year": 2023,
        "confidence_score": 88
      }
    ],
    "last_updated": "2025-09-24T09:47:53.027991"
  },
  "opi_2025_y51": {
    "id": 118,
    "name": "Opi 2025 Y51",
    "smiles": "CCN(CC)C(=O)[C@H]1CN([C@@H]2Cc3c[nH]c4cccc(c34)C2=C1)C",
    "molecular_weight": 318.47,
    "therapeutic_area": "Preclinical",
    "status": "Novel Research",
    "category": "novel_research",
    "patent_status": "Patent Pending",
    "patent_number": null,
    "safety_score": 81,
    "efficacy_score": 78,
    "drug_likeness": 59,
    "confidence_score": 96,
    "discovery_date": "2025-08-02T09:47:53.027995",
    "ip_status": "IP Opportunity Identified",
    "receptor_binding": {
      "Unknown": 67
    },
    "bioactivity_data": {
      "ic50_values": [
        405.433950865271
      ],
      "ki_values": [
        207.37920536406725,
        442.7473479123652,
        48.153937639562685
      ],
      "ec50_values": [
        863.5105833373212,
        1882.018012032563,
        1756.0498598023328,
        811.6898747852816
      ]
    },
    "research_notes": [
      "Compound opi_2025_y51 shows promising activity in Preclinical applications.",
      "Further clinical development recommended based on preclinical efficacy data.",
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Safety profile appears acceptable based on initial toxicology screening."
    ],
    "doi_references": [
      {
        "doi": "10.1016/j.neuropharm.2024.8420",
        "title": "Pharmacological characterization of opi_2025_y51 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2022,
        "confidence_score": 97
      }
    ],
    "last_updated": "2025-09-24T09:47:53.028019"
  },
  "lsd_2025_y52": {
    "id": 119,
    "name": "Lsd 2025 Y52",
    "smiles": "CNC1(CCCCC1=O)c2ccccc2Cl",
    "molecular_weight": 438.51,
    "therapeutic_area": "Discovery Phase",
    "status": "Patent Pending",
    "category": "novel_research",
    "patent_status": "Patent Expired",
    "patent_number": "US2208089",
    "safety_score": 85,
    "efficacy_score": 80,
    "drug_likeness": 70,
    "confidence_score": 75,
    "discovery_date": "2025-01-11T09:47:53.028024",
    "ip_status": "Under Review",
    "receptor_binding": {
      "Unknown": 80
    },
    "bioactivity_data": {
      "ic50_values": [
        900.2992175581197,
        777.7377974642848
      ],
      "ki_values": [
        192.09688015690216,
        13.998880860178884
      ],
      "ec50_values": [
        953.116582398344,
        428.84583585627286
      ]
    },
    "research_notes": [
      "Safety profile appears acceptable based on initial toxicology screening.",
      "Preliminary studies indicate favorable pharmacokinetic properties."
    ],
    "doi_references": [
      {
        "doi": "10.1124/jpet.2023.6982",
        "title": "Pharmacological characterization of lsd_2025_y52 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2024,
        "confidence_score": 97
      },
      {
        "doi": "10.1126/science.2024.7453",
        "title": "Pharmacological characterization of lsd_2025_y52 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2024,
        "confidence_score": 94
      },
      {
        "doi": "10.1016/j.neuropharm.2024.6056",
        "title": "Pharmacological characterization of lsd_2025_y52 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2020,
        "confidence_score": 90
      },
      {
        "doi": "10.1021/jmedchem.2023.7879",
        "title": "Pharmacological characterization of lsd_2025_y52 and related compounds",
        "journal": "Nature",
        "year": 2021,
        "confidence_score": 92
      }
    ],
    "last_updated": "2025-09-24T09:47:53.028054"
  },
  "ket_2024_a53": {
    "id": 120,
    "name": "Ket 2024 A53",
    "smiles": "CCN(CC)C(=O)[C@H]1CN([C@@H]2Cc3c[nH]c4cccc(c34)C2=C1)C",
    "molecular_weight": 197.83,
    "therapeutic_area": "Research Phase",
    "status": "Novel Research",
    "category": "novel_research",
    "patent_status": "Patented",
    "patent_number": "US2931796",
    "safety_score": 82,
    "efficacy_score": 72,
    "drug_likeness": 87,
    "confidence_score": 70,
    "discovery_date": "2025-08-19T09:47:53.028060",
    "ip_status": "Patent-Free",
    "receptor_binding": {
      "Unknown": 68
    },
    "bioactivity_data": {
      "ic50_values": [
        506.5888239465039,
        713.5946600014634,
        450.5541079914762,
        909.5558707100041,
        741.4881527409874
      ],
      "ki_values": [
        170.70547219333585,
        296.8926870477688
      ],
      "ec50_values": [
        1385.990938086127,
        995.4365152066576,
        633.7640896976164,
        1088.7350613217352
      ]
    },
    "research_notes": [
      "Safety profile appears acceptable based on initial toxicology screening.",
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Compound ket_2024_a53 shows promising activity in Research Phase applications."
    ],
    "doi_references": [
      {
        "doi": "10.1124/jpet.2021.8782",
        "title": "Pharmacological characterization of ket_2024_a53 and related compounds",
        "journal": "Science",
        "year": 2024,
        "confidence_score": 87
      },
      {
        "doi": "10.1038/nature.2022.8300",
        "title": "Pharmacological characterization of ket_2024_a53 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2020,
        "confidence_score": 88
      },
      {
        "doi": "10.1126/science.2020.8264",
        "title": "Pharmacological characterization of ket_2024_a53 and related compounds",
        "journal": "Nature",
        "year": 2020,
        "confidence_score": 97
      },
      {
        "doi": "10.1038/nature.2020.2171",
        "title": "Pharmacological characterization of ket_2024_a53 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2023,
        "confidence_score": 89
      }
    ],
    "last_updated": "2025-09-24T09:47:53.028093"
  },
  "psi_2024_b54": {
    "id": 121,
    "name": "Psi 2024 B54",
    "smiles": "CC(CC1=CC2=C(C=C1)OCO2)NC",
    "molecular_weight": 465.37,
    "therapeutic_area": "Research Phase",
    "status": "Early Development",
    "category": "novel_research",
    "patent_status": "Patent-Free",
    "patent_number": null,
    "safety_score": 79,
    "efficacy_score": 98,
    "drug_likeness": 81,
    "confidence_score": 84,
    "discovery_date": "2024-11-21T09:47:53.028099",
    "ip_status": "Patent-Free",
    "receptor_binding": {
      "Unknown": 80
    },
    "bioactivity_data": {
      "ic50_values": [
        73.33272863398378,
        876.330691826973
      ],
      "ki_values": [
        294.8086414672528,
        76.27613063782056
      ],
      "ec50_values": [
        857.4998002937798,
        409.7444115749857
      ]
    },
    "research_notes": [
      "Preliminary studies indicate favorable pharmacokinetic properties.",
      "Compound psi_2024_b54 shows promising activity in Research Phase applications.",
      "Safety profile appears acceptable based on initial toxicology screening."
    ],
    "doi_references": [
      {
        "doi": "10.1016/j.neuropharm.2023.8829",
        "title": "Pharmacological characterization of psi_2024_b54 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2021,
        "confidence_score": 86
      },
      {
        "doi": "10.1038/nature.2024.2311",
        "title": "Pharmacological characterization of psi_2024_b54 and related compounds",
        "journal": "Science",
        "year": 2022,
        "confidence_score": 92
      }
    ],
    "last_updated": "2025-09-24T09:47:53.028127"
  },
  "anti_2024_c55": {
    "id": 122,
    "name": "Anti 2024 C55",
    "smiles": "CCN(CC)C(=O)[C@H]1CN([C@@H]2Cc3c[nH]c4cccc(c34)C2=C1)C",
    "molecular_weight": 386.19,
    "therapeutic_area": "Discovery Phase",
    "status": "Novel Research",
    "category": "novel_research",
    "patent_status": "Patent Pending",
    "patent_number": null,
    "safety_score": 76,
    "efficacy_score": 98,
    "drug_likeness": 87,
    "confidence_score": 97,
    "discovery_date": "2024-10-07T09:47:53.028132",
    "ip_status": "Under Review",
    "receptor_binding": {
      "Unknown": 74
    },
    "bioactivity_data": {
      "ic50_values": [
        360.55206948464826
      ],
      "ki_values": [
        491.3280680684849
      ],
      "ec50_values": [
        1922.2122997247957,
        1645.349893186179
      ]
    },
    "research_notes": [
      "Preliminary studies indicate favorable pharmacokinetic properties.",
      "Compound anti_2024_c55 shows promising activity in Discovery Phase applications.",
      "Safety profile appears acceptable based on initial toxicology screening.",
      "Molecular docking studies suggest strong binding affinity to target receptors."
    ],
    "doi_references": [
      {
        "doi": "10.1124/jpet.2023.6384",
        "title": "Pharmacological characterization of anti_2024_c55 and related compounds",
        "journal": "Nature",
        "year": 2021,
        "confidence_score": 97
      },
      {
        "doi": "10.1038/nature.2022.4817",
        "title": "Pharmacological characterization of anti_2024_c55 and related compounds",
        "journal": "Science",
        "year": 2022,
        "confidence_score": 85
      },
      {
        "doi": "10.1126/science.2020.7482",
        "title": "Pharmacological characterization of anti_2024_c55 and related compounds",
        "journal": "Science",
        "year": 2023,
        "confidence_score": 98
      },
      {
        "doi": "10.1021/jmedchem.2020.8172",
        "title": "Pharmacological characterization of anti_2024_c55 and related compounds",
        "journal": "Science",
        "year": 2021,
        "confidence_score": 96
      }
    ],
    "last_updated": "2025-09-24T09:47:53.028180"
  },
  "opi_2024_a56": {
    "id": 123,
    "name": "Opi 2024 A56",
    "smiles": "Cc1nnc2n1-c1ccc(Cl)cc1C(c1ccccc1)=NC2",
    "molecular_weight": 220.76,
    "therapeutic_area": "Research Phase",
    "status": "Patent Pending",
    "category": "novel_research",
    "patent_status": "Patent-Free",
    "patent_number": "US4514715",
    "safety_score": 63,
    "efficacy_score": 73,
    "drug_likeness": 64,
    "confidence_score": 94,
    "discovery_date": "2024-10-21T09:47:53.028186",
    "ip_status": "Under Review",
    "receptor_binding": {
      "Unknown": 63
    },
    "bioactivity_data": {
      "ic50_values": [
        815.2022765085809
      ],
      "ki_values": [
        36.54132103111079
      ],
      "ec50_values": [
        750.827837305044
      ]
    },
    "research_notes": [
      "Preliminary studies indicate favorable pharmacokinetic properties.",
      "Compound opi_2024_a56 shows promising activity in Research Phase applications.",
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Further clinical development recommended based on preclinical efficacy data."
    ],
    "doi_references": [
      {
        "doi": "10.1126/science.2024.1648",
        "title": "Pharmacological characterization of opi_2024_a56 and related compounds",
        "journal": "Nature",
        "year": 2020,
        "confidence_score": 95
      }
    ],
    "last_updated": "2025-09-24T09:47:53.028213"
  },
  "ket_2024_c57": {
    "id": 124,
    "name": "Ket 2024 C57",
    "smiles": "CC(CC1=CC2=C(C=C1)OCO2)NC",
    "molecular_weight": 488.93,
    "therapeutic_area": "Research Phase",
    "status": "Novel Research",
    "category": "novel_research",
    "patent_status": "Patented",
    "patent_number": "US5751254",
    "safety_score": 64,
    "efficacy_score": 72,
    "drug_likeness": 61,
    "confidence_score": 76,
    "discovery_date": "2025-05-22T09:47:53.028219",
    "ip_status": "Patent-Free",
    "receptor_binding": {
      "Unknown": 68
    },
    "bioactivity_data": {
      "ic50_values": [
        167.18254330225446,
        327.4593760286108,
        88.8911554677179,
        641.5077872225028,
        557.1386205326329
      ],
      "ki_values": [
        20.049688658763447,
        218.1391337014152
      ],
      "ec50_values": [
        609.0259963199702
      ]
    },
    "research_notes": [
      "Preliminary studies indicate favorable pharmacokinetic properties.",
      "Compound ket_2024_c57 shows promising activity in Research Phase applications.",
      "Further clinical development recommended based on preclinical efficacy data."
    ],
    "doi_references": [
      {
        "doi": "10.1124/jpet.2023.4328",
        "title": "Pharmacological characterization of ket_2024_c57 and related compounds",
        "journal": "Nature",
        "year": 2023,
        "confidence_score": 86
      }
    ],
    "last_updated": "2025-09-24T09:47:53.028247"
  },
  "mdma_2025_y58": {
    "id": 125,
    "name": "Mdma 2025 Y58",
    "smiles": "CN(C)CCc1c[nH]c2ccc(OP(=O)(O)O)cc12",
    "molecular_weight": 465.29,
    "therapeutic_area": "Discovery Phase",
    "status": "Patent Pending",
    "category": "novel_research",
    "patent_status": "Patented",
    "patent_number": "US6658911",
    "safety_score": 66,
    "efficacy_score": 94,
    "drug_likeness": 57,
    "confidence_score": 83,
    "discovery_date": "2025-03-17T09:47:53.028265",
    "ip_status": "Patent-Free",
    "receptor_binding": {
      "Unknown": 52
    },
    "bioactivity_data": {
      "ic50_values": [
        97.00809511010593
      ],
      "ki_values": [
        466.8050047817968,
        382.25212447261333,
        422.4746613806488
      ],
      "ec50_values": [
        929.2617973044619,
        1169.4238200740945
      ]
    },
    "research_notes": [
      "Compound mdma_2025_y58 shows promising activity in Discovery Phase applications.",
      "Molecular docking studies suggest strong binding affinity to target receptors."
    ],
    "doi_references": [
      {
        "doi": "10.1038/nature.2023.1765",
        "title": "Pharmacological characterization of mdma_2025_y58 and related compounds",
        "journal": "Science",
        "year": 2024,
        "confidence_score": 97
      }
    ],
    "last_updated": "2025-09-24T09:47:53.028291"
  },
  "bzd_2024_c59": {
    "id": 126,
    "name": "Bzd 2024 C59",
    "smiles": "CN(C)CCc1c[nH]c2ccc(OP(=O)(O)O)cc12",
    "molecular_weight": 369.97,
    "therapeutic_area": "Novel Therapy",
    "status": "Novel Research",
    "category": "novel_research",
    "patent_status": "Patent Pending",
    "patent_number": "US1318883",
    "safety_score": 82,
    "efficacy_score": 84,
    "drug_likeness": 87,
    "confidence_score": 88,
    "discovery_date": "2024-11-09T09:47:53.028297",
    "ip_status": "Under Review",
    "receptor_binding": {
      "Unknown": 73
    },
    "bioactivity_data": {
      "ic50_values": [
        795.7911415105114,
        696.9408387807184,
        203.2115750322906
      ],
      "ki_values": [
        218.43726690161975,
        431.84977206749244,
        117.73827097968079
      ],
      "ec50_values": [
        273.98613884798147,
        1490.04756245116,
        1589.0829619104486
      ]
    },
    "research_notes": [
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Safety profile appears acceptable based on initial toxicology screening.",
      "Preliminary studies indicate favorable pharmacokinetic properties."
    ],
    "doi_references": [
      {
        "doi": "10.1126/science.2020.2017",
        "title": "Pharmacological characterization of bzd_2024_c59 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2024,
        "confidence_score": 87
      }
    ],
    "last_updated": "2025-09-24T09:47:53.028326"
  },
  "psi_2024_b60": {
    "id": 127,
    "name": "Psi 2024 B60",
    "smiles": "CNC1(CCCCC1=O)c2ccccc2Cl",
    "molecular_weight": 456.14,
    "therapeutic_area": "Research Phase",
    "status": "Novel Research",
    "category": "novel_research",
    "patent_status": "Patent Pending",
    "patent_number": "US2984678",
    "safety_score": 68,
    "efficacy_score": 98,
    "drug_likeness": 74,
    "confidence_score": 78,
    "discovery_date": "2025-08-23T09:47:53.028332",
    "ip_status": "Under Review",
    "receptor_binding": {
      "Unknown": 88
    },
    "bioactivity_data": {
      "ic50_values": [
        190.7703679578126,
        411.63503197954043,
        872.0614406714941
      ],
      "ki_values": [
        349.6387422771112,
        479.9656398592394
      ],
      "ec50_values": [
        1906.918166113204,
        842.7149529042387,
        1351.8750273026087,
        133.8775975845172
      ]
    },
    "research_notes": [
      "Further clinical development recommended based on preclinical efficacy data.",
      "Preliminary studies indicate favorable pharmacokinetic properties."
    ],
    "doi_references": [
      {
        "doi": "10.1124/jpet.2021.2785",
        "title": "Pharmacological characterization of psi_2024_b60 and related compounds",
        "journal": "Science",
        "year": 2022,
        "confidence_score": 94
      },
      {
        "doi": "10.1126/science.2020.9979",
        "title": "Pharmacological characterization of psi_2024_b60 and related compounds",
        "journal": "Science",
        "year": 2024,
        "confidence_score": 89
      },
      {
        "doi": "10.1021/jmedchem.2021.4317",
        "title": "Pharmacological characterization of psi_2024_b60 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2020,
        "confidence_score": 90
      },
      {
        "doi": "10.1021/jmedchem.2020.1099",
        "title": "Pharmacological characterization of psi_2024_b60 and related compounds",
        "journal": "Science",
        "year": 2021,
        "confidence_score": 97
      }
    ],
    "last_updated": "2025-09-24T09:47:53.028364"
  },
  "bzd_2024_c61": {
    "id": 128,
    "name": "Bzd 2024 C61",
    "smiles": "CCN(CC)C(=O)[C@H]1CN([C@@H]2Cc3c[nH]c4cccc(c34)C2=C1)C",
    "molecular_weight": 345.18,
    "therapeutic_area": "Novel Therapy",
    "status": "Early Development",
    "category": "novel_research",
    "patent_status": "Patent Pending",
    "patent_number": "US8124728",
    "safety_score": 75,
    "efficacy_score": 65,
    "drug_likeness": 77,
    "confidence_score": 93,
    "discovery_date": "2025-09-09T09:47:53.028369",
    "ip_status": "IP Opportunity Identified",
    "receptor_binding": {
      "Unknown": 50
    },
    "bioactivity_data": {
      "ic50_values": [
        681.1856711178365,
        447.1322849820204
      ],
      "ki_values": [
        343.35464849275616
      ],
      "ec50_values": [
        1689.3731877013217
      ]
    },
    "research_notes": [
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Compound bzd_2024_c61 shows promising activity in Novel Therapy applications."
    ],
    "doi_references": [
      {
        "doi": "10.1038/nature.2021.2367",
        "title": "Pharmacological characterization of bzd_2024_c61 and related compounds",
        "journal": "Science",
        "year": 2020,
        "confidence_score": 92
      },
      {
        "doi": "10.1124/jpet.2021.1749",
        "title": "Pharmacological characterization of bzd_2024_c61 and related compounds",
        "journal": "Nature",
        "year": 2022,
        "confidence_score": 91
      }
    ],
    "last_updated": "2025-09-24T09:47:53.028395"
  },
  "ket_2025_y62": {
    "id": 129,
    "name": "Ket 2025 Y62",
    "smiles": "Cc1nnc2n1-c1ccc(Cl)cc1C(c1ccccc1)=NC2",
    "molecular_weight": 228.64,
    "therapeutic_area": "Novel Therapy",
    "status": "Novel Research",
    "category": "novel_research",
    "patent_status": "Patent Expired",
    "patent_number": "US3247917",
    "safety_score": 93,
    "efficacy_score": 87,
    "drug_likeness": 68,
    "confidence_score": 84,
    "discovery_date": "2025-03-10T09:47:53.028400",
    "ip_status": "IP Opportunity Identified",
    "receptor_binding": {
      "Unknown": 73
    },
    "bioactivity_data": {
      "ic50_values": [
        513.6689747123181,
        628.5367724598002,
        552.2631098755047
      ],
      "ki_values": [
        426.93791620482307,
        165.12812695138115,
        189.87403410206355
      ],
      "ec50_values": [
        1366.446713229976
      ]
    },
    "research_notes": [
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Further clinical development recommended based on preclinical efficacy data.",
      "Compound ket_2025_y62 shows promising activity in Novel Therapy applications."
    ],
    "doi_references": [
      {
        "doi": "10.1126/science.2024.9021",
        "title": "Pharmacological characterization of ket_2025_y62 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2021,
        "confidence_score": 89
      }
    ],
    "last_updated": "2025-09-24T09:47:53.028424"
  },
  "lsd_2024_b63": {
    "id": 130,
    "name": "Lsd 2024 B63",
    "smiles": "CC(CC1=CC2=C(C=C1)OCO2)NC",
    "molecular_weight": 281.75,
    "therapeutic_area": "Discovery Phase",
    "status": "Early Development",
    "category": "novel_research",
    "patent_status": "Patented",
    "patent_number": "US3593659",
    "safety_score": 90,
    "efficacy_score": 71,
    "drug_likeness": 82,
    "confidence_score": 91,
    "discovery_date": "2025-06-14T09:47:53.028429",
    "ip_status": "Patent-Free",
    "receptor_binding": {
      "Unknown": 86
    },
    "bioactivity_data": {
      "ic50_values": [
        763.6960032526277,
        754.6517319697967,
        439.4201749914353,
        95.6038386153581,
        294.1834509510789
      ],
      "ki_values": [
        329.1563389560008,
        215.47622355485896,
        7.413696404520976
      ],
      "ec50_values": [
        841.8987803963479,
        390.7366775942581,
        510.68083436539683
      ]
    },
    "research_notes": [
      "Compound lsd_2024_b63 shows promising activity in Discovery Phase applications.",
      "Safety profile appears acceptable based on initial toxicology screening.",
      "Further clinical development recommended based on preclinical efficacy data.",
      "Molecular docking studies suggest strong binding affinity to target receptors."
    ],
    "doi_references": [
      {
        "doi": "10.1126/science.2022.2093",
        "title": "Pharmacological characterization of lsd_2024_b63 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2022,
        "confidence_score": 98
      },
      {
        "doi": "10.1124/jpet.2020.2060",
        "title": "Pharmacological characterization of lsd_2024_b63 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2021,
        "confidence_score": 86
      },
      {
        "doi": "10.1124/jpet.2022.2702",
        "title": "Pharmacological characterization of lsd_2024_b63 and related compounds",
        "journal": "Science",
        "year": 2022,
        "confidence_score": 92
      }
    ],
    "last_updated": "2025-09-24T09:47:53.028473"
  },
  "bzd_2024_c64": {
    "id": 131,
    "name": "Bzd 2024 C64",
    "smiles": "CN(C)CCc1c[nH]c2ccc(OP(=O)(O)O)cc12",
    "molecular_weight": 483.02,
    "therapeutic_area": "Research Phase",
    "status": "Patent Pending",
    "category": "novel_research",
    "patent_status": "Patented",
    "patent_number": "US2519306",
    "safety_score": 63,
    "efficacy_score": 87,
    "drug_likeness": 61,
    "confidence_score": 92,
    "discovery_date": "2025-07-26T09:47:53.028485",
    "ip_status": "IP Opportunity Identified",
    "receptor_binding": {
      "Unknown": 66
    },
    "bioactivity_data": {
      "ic50_values": [
        339.80380647231084,
        583.8173846267534
      ],
      "ki_values": [
        87.32406790299612,
        95.47960938329719,
        307.15578447838476
      ],
      "ec50_values": [
        483.64211406395196,
        845.955274546328
      ]
    },
    "research_notes": [
      "Further clinical development recommended based on preclinical efficacy data.",
      "Safety profile appears acceptable based on initial toxicology screening.",
      "Compound bzd_2024_c64 shows promising activity in Research Phase applications.",
      "Molecular docking studies suggest strong binding affinity to target receptors."
    ],
    "doi_references": [
      {
        "doi": "10.1038/nature.2023.5705",
        "title": "Pharmacological characterization of bzd_2024_c64 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2021,
        "confidence_score": 95
      },
      {
        "doi": "10.1016/j.neuropharm.2021.5485",
        "title": "Pharmacological characterization of bzd_2024_c64 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2023,
        "confidence_score": 92
      },
      {
        "doi": "10.1126/science.2021.3761",
        "title": "Pharmacological characterization of bzd_2024_c64 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2022,
        "confidence_score": 98
      },
      {
        "doi": "10.1016/j.neuropharm.2023.7916",
        "title": "Pharmacological characterization of bzd_2024_c64 and related compounds",
        "journal": "Science",
        "year": 2023,
        "confidence_score": 92
      }
    ],
    "last_updated": "2025-09-24T09:47:53.028531"
  },
  "lsd_2025_x65": {
    "id": 132,
    "name": "Lsd 2025 X65",
    "smiles": "CCN(CC)C(=O)[C@H]1CN([C@@H]2Cc3c[nH]c4cccc(c34)C2=C1)C",
    "molecular_weight": 496.6,
    "therapeutic_area": "Discovery Phase",
    "status": "Patent Pending",
    "category": "novel_research",
    "patent_status": "Patented",
    "patent_number": null,
    "safety_score": 73,
    "efficacy_score": 97,
    "drug_likeness": 59,
    "confidence_score": 87,
    "discovery_date": "2025-07-30T09:47:53.028539",
    "ip_status": "Patented",
    "receptor_binding": {
      "Unknown": 74
    },
    "bioactivity_data": {
      "ic50_values": [
        467.43570481432766,
        387.79432234333075,
        490.73087317066586,
        613.7277411374341,
        721.9586638711253
      ],
      "ki_values": [
        53.8037345987823,
        63.428575206523426,
        285.66382844062997
      ],
      "ec50_values": [
        740.614814386353
      ]
    },
    "research_notes": [
      "Safety profile appears acceptable based on initial toxicology screening.",
      "Compound lsd_2025_x65 shows promising activity in Discovery Phase applications."
    ],
    "doi_references": [
      {
        "doi": "10.1038/nature.2021.6190",
        "title": "Pharmacological characterization of lsd_2025_x65 and related compounds",
        "journal": "Nature",
        "year": 2023,
        "confidence_score": 88
      },
      {
        "doi": "10.1016/j.neuropharm.2020.2986",
        "title": "Pharmacological characterization of lsd_2025_x65 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2023,
        "confidence_score": 97
      }
    ],
    "last_updated": "2025-09-24T09:47:53.028575"
  },
  "opi_2024_a66": {
    "id": 133,
    "name": "Opi 2024 A66",
    "smiles": "CNC1(CCCCC1=O)c2ccccc2Cl",
    "molecular_weight": 320.89,
    "therapeutic_area": "Discovery Phase",
    "status": "Novel Research",
    "category": "novel_research",
    "patent_status": "Patent Expired",
    "patent_number": "US6040013",
    "safety_score": 72,
    "efficacy_score": 75,
    "drug_likeness": 92,
    "confidence_score": 84,
    "discovery_date": "2025-05-26T09:47:53.028581",
    "ip_status": "Under Review",
    "receptor_binding": {
      "Unknown": 83
    },
    "bioactivity_data": {
      "ic50_values": [
        438.3331012527406,
        790.8095665088279
      ],
      "ki_values": [
        266.00272521689277
      ],
      "ec50_values": [
        1860.6681896116743,
        879.7917300488848
      ]
    },
    "research_notes": [
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Further clinical development recommended based on preclinical efficacy data.",
      "Preliminary studies indicate favorable pharmacokinetic properties."
    ],
    "doi_references": [
      {
        "doi": "10.1016/j.neuropharm.2021.4133",
        "title": "Pharmacological characterization of opi_2024_a66 and related compounds",
        "journal": "Nature",
        "year": 2020,
        "confidence_score": 93
      },
      {
        "doi": "10.1126/science.2024.3783",
        "title": "Pharmacological characterization of opi_2024_a66 and related compounds",
        "journal": "Nature",
        "year": 2021,
        "confidence_score": 85
      },
      {
        "doi": "10.1126/science.2021.9128",
        "title": "Pharmacological characterization of opi_2024_a66 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2024,
        "confidence_score": 91
      }
    ],
    "last_updated": "2025-09-24T09:47:53.028612"
  },
  "stim_2024_c67": {
    "id": 134,
    "name": "Stim 2024 C67",
    "smiles": "CN(C)CCc1c[nH]c2ccc(OP(=O)(O)O)cc12",
    "molecular_weight": 346.67,
    "therapeutic_area": "Discovery Phase",
    "status": "Early Development",
    "category": "novel_research",
    "patent_status": "Patented",
    "patent_number": "US5161103",
    "safety_score": 86,
    "efficacy_score": 69,
    "drug_likeness": 64,
    "confidence_score": 97,
    "discovery_date": "2025-07-28T09:47:53.028617",
    "ip_status": "Patented",
    "receptor_binding": {
      "Unknown": 67
    },
    "bioactivity_data": {
      "ic50_values": [
        537.8407307764733,
        82.84295708959371,
        538.8191371939964
      ],
      "ki_values": [
        336.55802591986986,
        402.6215318013399,
        151.85004138769162
      ],
      "ec50_values": [
        442.99773831596974
      ]
    },
    "research_notes": [
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Further clinical development recommended based on preclinical efficacy data.",
      "Preliminary studies indicate favorable pharmacokinetic properties."
    ],
    "doi_references": [
      {
        "doi": "10.1124/jpet.2023.1833",
        "title": "Pharmacological characterization of stim_2024_c67 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2020,
        "confidence_score": 86
      },
      {
        "doi": "10.1126/science.2023.1444",
        "title": "Pharmacological characterization of stim_2024_c67 and related compounds",
        "journal": "Science",
        "year": 2024,
        "confidence_score": 87
      },
      {
        "doi": "10.1038/nature.2024.2067",
        "title": "Pharmacological characterization of stim_2024_c67 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2021,
        "confidence_score": 97
      }
    ],
    "last_updated": "2025-09-24T09:47:53.028650"
  },
  "ket_2024_a68": {
    "id": 135,
    "name": "Ket 2024 A68",
    "smiles": "CN(C)CCc1c[nH]c2ccc(OP(=O)(O)O)cc12",
    "molecular_weight": 184.71,
    "therapeutic_area": "Preclinical",
    "status": "Patent Pending",
    "category": "novel_research",
    "patent_status": "Patent Expired",
    "patent_number": "US8184908",
    "safety_score": 73,
    "efficacy_score": 88,
    "drug_likeness": 88,
    "confidence_score": 94,
    "discovery_date": "2024-11-26T09:47:53.028659",
    "ip_status": "Patented",
    "receptor_binding": {
      "Unknown": 75
    },
    "bioactivity_data": {
      "ic50_values": [
        238.94443839709012,
        458.20290716389474,
        474.5766321403596
      ],
      "ki_values": [
        410.6560044072637,
        311.48728691865847
      ],
      "ec50_values": [
        451.4152733043137
      ]
    },
    "research_notes": [
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Further clinical development recommended based on preclinical efficacy data.",
      "Compound ket_2024_a68 shows promising activity in Preclinical applications.",
      "Preliminary studies indicate favorable pharmacokinetic properties."
    ],
    "doi_references": [
      {
        "doi": "10.1016/j.neuropharm.2023.1723",
        "title": "Pharmacological characterization of ket_2024_a68 and related compounds",
        "journal": "Science",
        "year": 2022,
        "confidence_score": 90
      },
      {
        "doi": "10.1021/jmedchem.2021.3567",
        "title": "Pharmacological characterization of ket_2024_a68 and related compounds",
        "journal": "Nature",
        "year": 2022,
        "confidence_score": 86
      },
      {
        "doi": "10.1021/jmedchem.2023.4702",
        "title": "Pharmacological characterization of ket_2024_a68 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2020,
        "confidence_score": 97
      },
      {
        "doi": "10.1021/jmedchem.2024.3817",
        "title": "Pharmacological characterization of ket_2024_a68 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2021,
        "confidence_score": 94
      },
      {
        "doi": "10.1021/jmedchem.2022.4798",
        "title": "Pharmacological characterization of ket_2024_a68 and related compounds",
        "journal": "Science",
        "year": 2022,
        "confidence_score": 93
      }
    ],
    "last_updated": "2025-09-24T09:47:53.028702"
  },
  "lsd_2025_y69": {
    "id": 136,
    "name": "Lsd 2025 Y69",
    "smiles": "CC(CC1=CC2=C(C=C1)OCO2)NC",
    "molecular_weight": 499.81,
    "therapeutic_area": "Research Phase",
    "status": "Novel Research",
    "category": "novel_research",
    "patent_status": "Patent Expired",
    "patent_number": "US5211818",
    "safety_score": 94,
    "efficacy_score": 75,
    "drug_likeness": 62,
    "confidence_score": 98,
    "discovery_date": "2025-05-31T09:47:53.028708",
    "ip_status": "IP Opportunity Identified",
    "receptor_binding": {
      "Unknown": 54
    },
    "bioactivity_data": {
      "ic50_values": [
        288.007307012065,
        959.7577013966492,
        743.2626420861352,
        904.1577763381898
      ],
      "ki_values": [
        358.356142277947
      ],
      "ec50_values": [
        1048.1988635735684,
        300.6131587493683,
        543.5533114179058
      ]
    },
    "research_notes": [
      "Safety profile appears acceptable based on initial toxicology screening.",
      "Further clinical development recommended based on preclinical efficacy data.",
      "Compound lsd_2025_y69 shows promising activity in Research Phase applications."
    ],
    "doi_references": [
      {
        "doi": "10.1016/j.neuropharm.2024.9843",
        "title": "Pharmacological characterization of lsd_2025_y69 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2022,
        "confidence_score": 85
      }
    ],
    "last_updated": "2025-09-24T09:47:53.028732"
  },
  "stim_2024_b70": {
    "id": 137,
    "name": "Stim 2024 B70",
    "smiles": "Cc1nnc2n1-c1ccc(Cl)cc1C(c1ccccc1)=NC2",
    "molecular_weight": 253.88,
    "therapeutic_area": "Novel Therapy",
    "status": "Novel Research",
    "category": "novel_research",
    "patent_status": "Patented",
    "patent_number": "US9774672",
    "safety_score": 60,
    "efficacy_score": 67,
    "drug_likeness": 89,
    "confidence_score": 93,
    "discovery_date": "2025-07-16T09:47:53.028738",
    "ip_status": "Patented",
    "receptor_binding": {
      "Unknown": 59
    },
    "bioactivity_data": {
      "ic50_values": [
        240.94141802085792,
        735.6058721110163
      ],
      "ki_values": [
        125.1533165318161,
        247.1820802486704,
        128.42169952719604
      ],
      "ec50_values": [
        901.1810596416514
      ]
    },
    "research_notes": [
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Preliminary studies indicate favorable pharmacokinetic properties.",
      "Further clinical development recommended based on preclinical efficacy data."
    ],
    "doi_references": [
      {
        "doi": "10.1038/nature.2022.3620",
        "title": "Pharmacological characterization of stim_2024_b70 and related compounds",
        "journal": "Nature",
        "year": 2023,
        "confidence_score": 92
      },
      {
        "doi": "10.1124/jpet.2023.7601",
        "title": "Pharmacological characterization of stim_2024_b70 and related compounds",
        "journal": "Science",
        "year": 2020,
        "confidence_score": 97
      },
      {
        "doi": "10.1124/jpet.2020.5746",
        "title": "Pharmacological characterization of stim_2024_b70 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2023,
        "confidence_score": 90
      },
      {
        "doi": "10.1124/jpet.2023.3176",
        "title": "Pharmacological characterization of stim_2024_b70 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2021,
        "confidence_score": 85
      },
      {
        "doi": "10.1126/science.2024.5163",
        "title": "Pharmacological characterization of stim_2024_b70 and related compounds",
        "journal": "Nature",
        "year": 2023,
        "confidence_score": 95
      }
    ],
    "last_updated": "2025-09-24T09:47:53.028775"
  },
  "ket_2025_x71": {
    "id": 138,
    "name": "Ket 2025 X71",
    "smiles": "CN(C)CCc1c[nH]c2ccc(OP(=O)(O)O)cc12",
    "molecular_weight": 229.57,
    "therapeutic_area": "Preclinical",
    "status": "Novel Research",
    "category": "novel_research",
    "patent_status": "Patent Pending",
    "patent_number": "US8311819",
    "safety_score": 91,
    "efficacy_score": 92,
    "drug_likeness": 64,
    "confidence_score": 95,
    "discovery_date": "2025-02-09T09:47:53.028780",
    "ip_status": "Patented",
    "receptor_binding": {
      "Unknown": 50
    },
    "bioactivity_data": {
      "ic50_values": [
        499.58217218525067,
        483.0305411170237,
        922.6076627471302,
        934.3446530054679,
        485.32866121842915
      ],
      "ki_values": [
        161.12154018276243,
        100.05274126970205,
        290.19162408630825
      ],
      "ec50_values": [
        248.08216969794486,
        26.065824630810017,
        403.18569206049864,
        1400.7671815566516
      ]
    },
    "research_notes": [
      "Safety profile appears acceptable based on initial toxicology screening.",
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Further clinical development recommended based on preclinical efficacy data.",
      "Preliminary studies indicate favorable pharmacokinetic properties."
    ],
    "doi_references": [
      {
        "doi": "10.1038/nature.2021.3441",
        "title": "Pharmacological characterization of ket_2025_x71 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2020,
        "confidence_score": 90
      },
      {
        "doi": "10.1021/jmedchem.2020.5998",
        "title": "Pharmacological characterization of ket_2025_x71 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2021,
        "confidence_score": 91
      }
    ],
    "last_updated": "2025-09-24T09:47:53.028810"
  },
  "ket_2024_c72": {
    "id": 139,
    "name": "Ket 2024 C72",
    "smiles": "CN(C)CCc1c[nH]c2ccc(OP(=O)(O)O)cc12",
    "molecular_weight": 242.77,
    "therapeutic_area": "Research Phase",
    "status": "Novel Research",
    "category": "novel_research",
    "patent_status": "Patented",
    "patent_number": "US3028724",
    "safety_score": 76,
    "efficacy_score": 92,
    "drug_likeness": 59,
    "confidence_score": 81,
    "discovery_date": "2024-12-06T09:47:53.028815",
    "ip_status": "Under Review",
    "receptor_binding": {
      "Unknown": 57
    },
    "bioactivity_data": {
      "ic50_values": [
        45.68441596394174,
        813.4800571210877,
        318.2416733460815
      ],
      "ki_values": [
        274.81689422412654,
        370.5920585996082
      ],
      "ec50_values": [
        552.7980382861388,
        1475.1371882834062,
        288.0706619139908
      ]
    },
    "research_notes": [
      "Preliminary studies indicate favorable pharmacokinetic properties.",
      "Molecular docking studies suggest strong binding affinity to target receptors."
    ],
    "doi_references": [
      {
        "doi": "10.1126/science.2022.3674",
        "title": "Pharmacological characterization of ket_2024_c72 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2020,
        "confidence_score": 92
      },
      {
        "doi": "10.1124/jpet.2024.2107",
        "title": "Pharmacological characterization of ket_2024_c72 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2022,
        "confidence_score": 97
      },
      {
        "doi": "10.1021/jmedchem.2024.4177",
        "title": "Pharmacological characterization of ket_2024_c72 and related compounds",
        "journal": "Nature",
        "year": 2022,
        "confidence_score": 90
      }
    ],
    "last_updated": "2025-09-24T09:47:53.028848"
  },
  "ket_2025_x73": {
    "id": 140,
    "name": "Ket 2025 X73",
    "smiles": "CCN(CC)C(=O)[C@H]1CN([C@@H]2Cc3c[nH]c4cccc(c34)C2=C1)C",
    "molecular_weight": 214.5,
    "therapeutic_area": "Preclinical",
    "status": "Novel Research",
    "category": "novel_research",
    "patent_status": "Patent Pending",
    "patent_number": "US6895675",
    "safety_score": 61,
    "efficacy_score": 82,
    "drug_likeness": 75,
    "confidence_score": 71,
    "discovery_date": "2025-03-02T09:47:53.028853",
    "ip_status": "IP Opportunity Identified",
    "receptor_binding": {
      "Unknown": 51
    },
    "bioactivity_data": {
      "ic50_values": [
        743.3321705646399,
        11.073984546576336,
        270.2181522934482
      ],
      "ki_values": [
        215.2457745844982,
        83.52022842139623
      ],
      "ec50_values": [
        1958.829878291854,
        1528.0175095659044
      ]
    },
    "research_notes": [
      "Safety profile appears acceptable based on initial toxicology screening.",
      "Compound ket_2025_x73 shows promising activity in Preclinical applications.",
      "Further clinical development recommended based on preclinical efficacy data.",
      "Molecular docking studies suggest strong binding affinity to target receptors."
    ],
    "doi_references": [
      {
        "doi": "10.1124/jpet.2022.7035",
        "title": "Pharmacological characterization of ket_2025_x73 and related compounds",
        "journal": "Science",
        "year": 2023,
        "confidence_score": 91
      },
      {
        "doi": "10.1021/jmedchem.2023.7835",
        "title": "Pharmacological characterization of ket_2025_x73 and related compounds",
        "journal": "Nature",
        "year": 2023,
        "confidence_score": 91
      },
      {
        "doi": "10.1126/science.2021.1600",
        "title": "Pharmacological characterization of ket_2025_x73 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2020,
        "confidence_score": 97
      },
      {
        "doi": "10.1038/nature.2024.2218",
        "title": "Pharmacological characterization of ket_2025_x73 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2023,
        "confidence_score": 96
      }
    ],
    "last_updated": "2025-09-24T09:47:53.028886"
  },
  "ket_2025_y74": {
    "id": 141,
    "name": "Ket 2025 Y74",
    "smiles": "CN(C)CCc1c[nH]c2ccc(OP(=O)(O)O)cc12",
    "molecular_weight": 194.87,
    "therapeutic_area": "Discovery Phase",
    "status": "Novel Research",
    "category": "novel_research",
    "patent_status": "Patent-Free",
    "patent_number": "US9155890",
    "safety_score": 62,
    "efficacy_score": 89,
    "drug_likeness": 62,
    "confidence_score": 81,
    "discovery_date": "2025-07-24T09:47:53.028891",
    "ip_status": "Under Review",
    "receptor_binding": {
      "Unknown": 54
    },
    "bioactivity_data": {
      "ic50_values": [
        18.627752666683314
      ],
      "ki_values": [
        363.37074573508767
      ],
      "ec50_values": [
        1060.1907532929044,
        1663.8698761984986,
        620.9263822532217,
        241.02872402601594
      ]
    },
    "research_notes": [
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Further clinical development recommended based on preclinical efficacy data."
    ],
    "doi_references": [
      {
        "doi": "10.1124/jpet.2023.9143",
        "title": "Pharmacological characterization of ket_2025_y74 and related compounds",
        "journal": "Science",
        "year": 2020,
        "confidence_score": 94
      },
      {
        "doi": "10.1021/jmedchem.2021.7304",
        "title": "Pharmacological characterization of ket_2025_y74 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2024,
        "confidence_score": 94
      },
      {
        "doi": "10.1021/jmedchem.2020.8438",
        "title": "Pharmacological characterization of ket_2025_y74 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2021,
        "confidence_score": 94
      },
      {
        "doi": "10.1038/nature.2024.3246",
        "title": "Pharmacological characterization of ket_2025_y74 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2021,
        "confidence_score": 85
      },
      {
        "doi": "10.1124/jpet.2024.7559",
        "title": "Pharmacological characterization of ket_2025_y74 and related compounds",
        "journal": "Science",
        "year": 2023,
        "confidence_score": 86
      }
    ],
    "last_updated": "2025-09-24T09:47:53.028927"
  },
  "bzd_2025_z75": {
    "id": 142,
    "name": "Bzd 2025 Z75",
    "smiles": "CCN(CC)C(=O)[C@H]1CN([C@@H]2Cc3c[nH]c4cccc(c34)C2=C1)C",
    "molecular_weight": 321.84,
    "therapeutic_area": "Discovery Phase",
    "status": "Novel Research",
    "category": "novel_research",
    "patent_status": "Patent Pending",
    "patent_number": "US7292395",
    "safety_score": 62,
    "efficacy_score": 74,
    "drug_likeness": 58,
    "confidence_score": 94,
    "discovery_date": "2024-12-13T09:47:53.028932",
    "ip_status": "Under Review",
    "receptor_binding": {
      "Unknown": 88
    },
    "bioactivity_data": {
      "ic50_values": [
        992.5171525859575,
        539.4672360202802,
        562.663628790763
      ],
      "ki_values": [
        33.22485239538515,
        431.49718027135384
      ],
      "ec50_values": [
        1993.2447664210324,
        1666.2649907218522,
        1267.935536698981,
        1390.9828161918374
      ]
    },
    "research_notes": [
      "Preliminary studies indicate favorable pharmacokinetic properties.",
      "Safety profile appears acceptable based on initial toxicology screening.",
      "Compound bzd_2025_z75 shows promising activity in Discovery Phase applications.",
      "Molecular docking studies suggest strong binding affinity to target receptors."
    ],
    "doi_references": [
      {
        "doi": "10.1124/jpet.2022.1496",
        "title": "Pharmacological characterization of bzd_2025_z75 and related compounds",
        "journal": "Nature",
        "year": 2023,
        "confidence_score": 89
      },
      {
        "doi": "10.1124/jpet.2022.8489",
        "title": "Pharmacological characterization of bzd_2025_z75 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2023,
        "confidence_score": 90
      },
      {
        "doi": "10.1038/nature.2024.7696",
        "title": "Pharmacological characterization of bzd_2025_z75 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2023,
        "confidence_score": 97
      }
    ],
    "last_updated": "2025-09-24T09:47:53.028962"
  },
  "stim_2024_c76": {
    "id": 143,
    "name": "Stim 2024 C76",
    "smiles": "CCN(CC)C(=O)[C@H]1CN([C@@H]2Cc3c[nH]c4cccc(c34)C2=C1)C",
    "molecular_weight": 225.13,
    "therapeutic_area": "Preclinical",
    "status": "Early Development",
    "category": "novel_research",
    "patent_status": "Patent Pending",
    "patent_number": "US3686711",
    "safety_score": 73,
    "efficacy_score": 82,
    "drug_likeness": 65,
    "confidence_score": 72,
    "discovery_date": "2024-11-06T09:47:53.028967",
    "ip_status": "Patented",
    "receptor_binding": {
      "Unknown": 72
    },
    "bioactivity_data": {
      "ic50_values": [
        413.068341683592,
        205.7643148550352,
        819.8439287924715,
        400.70449400854744
      ],
      "ki_values": [
        329.3871808408911,
        341.3320872424399,
        410.2867309343341
      ],
      "ec50_values": [
        1961.6050984314766,
        1070.0301702670456,
        130.42137349021988,
        1810.9484970779338
      ]
    },
    "research_notes": [
      "Compound stim_2024_c76 shows promising activity in Preclinical applications.",
      "Preliminary studies indicate favorable pharmacokinetic properties.",
      "Further clinical development recommended based on preclinical efficacy data.",
      "Safety profile appears acceptable based on initial toxicology screening."
    ],
    "doi_references": [
      {
        "doi": "10.1021/jmedchem.2020.4198",
        "title": "Pharmacological characterization of stim_2024_c76 and related compounds",
        "journal": "Nature",
        "year": 2022,
        "confidence_score": 96
      }
    ],
    "last_updated": "2025-09-24T09:47:53.028995"
  },
  "mdma_2025_x77": {
    "id": 144,
    "name": "Mdma 2025 X77",
    "smiles": "Cc1nnc2n1-c1ccc(Cl)cc1C(c1ccccc1)=NC2",
    "molecular_weight": 470.58,
    "therapeutic_area": "Novel Therapy",
    "status": "Early Development",
    "category": "novel_research",
    "patent_status": "Patent Pending",
    "patent_number": null,
    "safety_score": 70,
    "efficacy_score": 91,
    "drug_likeness": 78,
    "confidence_score": 80,
    "discovery_date": "2025-02-02T09:47:53.029000",
    "ip_status": "Under Review",
    "receptor_binding": {
      "Unknown": 69
    },
    "bioactivity_data": {
      "ic50_values": [
        606.2655706680989,
        710.9110549983308,
        590.6630398643655,
        471.44754784739126
      ],
      "ki_values": [
        185.33706933128354
      ],
      "ec50_values": [
        234.98495808037575,
        1302.0994946200537
      ]
    },
    "research_notes": [
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Further clinical development recommended based on preclinical efficacy data.",
      "Compound mdma_2025_x77 shows promising activity in Novel Therapy applications."
    ],
    "doi_references": [
      {
        "doi": "10.1038/nature.2024.1258",
        "title": "Pharmacological characterization of mdma_2025_x77 and related compounds",
        "journal": "Nature",
        "year": 2021,
        "confidence_score": 86
      }
    ],
    "last_updated": "2025-09-24T09:47:53.029027"
  },
  "ket_2025_x78": {
    "id": 145,
    "name": "Ket 2025 X78",
    "smiles": "CC(CC1=CC2=C(C=C1)OCO2)NC",
    "molecular_weight": 342.25,
    "therapeutic_area": "Discovery Phase",
    "status": "Patent Pending",
    "category": "novel_research",
    "patent_status": "Patent Pending",
    "patent_number": null,
    "safety_score": 65,
    "efficacy_score": 74,
    "drug_likeness": 95,
    "confidence_score": 92,
    "discovery_date": "2024-11-05T09:47:53.029035",
    "ip_status": "Patented",
    "receptor_binding": {
      "Unknown": 73
    },
    "bioactivity_data": {
      "ic50_values": [
        763.5368568850383
      ],
      "ki_values": [
        205.66206999202566,
        233.0821679159471
      ],
      "ec50_values": [
        1069.6013831491869,
        80.9991213599905,
        1122.0511174457042
      ]
    },
    "research_notes": [
      "Compound ket_2025_x78 shows promising activity in Discovery Phase applications.",
      "Safety profile appears acceptable based on initial toxicology screening."
    ],
    "doi_references": [
      {
        "doi": "10.1021/jmedchem.2021.4431",
        "title": "Pharmacological characterization of ket_2025_x78 and related compounds",
        "journal": "Nature",
        "year": 2023,
        "confidence_score": 98
      },
      {
        "doi": "10.1126/science.2022.2206",
        "title": "Pharmacological characterization of ket_2025_x78 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2022,
        "confidence_score": 88
      },
      {
        "doi": "10.1124/jpet.2021.5260",
        "title": "Pharmacological characterization of ket_2025_x78 and related compounds",
        "journal": "Nature",
        "year": 2020,
        "confidence_score": 93
      },
      {
        "doi": "10.1124/jpet.2023.9324",
        "title": "Pharmacological characterization of ket_2025_x78 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2023,
        "confidence_score": 88
      },
      {
        "doi": "10.1016/j.neuropharm.2022.4208",
        "title": "Pharmacological characterization of ket_2025_x78 and related compounds",
        "journal": "Nature",
        "year": 2023,
        "confidence_score": 89
      }
    ],
    "last_updated": "2025-09-24T09:47:53.029074"
  },
  "stim_2025_z79": {
    "id": 146,
    "name": "Stim 2025 Z79",
    "smiles": "CNC1(CCCCC1=O)c2ccccc2Cl",
    "molecular_weight": 486.35,
    "therapeutic_area": "Research Phase",
    "status": "Novel Research",
    "category": "novel_research",
    "patent_status": "Patent Pending",
    "patent_number": "US6856423",
    "safety_score": 84,
    "efficacy_score": 77,
    "drug_likeness": 69,
    "confidence_score": 96,
    "discovery_date": "2025-07-22T09:47:53.029080",
    "ip_status": "Patent-Free",
    "receptor_binding": {
      "Unknown": 50
    },
    "bioactivity_data": {
      "ic50_values": [
        102.66297585508721,
        338.9972078344534
      ],
      "ki_values": [
        426.175722724453,
        147.63411346288143
      ],
      "ec50_values": [
        445.2057930380625,
        859.4033601679694
      ]
    },
    "research_notes": [
      "Safety profile appears acceptable based on initial toxicology screening.",
      "Preliminary studies indicate favorable pharmacokinetic properties."
    ],
    "doi_references": [
      {
        "doi": "10.1126/science.2020.2750",
        "title": "Pharmacological characterization of stim_2025_z79 and related compounds",
        "journal": "Nature",
        "year": 2020,
        "confidence_score": 91
      },
      {
        "doi": "10.1038/nature.2022.3905",
        "title": "Pharmacological characterization of stim_2025_z79 and related compounds",
        "journal": "Science",
        "year": 2020,
        "confidence_score": 91
      },
      {
        "doi": "10.1021/jmedchem.2021.5864",
        "title": "Pharmacological characterization of stim_2025_z79 and related compounds",
        "journal": "Nature",
        "year": 2020,
        "confidence_score": 89
      }
    ],
    "last_updated": "2025-09-24T09:47:53.029109"
  },
  "lsd_2024_a80": {
    "id": 147,
    "name": "Lsd 2024 A80",
    "smiles": "Cc1nnc2n1-c1ccc(Cl)cc1C(c1ccccc1)=NC2",
    "molecular_weight": 326.13,
    "therapeutic_area": "Research Phase",
    "status": "Early Development",
    "category": "novel_research",
    "patent_status": "Patented",
    "patent_number": null,
    "safety_score": 78,
    "efficacy_score": 75,
    "drug_likeness": 65,
    "confidence_score": 72,
    "discovery_date": "2024-10-15T09:47:53.029114",
    "ip_status": "IP Opportunity Identified",
    "receptor_binding": {
      "Unknown": 58
    },
    "bioactivity_data": {
      "ic50_values": [
        700.3136295052035,
        19.51130774614669,
        792.0313269509518,
        723.5455172637623
      ],
      "ki_values": [
        352.5951599279922,
        205.3369845093031
      ],
      "ec50_values": [
        317.8765328141341,
        1924.3916079678932
      ]
    },
    "research_notes": [
      "Safety profile appears acceptable based on initial toxicology screening.",
      "Further clinical development recommended based on preclinical efficacy data."
    ],
    "doi_references": [
      {
        "doi": "10.1124/jpet.2022.2886",
        "title": "Pharmacological characterization of lsd_2024_a80 and related compounds",
        "journal": "Nature",
        "year": 2021,
        "confidence_score": 89
      }
    ],
    "last_updated": "2025-09-24T09:47:53.029165"
  },
  "bzd_2025_y81": {
    "id": 148,
    "name": "Bzd 2025 Y81",
    "smiles": "Cc1nnc2n1-c1ccc(Cl)cc1C(c1ccccc1)=NC2",
    "molecular_weight": 199.66,
    "therapeutic_area": "Discovery Phase",
    "status": "Early Development",
    "category": "novel_research",
    "patent_status": "Patent-Free",
    "patent_number": "US2522243",
    "safety_score": 60,
    "efficacy_score": 67,
    "drug_likeness": 62,
    "confidence_score": 70,
    "discovery_date": "2025-07-23T09:47:53.029170",
    "ip_status": "Patented",
    "receptor_binding": {
      "Unknown": 58
    },
    "bioactivity_data": {
      "ic50_values": [
        294.1468807163679,
        161.40206413354292
      ],
      "ki_values": [
        341.6319189071454,
        245.45216581268085,
        171.3521970241335
      ],
      "ec50_values": [
        660.779780989436,
        1981.0331401595336
      ]
    },
    "research_notes": [
      "Further clinical development recommended based on preclinical efficacy data.",
      "Safety profile appears acceptable based on initial toxicology screening."
    ],
    "doi_references": [
      {
        "doi": "10.1126/science.2024.1918",
        "title": "Pharmacological characterization of bzd_2025_y81 and related compounds",
        "journal": "Nature",
        "year": 2024,
        "confidence_score": 98
      }
    ],
    "last_updated": "2025-09-24T09:47:53.029195"
  },
  "lsd_2024_c82": {
    "id": 149,
    "name": "Lsd 2024 C82",
    "smiles": "CCN(CC)C(=O)[C@H]1CN([C@@H]2Cc3c[nH]c4cccc(c34)C2=C1)C",
    "molecular_weight": 173.73,
    "therapeutic_area": "Preclinical",
    "status": "Novel Research",
    "category": "novel_research",
    "patent_status": "Patent-Free",
    "patent_number": "US5707846",
    "safety_score": 64,
    "efficacy_score": 96,
    "drug_likeness": 94,
    "confidence_score": 94,
    "discovery_date": "2025-08-16T09:47:53.029201",
    "ip_status": "Under Review",
    "receptor_binding": {
      "Unknown": 83
    },
    "bioactivity_data": {
      "ic50_values": [
        394.4642861590686
      ],
      "ki_values": [
        247.75320753390972,
        233.51459029198486,
        391.6291535761578
      ],
      "ec50_values": [
        1765.8888927367889,
        820.5335540504467,
        1796.8970862905492
      ]
    },
    "research_notes": [
      "Safety profile appears acceptable based on initial toxicology screening.",
      "Compound lsd_2024_c82 shows promising activity in Preclinical applications.",
      "Further clinical development recommended based on preclinical efficacy data.",
      "Preliminary studies indicate favorable pharmacokinetic properties."
    ],
    "doi_references": [
      {
        "doi": "10.1126/science.2021.4869",
        "title": "Pharmacological characterization of lsd_2024_c82 and related compounds",
        "journal": "Nature",
        "year": 2021,
        "confidence_score": 98
      },
      {
        "doi": "10.1038/nature.2021.2801",
        "title": "Pharmacological characterization of lsd_2024_c82 and related compounds",
        "journal": "Science",
        "year": 2021,
        "confidence_score": 86
      },
      {
        "doi": "10.1021/jmedchem.2024.7392",
        "title": "Pharmacological characterization of lsd_2024_c82 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2021,
        "confidence_score": 95
      },
      {
        "doi": "10.1021/jmedchem.2020.3715",
        "title": "Pharmacological characterization of lsd_2024_c82 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2020,
        "confidence_score": 85
      },
      {
        "doi": "10.1016/j.neuropharm.2021.3441",
        "title": "Pharmacological characterization of lsd_2024_c82 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2020,
        "confidence_score": 93
      }
    ],
    "last_updated": "2025-09-24T09:47:53.029248"
  },
  "ket_2025_z83": {
    "id": 150,
    "name": "Ket 2025 Z83",
    "smiles": "CN(C)CCc1c[nH]c2ccc(OP(=O)(O)O)cc12",
    "molecular_weight": 319.22,
    "therapeutic_area": "Novel Therapy",
    "status": "Patent Pending",
    "category": "novel_research",
    "patent_status": "Patent Pending",
    "patent_number": "US2644420",
    "safety_score": 78,
    "efficacy_score": 84,
    "drug_likeness": 86,
    "confidence_score": 73,
    "discovery_date": "2025-07-10T09:47:53.029254",
    "ip_status": "IP Opportunity Identified",
    "receptor_binding": {
      "Unknown": 61
    },
    "bioactivity_data": {
      "ic50_values": [
        419.90312599490085,
        114.14327098429958,
        560.3612713751891,
        451.63371982622766
      ],
      "ki_values": [
        402.6797184598008,
        138.34986628477165,
        456.5982403934623
      ],
      "ec50_values": [
        875.9063519331582,
        948.2110164314821,
        31.826238530035933,
        1411.2735091028007
      ]
    },
    "research_notes": [
      "Safety profile appears acceptable based on initial toxicology screening.",
      "Further clinical development recommended based on preclinical efficacy data."
    ],
    "doi_references": [
      {
        "doi": "10.1124/jpet.2024.9406",
        "title": "Pharmacological characterization of ket_2025_z83 and related compounds",
        "journal": "Nature",
        "year": 2021,
        "confidence_score": 96
      },
      {
        "doi": "10.1126/science.2021.5242",
        "title": "Pharmacological characterization of ket_2025_z83 and related compounds",
        "journal": "Nature",
        "year": 2024,
        "confidence_score": 91
      },
      {
        "doi": "10.1021/jmedchem.2023.4778",
        "title": "Pharmacological characterization of ket_2025_z83 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2020,
        "confidence_score": 95
      }
    ],
    "last_updated": "2025-09-24T09:47:53.029284"
  },
  "stim_2025_x84": {
    "id": 151,
    "name": "Stim 2025 X84",
    "smiles": "CC(CC1=CC2=C(C=C1)OCO2)NC",
    "molecular_weight": 475.07,
    "therapeutic_area": "Research Phase",
    "status": "Early Development",
    "category": "novel_research",
    "patent_status": "Patent-Free",
    "patent_number": "US5202277",
    "safety_score": 69,
    "efficacy_score": 93,
    "drug_likeness": 70,
    "confidence_score": 94,
    "discovery_date": "2025-08-25T09:47:53.029290",
    "ip_status": "Under Review",
    "receptor_binding": {
      "Unknown": 64
    },
    "bioactivity_data": {
      "ic50_values": [
        179.5782814042949,
        55.511425401321766,
        465.28375400909,
        506.29524879213074,
        84.43588602833871
      ],
      "ki_values": [
        316.19407770557325,
        223.2376426646872
      ],
      "ec50_values": [
        1751.114577799209,
        693.3540751968013
      ]
    },
    "research_notes": [
      "Compound stim_2025_x84 shows promising activity in Research Phase applications.",
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Preliminary studies indicate favorable pharmacokinetic properties."
    ],
    "doi_references": [
      {
        "doi": "10.1124/jpet.2020.5763",
        "title": "Pharmacological characterization of stim_2025_x84 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2022,
        "confidence_score": 85
      }
    ],
    "last_updated": "2025-09-24T09:47:53.029314"
  },
  "lsd_2025_y85": {
    "id": 152,
    "name": "Lsd 2025 Y85",
    "smiles": "Cc1nnc2n1-c1ccc(Cl)cc1C(c1ccccc1)=NC2",
    "molecular_weight": 186.01,
    "therapeutic_area": "Discovery Phase",
    "status": "Early Development",
    "category": "novel_research",
    "patent_status": "Patent-Free",
    "patent_number": "US5322208",
    "safety_score": 67,
    "efficacy_score": 73,
    "drug_likeness": 88,
    "confidence_score": 95,
    "discovery_date": "2024-12-02T09:47:53.029320",
    "ip_status": "Patent-Free",
    "receptor_binding": {
      "Unknown": 62
    },
    "bioactivity_data": {
      "ic50_values": [
        174.84786287917757,
        33.19805324704176,
        539.85102018835,
        133.405371375778,
        844.9583659677495
      ],
      "ki_values": [
        8.19148781915572,
        107.51403293464574,
        234.91200485628025
      ],
      "ec50_values": [
        599.7903564909877,
        1565.862231418633,
        454.4740224609746,
        1057.5533088426582
      ]
    },
    "research_notes": [
      "Safety profile appears acceptable based on initial toxicology screening.",
      "Further clinical development recommended based on preclinical efficacy data.",
      "Preliminary studies indicate favorable pharmacokinetic properties."
    ],
    "doi_references": [
      {
        "doi": "10.1038/nature.2021.4502",
        "title": "Pharmacological characterization of lsd_2025_y85 and related compounds",
        "journal": "Nature",
        "year": 2022,
        "confidence_score": 97
      },
      {
        "doi": "10.1021/jmedchem.2022.9156",
        "title": "Pharmacological characterization of lsd_2025_y85 and related compounds",
        "journal": "Science",
        "year": 2023,
        "confidence_score": 96
      },
      {
        "doi": "10.1016/j.neuropharm.2022.7921",
        "title": "Pharmacological characterization of lsd_2025_y85 and related compounds",
        "journal": "Nature",
        "year": 2021,
        "confidence_score": 93
      },
      {
        "doi": "10.1038/nature.2023.4201",
        "title": "Pharmacological characterization of lsd_2025_y85 and related compounds",
        "journal": "Nature",
        "year": 2023,
        "confidence_score": 95
      }
    ],
    "last_updated": "2025-09-24T09:47:53.029356"
  },
  "psi_2024_a86": {
    "id": 153,
    "name": "Psi 2024 A86",
    "smiles": "CNC1(CCCCC1=O)c2ccccc2Cl",
    "molecular_weight": 461.49,
    "therapeutic_area": "Novel Therapy",
    "status": "Novel Research",
    "category": "novel_research",
    "patent_status": "Patent Expired",
    "patent_number": "US2687797",
    "safety_score": 67,
    "efficacy_score": 97,
    "drug_likeness": 79,
    "confidence_score": 83,
    "discovery_date": "2025-07-30T09:47:53.029361",
    "ip_status": "Under Review",
    "receptor_binding": {
      "Unknown": 80
    },
    "bioactivity_data": {
      "ic50_values": [
        373.1017968891545,
        94.18179991090338,
        223.0156265032363,
        31.290337408530064
      ],
      "ki_values": [
        487.59719976120766,
        317.63695208179706,
        7.894719086201037
      ],
      "ec50_values": [
        893.8593921410752,
        674.8119665254046,
        843.0309695947894,
        4.220963393464936
      ]
    },
    "research_notes": [
      "Preliminary studies indicate favorable pharmacokinetic properties.",
      "Safety profile appears acceptable based on initial toxicology screening.",
      "Compound psi_2024_a86 shows promising activity in Novel Therapy applications."
    ],
    "doi_references": [
      {
        "doi": "10.1021/jmedchem.2021.7452",
        "title": "Pharmacological characterization of psi_2024_a86 and related compounds",
        "journal": "Nature",
        "year": 2021,
        "confidence_score": 96
      },
      {
        "doi": "10.1126/science.2021.8194",
        "title": "Pharmacological characterization of psi_2024_a86 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2022,
        "confidence_score": 95
      },
      {
        "doi": "10.1038/nature.2020.7650",
        "title": "Pharmacological characterization of psi_2024_a86 and related compounds",
        "journal": "Nature",
        "year": 2021,
        "confidence_score": 93
      }
    ],
    "last_updated": "2025-09-24T09:47:53.029398"
  },
  "anti_2024_c87": {
    "id": 154,
    "name": "Anti 2024 C87",
    "smiles": "CNC1(CCCCC1=O)c2ccccc2Cl",
    "molecular_weight": 223.74,
    "therapeutic_area": "Research Phase",
    "status": "Patent Pending",
    "category": "novel_research",
    "patent_status": "Patent Pending",
    "patent_number": "US8710717",
    "safety_score": 94,
    "efficacy_score": 66,
    "drug_likeness": 91,
    "confidence_score": 85,
    "discovery_date": "2024-10-21T09:47:53.029403",
    "ip_status": "Patented",
    "receptor_binding": {
      "Unknown": 79
    },
    "bioactivity_data": {
      "ic50_values": [
        726.5268749840334,
        439.23154811849145,
        236.43293663235687,
        352.4038243787024
      ],
      "ki_values": [
        118.32669163819926,
        59.98834152467992
      ],
      "ec50_values": [
        1286.6155426410764
      ]
    },
    "research_notes": [
      "Further clinical development recommended based on preclinical efficacy data.",
      "Compound anti_2024_c87 shows promising activity in Research Phase applications.",
      "Safety profile appears acceptable based on initial toxicology screening.",
      "Molecular docking studies suggest strong binding affinity to target receptors."
    ],
    "doi_references": [
      {
        "doi": "10.1021/jmedchem.2020.9097",
        "title": "Pharmacological characterization of anti_2024_c87 and related compounds",
        "journal": "Science",
        "year": 2021,
        "confidence_score": 91
      }
    ],
    "last_updated": "2025-09-24T09:47:53.029428"
  },
  "psi_2024_c88": {
    "id": 155,
    "name": "Psi 2024 C88",
    "smiles": "CCN(CC)C(=O)[C@H]1CN([C@@H]2Cc3c[nH]c4cccc(c34)C2=C1)C",
    "molecular_weight": 398.91,
    "therapeutic_area": "Discovery Phase",
    "status": "Early Development",
    "category": "novel_research",
    "patent_status": "Patent-Free",
    "patent_number": null,
    "safety_score": 78,
    "efficacy_score": 70,
    "drug_likeness": 60,
    "confidence_score": 86,
    "discovery_date": "2025-03-04T09:47:53.029436",
    "ip_status": "Patented",
    "receptor_binding": {
      "Unknown": 78
    },
    "bioactivity_data": {
      "ic50_values": [
        740.2784167503673,
        325.1176849603173,
        997.3491860032584,
        759.7068128959478,
        384.14776564801303
      ],
      "ki_values": [
        192.37333434553088,
        453.1878110638852,
        299.20304394066335
      ],
      "ec50_values": [
        852.2632748189869
      ]
    },
    "research_notes": [
      "Preliminary studies indicate favorable pharmacokinetic properties.",
      "Further clinical development recommended based on preclinical efficacy data.",
      "Safety profile appears acceptable based on initial toxicology screening."
    ],
    "doi_references": [
      {
        "doi": "10.1016/j.neuropharm.2022.9536",
        "title": "Pharmacological characterization of psi_2024_c88 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2023,
        "confidence_score": 87
      },
      {
        "doi": "10.1021/jmedchem.2023.4564",
        "title": "Pharmacological characterization of psi_2024_c88 and related compounds",
        "journal": "Science",
        "year": 2021,
        "confidence_score": 85
      }
    ],
    "last_updated": "2025-09-24T09:47:53.029463"
  },
  "opi_2025_z89": {
    "id": 156,
    "name": "Opi 2025 Z89",
    "smiles": "CCN(CC)C(=O)[C@H]1CN([C@@H]2Cc3c[nH]c4cccc(c34)C2=C1)C",
    "molecular_weight": 180.11,
    "therapeutic_area": "Research Phase",
    "status": "Novel Research",
    "category": "novel_research",
    "patent_status": "Patent Pending",
    "patent_number": "US4701885",
    "safety_score": 62,
    "efficacy_score": 76,
    "drug_likeness": 64,
    "confidence_score": 97,
    "discovery_date": "2025-04-25T09:47:53.029469",
    "ip_status": "Under Review",
    "receptor_binding": {
      "Unknown": 90
    },
    "bioactivity_data": {
      "ic50_values": [
        667.7901270116301,
        664.6472353305059,
        40.268719880418416
      ],
      "ki_values": [
        349.4057671119898,
        489.02646543001606,
        377.82335337939094
      ],
      "ec50_values": [
        888.2879912311303,
        1640.5953231532517,
        1633.348871139308
      ]
    },
    "research_notes": [
      "Compound opi_2025_z89 shows promising activity in Research Phase applications.",
      "Further clinical development recommended based on preclinical efficacy data.",
      "Safety profile appears acceptable based on initial toxicology screening."
    ],
    "doi_references": [
      {
        "doi": "10.1016/j.neuropharm.2020.1836",
        "title": "Pharmacological characterization of opi_2025_z89 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2021,
        "confidence_score": 92
      },
      {
        "doi": "10.1038/nature.2021.9948",
        "title": "Pharmacological characterization of opi_2025_z89 and related compounds",
        "journal": "Science",
        "year": 2024,
        "confidence_score": 96
      },
      {
        "doi": "10.1124/jpet.2023.4286",
        "title": "Pharmacological characterization of opi_2025_z89 and related compounds",
        "journal": "Nature",
        "year": 2020,
        "confidence_score": 89
      }
    ],
    "last_updated": "2025-09-24T09:47:53.029502"
  },
  "mdma_2025_z90": {
    "id": 157,
    "name": "Mdma 2025 Z90",
    "smiles": "CNC1(CCCCC1=O)c2ccccc2Cl",
    "molecular_weight": 266.51,
    "therapeutic_area": "Discovery Phase",
    "status": "Patent Pending",
    "category": "novel_research",
    "patent_status": "Patent Pending",
    "patent_number": null,
    "safety_score": 65,
    "efficacy_score": 92,
    "drug_likeness": 72,
    "confidence_score": 89,
    "discovery_date": "2025-09-20T09:47:53.029506",
    "ip_status": "Under Review",
    "receptor_binding": {
      "Unknown": 80
    },
    "bioactivity_data": {
      "ic50_values": [
        972.7930138257385
      ],
      "ki_values": [
        126.62109801767546
      ],
      "ec50_values": [
        291.09027041617156,
        826.1718372919419,
        787.8087731469426
      ]
    },
    "research_notes": [
      "Safety profile appears acceptable based on initial toxicology screening.",
      "Molecular docking studies suggest strong binding affinity to target receptors."
    ],
    "doi_references": [
      {
        "doi": "10.1124/jpet.2024.8659",
        "title": "Pharmacological characterization of mdma_2025_z90 and related compounds",
        "journal": "Nature",
        "year": 2020,
        "confidence_score": 94
      },
      {
        "doi": "10.1126/science.2023.3033",
        "title": "Pharmacological characterization of mdma_2025_z90 and related compounds",
        "journal": "Science",
        "year": 2023,
        "confidence_score": 92
      },
      {
        "doi": "10.1016/j.neuropharm.2023.7182",
        "title": "Pharmacological characterization of mdma_2025_z90 and related compounds",
        "journal": "Science",
        "year": 2023,
        "confidence_score": 91
      },
      {
        "doi": "10.1016/j.neuropharm.2021.5002",
        "title": "Pharmacological characterization of mdma_2025_z90 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2024,
        "confidence_score": 88
      }
    ],
    "last_updated": "2025-09-24T09:47:53.029541"
  },
  "ket_2025_y91": {
    "id": 158,
    "name": "Ket 2025 Y91",
    "smiles": "CN(C)CCc1c[nH]c2ccc(OP(=O)(O)O)cc12",
    "molecular_weight": 409.88,
    "therapeutic_area": "Novel Therapy",
    "status": "Novel Research",
    "category": "novel_research",
    "patent_status": "Patent Pending",
    "patent_number": "US2518870",
    "safety_score": 60,
    "efficacy_score": 90,
    "drug_likeness": 79,
    "confidence_score": 93,
    "discovery_date": "2024-12-03T09:47:53.029546",
    "ip_status": "Patent-Free",
    "receptor_binding": {
      "Unknown": 56
    },
    "bioactivity_data": {
      "ic50_values": [
        724.3969474807033,
        790.8211772928113,
        511.88898095022626,
        357.75349725901725
      ],
      "ki_values": [
        300.793497136625,
        312.8065631877007
      ],
      "ec50_values": [
        1214.4977349050112
      ]
    },
    "research_notes": [
      "Safety profile appears acceptable based on initial toxicology screening.",
      "Compound ket_2025_y91 shows promising activity in Novel Therapy applications.",
      "Preliminary studies indicate favorable pharmacokinetic properties."
    ],
    "doi_references": [
      {
        "doi": "10.1126/science.2023.4143",
        "title": "Pharmacological characterization of ket_2025_y91 and related compounds",
        "journal": "Science",
        "year": 2020,
        "confidence_score": 96
      },
      {
        "doi": "10.1126/science.2023.2038",
        "title": "Pharmacological characterization of ket_2025_y91 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2022,
        "confidence_score": 95
      },
      {
        "doi": "10.1016/j.neuropharm.2023.9868",
        "title": "Pharmacological characterization of ket_2025_y91 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2024,
        "confidence_score": 97
      },
      {
        "doi": "10.1016/j.neuropharm.2020.5406",
        "title": "Pharmacological characterization of ket_2025_y91 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2024,
        "confidence_score": 86
      },
      {
        "doi": "10.1126/science.2024.9745",
        "title": "Pharmacological characterization of ket_2025_y91 and related compounds",
        "journal": "Science",
        "year": 2022,
        "confidence_score": 97
      }
    ],
    "last_updated": "2025-09-24T09:47:53.029607"
  },
  "ket_2025_z92": {
    "id": 159,
    "name": "Ket 2025 Z92",
    "smiles": "CC(CC1=CC2=C(C=C1)OCO2)NC",
    "molecular_weight": 195.15,
    "therapeutic_area": "Novel Therapy",
    "status": "Early Development",
    "category": "novel_research",
    "patent_status": "Patent Pending",
    "patent_number": "US6735463",
    "safety_score": 62,
    "efficacy_score": 86,
    "drug_likeness": 76,
    "confidence_score": 77,
    "discovery_date": "2024-12-28T09:47:53.029613",
    "ip_status": "Patent-Free",
    "receptor_binding": {
      "Unknown": 69
    },
    "bioactivity_data": {
      "ic50_values": [
        581.3696875093507,
        36.88635040051598,
        697.8731170892258,
        14.163304822315986,
        467.8954282712542
      ],
      "ki_values": [
        413.14772412042487,
        182.7481460235058,
        279.68255340740166
      ],
      "ec50_values": [
        174.56054894007482,
        940.0445134627859
      ]
    },
    "research_notes": [
      "Safety profile appears acceptable based on initial toxicology screening.",
      "Molecular docking studies suggest strong binding affinity to target receptors."
    ],
    "doi_references": [
      {
        "doi": "10.1126/science.2021.8204",
        "title": "Pharmacological characterization of ket_2025_z92 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2023,
        "confidence_score": 94
      },
      {
        "doi": "10.1038/nature.2022.5028",
        "title": "Pharmacological characterization of ket_2025_z92 and related compounds",
        "journal": "Science",
        "year": 2021,
        "confidence_score": 87
      },
      {
        "doi": "10.1124/jpet.2020.8300",
        "title": "Pharmacological characterization of ket_2025_z92 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2024,
        "confidence_score": 96
      },
      {
        "doi": "10.1016/j.neuropharm.2023.9605",
        "title": "Pharmacological characterization of ket_2025_z92 and related compounds",
        "journal": "Science",
        "year": 2022,
        "confidence_score": 87
      }
    ],
    "last_updated": "2025-09-24T09:47:53.029646"
  },
  "lsd_2024_a93": {
    "id": 160,
    "name": "Lsd 2024 A93",
    "smiles": "CCN(CC)C(=O)[C@H]1CN([C@@H]2Cc3c[nH]c4cccc(c34)C2=C1)C",
    "molecular_weight": 461.99,
    "therapeutic_area": "Discovery Phase",
    "status": "Novel Research",
    "category": "novel_research",
    "patent_status": "Patent Pending",
    "patent_number": "US7998542",
    "safety_score": 67,
    "efficacy_score": 95,
    "drug_likeness": 86,
    "confidence_score": 78,
    "discovery_date": "2024-12-24T09:47:53.029651",
    "ip_status": "Under Review",
    "receptor_binding": {
      "Unknown": 50
    },
    "bioactivity_data": {
      "ic50_values": [
        787.6392946122845
      ],
      "ki_values": [
        1.3823815703038096,
        315.8203165370242,
        360.01028284984386
      ],
      "ec50_values": [
        397.76272205883686,
        950.4046990293385,
        245.77168490900758
      ]
    },
    "research_notes": [
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Further clinical development recommended based on preclinical efficacy data.",
      "Preliminary studies indicate favorable pharmacokinetic properties."
    ],
    "doi_references": [
      {
        "doi": "10.1126/science.2021.2597",
        "title": "Pharmacological characterization of lsd_2024_a93 and related compounds",
        "journal": "Science",
        "year": 2020,
        "confidence_score": 91
      },
      {
        "doi": "10.1038/nature.2024.8085",
        "title": "Pharmacological characterization of lsd_2024_a93 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2023,
        "confidence_score": 98
      },
      {
        "doi": "10.1038/nature.2021.1818",
        "title": "Pharmacological characterization of lsd_2024_a93 and related compounds",
        "journal": "Science",
        "year": 2024,
        "confidence_score": 88
      },
      {
        "doi": "10.1038/nature.2024.2146",
        "title": "Pharmacological characterization of lsd_2024_a93 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2022,
        "confidence_score": 92
      },
      {
        "doi": "10.1124/jpet.2021.6702",
        "title": "Pharmacological characterization of lsd_2024_a93 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2023,
        "confidence_score": 88
      }
    ],
    "last_updated": "2025-09-24T09:47:53.029692"
  },
  "psi_2025_x94": {
    "id": 161,
    "name": "Psi 2025 X94",
    "smiles": "CN(C)CCc1c[nH]c2ccc(OP(=O)(O)O)cc12",
    "molecular_weight": 322.13,
    "therapeutic_area": "Research Phase",
    "status": "Novel Research",
    "category": "novel_research",
    "patent_status": "Patent-Free",
    "patent_number": "US2932318",
    "safety_score": 93,
    "efficacy_score": 66,
    "drug_likeness": 83,
    "confidence_score": 82,
    "discovery_date": "2024-12-10T09:47:53.029698",
    "ip_status": "IP Opportunity Identified",
    "receptor_binding": {
      "Unknown": 53
    },
    "bioactivity_data": {
      "ic50_values": [
        776.5058374039933,
        658.7698331681709
      ],
      "ki_values": [
        90.74775482011447
      ],
      "ec50_values": [
        1724.3274725379488
      ]
    },
    "research_notes": [
      "Safety profile appears acceptable based on initial toxicology screening.",
      "Further clinical development recommended based on preclinical efficacy data.",
      "Compound psi_2025_x94 shows promising activity in Research Phase applications.",
      "Preliminary studies indicate favorable pharmacokinetic properties."
    ],
    "doi_references": [
      {
        "doi": "10.1038/nature.2022.1034",
        "title": "Pharmacological characterization of psi_2025_x94 and related compounds",
        "journal": "Science",
        "year": 2023,
        "confidence_score": 96
      },
      {
        "doi": "10.1124/jpet.2020.2837",
        "title": "Pharmacological characterization of psi_2025_x94 and related compounds",
        "journal": "Nature",
        "year": 2022,
        "confidence_score": 97
      },
      {
        "doi": "10.1126/science.2020.5855",
        "title": "Pharmacological characterization of psi_2025_x94 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2022,
        "confidence_score": 93
      },
      {
        "doi": "10.1021/jmedchem.2024.8777",
        "title": "Pharmacological characterization of psi_2025_x94 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2023,
        "confidence_score": 97
      }
    ],
    "last_updated": "2025-09-24T09:47:53.029730"
  },
  "psi_2025_y95": {
    "id": 162,
    "name": "Psi 2025 Y95",
    "smiles": "CNC1(CCCCC1=O)c2ccccc2Cl",
    "molecular_weight": 258.19,
    "therapeutic_area": "Research Phase",
    "status": "Novel Research",
    "category": "novel_research",
    "patent_status": "Patented",
    "patent_number": "US6910338",
    "safety_score": 75,
    "efficacy_score": 98,
    "drug_likeness": 69,
    "confidence_score": 76,
    "discovery_date": "2025-07-12T09:47:53.029735",
    "ip_status": "IP Opportunity Identified",
    "receptor_binding": {
      "Unknown": 88
    },
    "bioactivity_data": {
      "ic50_values": [
        425.8802952975935,
        409.77088801512417,
        885.2846591372025
      ],
      "ki_values": [
        273.75495583869014,
        67.10118791900076
      ],
      "ec50_values": [
        328.8734146234906,
        573.3572651261092,
        327.22082926691553
      ]
    },
    "research_notes": [
      "Further clinical development recommended based on preclinical efficacy data.",
      "Safety profile appears acceptable based on initial toxicology screening."
    ],
    "doi_references": [
      {
        "doi": "10.1038/nature.2024.2739",
        "title": "Pharmacological characterization of psi_2025_y95 and related compounds",
        "journal": "Nature",
        "year": 2020,
        "confidence_score": 90
      },
      {
        "doi": "10.1021/jmedchem.2021.2436",
        "title": "Pharmacological characterization of psi_2025_y95 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2020,
        "confidence_score": 94
      },
      {
        "doi": "10.1124/jpet.2024.9425",
        "title": "Pharmacological characterization of psi_2025_y95 and related compounds",
        "journal": "Nature",
        "year": 2021,
        "confidence_score": 86
      }
    ],
    "last_updated": "2025-09-24T09:47:53.029768"
  },
  "anti_2024_b96": {
    "id": 163,
    "name": "Anti 2024 B96",
    "smiles": "CCN(CC)C(=O)[C@H]1CN([C@@H]2Cc3c[nH]c4cccc(c34)C2=C1)C",
    "molecular_weight": 319.27,
    "therapeutic_area": "Novel Therapy",
    "status": "Early Development",
    "category": "novel_research",
    "patent_status": "Patent Expired",
    "patent_number": null,
    "safety_score": 85,
    "efficacy_score": 76,
    "drug_likeness": 73,
    "confidence_score": 79,
    "discovery_date": "2025-03-02T09:47:53.029773",
    "ip_status": "Patent-Free",
    "receptor_binding": {
      "Unknown": 58
    },
    "bioactivity_data": {
      "ic50_values": [
        873.3124517254752
      ],
      "ki_values": [
        397.10193921377106
      ],
      "ec50_values": [
        577.9783165388184,
        77.29692484576856
      ]
    },
    "research_notes": [
      "Safety profile appears acceptable based on initial toxicology screening.",
      "Molecular docking studies suggest strong binding affinity to target receptors.",
      "Preliminary studies indicate favorable pharmacokinetic properties.",
      "Further clinical development recommended based on preclinical efficacy data."
    ],
    "doi_references": [
      {
        "doi": "10.1124/jpet.2024.8520",
        "title": "Pharmacological characterization of anti_2024_b96 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2024,
        "confidence_score": 93
      },
      {
        "doi": "10.1038/nature.2021.1692",
        "title": "Pharmacological characterization of anti_2024_b96 and related compounds",
        "journal": "Journal of Medicinal Chemistry",
        "year": 2022,
        "confidence_score": 90
      }
    ],
    "last_updated": "2025-09-24T09:47:53.029803"
  },
  "anti_2024_a97": {
    "id": 164,
    "name": "Anti 2024 A97",
    "smiles": "Cc1nnc2n1-c1ccc(Cl)cc1C(c1ccccc1)=NC2",
    "molecular_weight": 276.66,
    "therapeutic_area": "Preclinical",
    "status": "Patent Pending",
    "category": "novel_research",
    "patent_status": "Patent Pending",
    "patent_number": null,
    "safety_score": 90,
    "efficacy_score": 65,
    "drug_likeness": 91,
    "confidence_score": 87,
    "discovery_date": "2024-10-14T09:47:53.029808",
    "ip_status": "Under Review",
    "receptor_binding": {
      "Unknown": 53
    },
    "bioactivity_data": {
      "ic50_values": [
        412.8948618038084,
        474.20451763757626
      ],
      "ki_values": [
        108.57278042186476,
        256.23950895683123
      ],
      "ec50_values": [
        1417.274589700961,
        1240.166093006648,
        607.4886900462795,
        1252.2479328076708
      ]
    },
    "research_notes": [
      "Compound anti_2024_a97 shows promising activity in Preclinical applications.",
      "Further clinical development recommended based on preclinical efficacy data."
    ],
    "doi_references": [
      {
        "doi": "10.1124/jpet.2020.1195",
        "title": "Pharmacological characterization of anti_2024_a97 and related compounds",
        "journal": "Science",
        "year": 2022,
        "confidence_score": 89
      }
    ],
    "last_updated": "2025-09-24T09:47:53.029833"
  },
  "psi_2025_y98": {
    "id": 165,
    "name": "Psi 2025 Y98",
    "smiles": "CNC1(CCCCC1=O)c2ccccc2Cl",
    "molecular_weight": 320.63,
    "therapeutic_area": "Discovery Phase",
    "status": "Early Development",
    "category": "novel_research",
    "patent_status": "Patent Expired",
    "patent_number": "US1922427",
    "safety_score": 77,
    "efficacy_score": 67,
    "drug_likeness": 78,
    "confidence_score": 72,
    "discovery_date": "2024-12-10T09:47:53.029840",
    "ip_status": "IP Opportunity Identified",
    "receptor_binding": {
      "Unknown": 87
    },
    "bioactivity_data": {
      "ic50_values": [
        239.2744648502297,
        891.6937774724331
      ],
      "ki_values": [
        374.76701973432375,
        88.78450051937499,
        89.43504976821785
      ],
      "ec50_values": [
        1407.8764492789858,
        297.05388570550923,
        1105.6312685080457
      ]
    },
    "research_notes": [
      "Compound psi_2025_y98 shows promising activity in Discovery Phase applications.",
      "Further clinical development recommended based on preclinical efficacy data.",
      "Preliminary studies indicate favorable pharmacokinetic properties."
    ],
    "doi_references": [
      {
        "doi": "10.1016/j.neuropharm.2023.2660",
        "title": "Pharmacological characterization of psi_2025_y98 and related compounds",
        "journal": "Nature",
        "year": 2020,
        "confidence_score": 94
      }
    ],
    "last_updated": "2025-09-24T09:47:53.029864"
  },
  "opi_2025_x99": {
    "id": 166,
    "name": "Opi 2025 X99",
    "smiles": "CNC1(CCCCC1=O)c2ccccc2Cl",
    "molecular_weight": 443.45,
    "therapeutic_area": "Preclinical",
    "status": "Patent Pending",
    "category": "novel_research",
    "patent_status": "Patented",
    "patent_number": "US1432976",
    "safety_score": 72,
    "efficacy_score": 84,
    "drug_likeness": 66,
    "confidence_score": 83,
    "discovery_date": "2025-01-23T09:47:53.029870",
    "ip_status": "IP Opportunity Identified",
    "receptor_binding": {
      "Unknown": 89
    },
    "bioactivity_data": {
      "ic50_values": [
        575.4165825184901,
        151.07403082362472,
        187.62834801757657,
        678.3707161085593,
        852.947030915992
      ],
      "ki_values": [
        143.41247608832896
      ],
      "ec50_values": [
        620.1332203197258,
        657.1251771418445
      ]
    },
    "research_notes": [
      "Further clinical development recommended based on preclinical efficacy data.",
      "Compound opi_2025_x99 shows promising activity in Preclinical applications.",
      "Safety profile appears acceptable based on initial toxicology screening.",
      "Molecular docking studies suggest strong binding affinity to target receptors."
    ],
    "doi_references": [
      {
        "doi": "10.1126/science.2022.2583",
        "title": "Pharmacological characterization of opi_2025_x99 and related compounds",
        "journal": "Science",
        "year": 2022,
        "confidence_score": 98
      },
      {
        "doi": "10.1016/j.neuropharm.2023.2313",
        "title": "Pharmacological characterization of opi_2025_x99 and related compounds",
        "journal": "Nature",
        "year": 2023,
        "confidence_score": 87
      },
      {
        "doi": "10.1124/jpet.2020.5137",
        "title": "Pharmacological characterization of opi_2025_x99 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2022,
        "confidence_score": 85
      },
      {
        "doi": "10.1126/science.2023.9017",
        "title": "Pharmacological characterization of opi_2025_x99 and related compounds",
        "journal": "Nature",
        "year": 2020,
        "confidence_score": 91
      },
      {
        "doi": "10.1021/jmedchem.2024.4298",
        "title": "Pharmacological characterization of opi_2025_x99 and related compounds",
        "journal": "Neuropharmacology",
        "year": 2023,
        "confidence_score": 90
      }
    ],
    "last_updated": "2025-09-24T09:47:53.029909"
  }
}